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Mycobacterium tuberculosis; too smart to handle?
Tuberculosis, a disease of  all times
Tuberculosis (TB) is a disease that co-evolved with mankind for many thousands of  years [1] and 
remains responsible for many deaths every year. Approximately 8.7 million new TB cases were 
identified in 2011 and 1.4 million individuals died of  TB in the same year [2]. The first signs of  
human TB existence can be traced back over 9,000 years ago (7000 B.C.) as shown by DNA and 
mycolic acid markers detected in human skeletal remains [3]. TB has had many names over time, 
which refer to consequences of  the disease. At the Hippocratic era (460-370 BC) TB was known 
as consumption or phthisis (Greek for consumption), referring to progressive emaciation or weight 
loss due to the disease. Later, during the middle ages TB was referred to as the white plague. At 
this time, TB was accountable for the death of  one-fourth of  the whole European population 
and it was even thought that the survival of  the European race was at stake [4]. The mechanism 
and source of  the disease remained unknown until the late 19th century. Continuing the work of  
many researchers who had tried to identify the source of  TB, including Jakob Henle, Jean Antoine 
Villemin and Theodor Klebs, Robert Koch finally identified Mycobacterium tuberculosis (Mtb) to be 
the causative agent and was awarded the Nobel prize in 1905 for his work [5;6]. Unfortunately, 
despite intense efforts to reduce TB, including improved public health care and therapies [7-9], 
TB continues to remain one of  the leading causes of  death due to infectious disease worldwide [2]. 
Mycobacterium tuberculosis infection: From latent infection to active disease 
Transmission occurs via inhalation of  Mtb loaded aerosols that are spread by coughing pulmonary 
TB patients. The bacilli enter the alveolar space in the lungs where they are taken up by phagocytes 
including alveolar macrophages, dendritic cells but also pulmonary epithelial cells. Mtb is taken 
up in intracellular compartments called phagosomes. Both neutrophils and monocytes are then 
attracted to the site of  infection, and monocytes subsequently mature into macrophages which are 
better at taking up and inhibiting Mtb. The precise functions of  neutrophils remain unclear as they 
have protective properties at the time of  infection but become detrimental at later stages [10-12]. 
Eventually, the attraction of  innate cells to the site of  initial infection results in the formation of  
the primary granuloma (Ghon complex) [13]. Pathogen loaded dendritic cells (DC) subsequently 
migrate to the mediastinal lymph nodes (MLN), which drain the lungs, where they start presenting 
antigens to the T and B cells [14;15]. Once the adaptive immune system is triggered, T-effector 
cells are recruited to the site of  infection, where they can exert their function and further shape 
the granuloma [16]. 
Intriguingly, this triggering of  adaptive immune responses in TB is significantly delayed 
compared to infections with other pathogens and, in addition, triggered innate and adaptive 
immune cells often cannot efficiently eliminate Mtb. Here, Mtb itself  plays an important role as 










































apoptosis [17], induction of  anti-inflammatory responses, such as production of  anti-inflammatory 
cytokines by innate cells and generation of  regulatory T cells (Tregs) [18-20], delay in transport 
of  infected, or antigen-loaded DC to the MLN [14;15;21], delay in priming and recruitment of  
innate and adaptive cells to the site of  infection [18;22], preventing phago-lysosome fusion [23-
25], detoxification of  reactive oxygen species and reactive nitrogen intermediates [26], inhibition 
of  MHC class II presentation [27], and reduced activation of  antigen-specific T cells at the site 
of  infection [28;29]. These mechanisms hamper a rapid response of  adaptive immune cells, and 
enable Mtb to survive intracellularly [22;30;31]. Remarkably, Mtb can also infect bone marrow 
derived mesenchymal stem cells (BM-MSC) that reside in the bone marrow and use these cells as 
a hitherto unknown niche and hideout from immune patrol [32].
At first sight, the formation of  granulomas seems to be beneficial for the host since it contains 
infection locally. However, recent data challenge this dogma and show that Mtb also benefits 
from granuloma formation, since it is able to use freshly recruited cells as novel niches, leading to 
dissemination [33]. Of  special interest, the presence of  Mtb ESAT-6 protein is required for well-
formed granulomas as it triggers recruitment of  macrophages via host matrix metalloproteinase 
9 (MMP9) [34;35]. In addition, further spread is enhanced by Mtb (ESAT-6) induced necrosis of  
infected host cells e.g. [36-39] and inhibition of  protective apoptosis e.g. [37;38;40;41], although 
other studies showed that (ESAT-6 induced) apoptosis is beneficial for Mtb e.g. [33;42-44], thus the 
exact effect of  host cell death mechanisms on Mtb are yet undefined. 
Ultimately, the combination of  host pressure and Mtb immune escape mechanisms can result 
in an established balance between host and pathogen, i.e. latent Mtb infection (LTBI). This 
balance between pathogen and host enables Mtb to reside for decades at the site of  infection. 
LTBI individuals are thus Mtb infected but lack any clinical symptoms. However, latent infection 
can reactivate and lead to active disease: 5 to 10% of  LTBI will develop TB during their lifetime 
and half  of  these cases will develop within two-five years after infection [45-47]. Nevertheless, 
reactivation after decades of  latent infection has also been described [48]. Of  note, these numbers 
are difficult to interpret partly because it is unknown what percentage of  LTBI is able to clear the 
infection completely. It is believed that Mtb in LTBI mostly enters a dormant state, adapting to the 
harsh environment in the host while awaiting a possible chance to reactivate and spread. Once an 
imbalance occurs between host and pathogen, due to weakened host immunity, bacteria will be 
able to reactivate [31] and necrotic regions will develop within the granuloma, leading to caseous 
necrotic lesions. These lesions can liquefy which ultimately leads to leakage of  caseum into the 
airways, resulting in a contagious TB case [13;16]. 
A very high risk of  TB reactivation is observed in individuals that are immune deficient. These 
include: (i) HIV infected individuals particularly those with reduced (<200) CD4+ T-cell counts 
[49-51], (ii) individuals undergoing anti-TNF treatment [52;53], and (iii) patients with genetic 
disorders in genes coding for receptors and cytokines involved in type-1 immunity and the Th1 
cascade [54-56]. Thus, Mtb infection can result in a broad spectrum of  stages, ranging from (likely) 











































Efforts to Tackle TB
The timely detection and treatment of  TB, and its prevention by vaccination are the two 
major tasks that the WHO has embraced to reduce the burden of  TB. Here we will focus on 
immunological aspects of  these tasks, and discuss immune-based detection techniques as well as 
vaccination against Mtb. Treatment of  Mtb will not be further discussed in this chapter. 
Detection of  latent Mtb infection
Detection of  Mtb infection is of  major importance for adequate control of  TB. Mtb infection can 
be determined in the sputum of  active TB patients, using a smear microscopy test and bacterial 
culturing, or nucleic acid amplification tests to detect Mtb DNA (NAATs e.g: Xpert MTB/RIF® 
assay) complemented with chest X-rays [58;59]. Unfortunately, the presence of  viable bacteria 
cannot be determined in LTBI. To verify Mtb exposure in this population an indirect test is 
required, analyzing the immune responses towards mycobacterial products. 
Tuberculin skin test. Koch introduced tuberculin, an extract from tubercle bacilli dissolved 
in glycerine, as a new medicine to treat tuberculosis, however this unfortunately failed [60]. A 
few years later, Clemens Freiherr von Pirquet showed that Koch’s tuberculin could be used as a 
tool to identify latent Mtb infection, by injecting the substance intracutaneously, which resulted 
in a delayed hypersensitivity (DTH) response in exposed individuals. Charles Mantoux further 
developed this diagnostic technique and in 1908, Florence Seibert improved tuberculin to purified 
protein derivative (PPD), which is still in use today [5;61]. This technique is currently known 
as the tuberculin skin test (TST) or Mantoux test. Unfortunately, cross-reactivity of  PPD with 
nontuberculous mycobacteria (NTM) and the vaccine strain Mycobacterium bovis Bacille Calmette-
Guérin (BCG) reduces the specificity of  the TST [62-65]. Exposure to NTMs is very common as 
they reside in many sources in the host environment such as soil and natural waters [66;67]. One 
study found NTM to be abundantly present in showerhead biofilms [68]. A practical drawback of  
the TST is that it requires two visits, can induce boosting effects upon multiple TST testing and 
can be false negative in immunocompromised (e.g. HIV infected) individuals. 
Interferon-Gamma Release Assays (IGRAs). To increase the specificity of  Mtb diagnosis, a new 
technique was introduced. This technique is based on antigen specific interferon-gamma (IFN-γ) 
secretion upon stimulation with peptides from the highly specific and immunogenic Mtb antigens 
early-secreted antigen 6 (ESAT-6), culture filtrate protein 10 (CFP-10) and TB7.7. These tests 
are widely known as Interferon-Gamma Release Assays (IGRAs). In contrast to the TST, false 
negative responses due to Mtb specific anergy can be identified since both a positive and negative 
control are included [69]. Multiple studies have shown that IGRAs have enhanced specificity 
over TST [70-72], although most of  these studies were performed in high-income countries such 
that the results cannot directly be extrapolated to low and middle income countries with higher 










































[75;76]. Due to the lack of  sufficient evidence IGRAs are not recommended for use in low and 
middle income countries [74]. Furthermore, discordant results between TST and IGRA results 
have been documented which often remain poorly explained [77]. Despite the relative success of  
IGRAs in low endemic settings, it has not proved possible to use these tests to discriminate between 
recent and remote Mtb infection, and also not between active and latent Mtb infection. Recently 
an Mtb antigen, Rv2628, was described to be recognized by remote Mtb infected individuals, but 
not by recent Mtb infected individuals, suggesting a role as discriminatory marker [78]. Although 
the specificity is increased, the IGRA antigens are not fully restricted to Mtb as homologs of  these 
proteins are also present in Mycobacterium leprae [79;80] Mycobacterium kansasii, Mycobacterium szulgai, 
Mycobacterium riyadhense and Mycobacterium marinum. Also, testing too soon after Mtb infection might 
result in false negative outcomes [81]. 
Importantly, as already indicated, these two tests determine Mtb exposure indirectly. Responses 
towards Mtb products can be detected, but this does not directly indicate that viable bacilli are 
still present. It may be that either the infection has been cleared but immune responses persist, or 
that Mtb bacilli are still present. Altogether, although latent Mtb infection detection methods are 
available, improvement is definitely required. 
Vaccine development
Despite the availability of  diagnostic tests and TB treatments, TB remains difficult to eradicate. 
One major concern is the rapid development of  (extensively) multidrug resistant (XDR/MDR) 
Mtb strains. At this moment even strains are known which are resistant to all current drugs 
available (totally drug resistant Mtb, TDR) [82]. Therefore, robust Mtb vaccines are needed to 
prevent further development of  TB outbreaks that cannot be controlled using current drugs. 
Current TB vaccine. In 1921, Albert Calmette and Camille Guérin developed the first vaccine 
against TB. They cultured Mycobacterium bovis (M. bovis) until it became avirulent (due to the loss 
of  genetic regions, including RD1[83]) and designated the vaccine as M. bovis Bacille Calmette-
Guérin (BCG) [5;84]. BCG is still the only vaccine available at this moment. The effect of  BCG 
has widely been studied in many countries and showed its protective value towards disseminated 
and meningeal childhood TB [85] as well as to a certain level against leprosy, which is caused by 
Mycobacterium leprae [86;87]. Unfortunately, BCG vaccination results in highly variable protection 
against pulmonary TB in adults [88], which is the most common form of  TB. Importantly, 
pulmonary TB is, together with the rare laryngeal TB, the only form of  TB accountable for 
further transmission of  disease. The effect of  BCG can be diminished due to co-infections with 
NTM or helminthes [89-91]. In addition to the highly variable protection, BCG vaccination, 
which is a live attenuated vaccine, can lead to severe infection in immune deficient individuals [92] 
[54]. The lack of  BCG’s efficacy against pulmonary TB and its severe adverse effects in immune 
deficiencies clearly show that there is a significant need for improved TB vaccines which are both 











































Novel TB vaccines. Mtb vaccines need to trigger cellular immunity to induce protection against 
Mtb as the bacterium resides intracellular in phagosomes such that antibodies cannot easily reach 
the pathogen. Importantly, Th1 immunity was previously shown to play an important role in the 
control of  Mtb infection [16]. New preventive TB vaccines can either be used as booster vaccines 
on top of  previous BCG vaccination, or as individual, priming vaccines. The three different types 
of  vaccines currently under study are (i) live attenuated and/or genetically modified mycobacterial 
vaccines, (ii) killed (fragmented) whole bacteria and (iii) subunit vaccines. Notably, the development 
of  therapeutic vaccines is of  significant interest. The goal of  this vaccine is to prevent reactivation 
of  Mtb in LTBI by enhancing the control of  infection. At this moment, over 12 vaccines already 
entered clinical trials, whereas over 40 vaccines are currently in the pre-clinical phase [16]. 
The live attenuated and/or genetically modified mycobacteria are developed to be used as 
priming vaccines, meant to replace BCG. These improved vaccines should be more immunogenic, 
maintain this immune response for a longer period of  time and be safer in immune-deficient 
individuals. Recombinant BCG (rBCG) modifications include i) introduction or over-expression of  
specific Mtb antigens which are lacking from BCG, and ii) improvement of  antigen presentation by 
genetic modification of  important pathways [16]. One of  these rBCG vaccines is rBCGΔUrec:Hly+ 
(VPM1002). rBCGΔUrec:Hly+ expresses listeriolysin (Hly) which is responsible for rBCGs escape 
from phagosomes into the cytosol. Urease C (UreC), a protein involved in preventing phagosomal 
acidification, was removed to improve the effect of  Hly, which functions most optimal under acidic 
conditions. This rBCG had a better vaccine potential compared to its parental strain [93]. Apoptosis 
of  infected cells was promoted and increased CD4+ as well as CD8+ T-cell responses was observed, 
possibly due to enhanced cross priming. The vaccine has entered phase IIa trials [94]. Other 
rBCG vaccines include strains that overexpress antigens such as Ag85B (rBCG30) [95] and RD1 
antigens [96]. Aeras-422, a vaccine that resembles rBCGΔUrec:Hly+, expresses perfringolysin, 
but also overexpresses Ag85A, Ag85B and Rv3407 [97]. The combination of  induced escape 
into the cytosol and overexpression of  immunogenic antigens in one vaccine appears to have an 
improved efficacy. However this vaccine induced side effects such as the occurrence of  shingles 
urging termination of  the phase I trial [16;98;99]. 
Using Mtb strains for vaccine purposes requires special attention, it is important that 
attenuated strains are not virulent and therefore at least two independent loci, e.g. involved in 
essential metabolic pathways (autotrophy) or virulence, should be deleted, preventing reversion 
of  virulence [100;101]. Currently several attenuated Mtb strains are under study as potential 
vaccines. The attenuated Mtb ΔsecA2ΔlysA [102] and Mtb ΔfbpAΔsapM [103] are examples of  
such mutant strains and are in a very early stage of  analysis. Two other attenuated Mtb strains, Mtb 
ΔRD1ΔpanCD [104] and Mtb ΔPhoP (SO2), have already been studied for some time, showing 
promising immunogenicity and safety results. In order to comply to a consensus reached at a 
WHO Geneva meeting in 2004 [100;101;105], the SO2 strain has been further improved by 










































has now entered phase I clinical trial to analyze its safety in humans. Interestingly, a novel potential 
vaccine strain was developed consisting of  an attenuated Mtb strain expressing HIV antigens to 
prevent both Mtb and HIV infections [106]. 
In contrast to live attenuated and/or genetically modified mycobacteria vaccines, non-live 
subunit vaccines were initially developed to be used as booster on top of  BCG vaccination or to 
enable novel live attenuated and/or genetically modified mycobacterial vaccines to enhance the 
long-lived immune memory response against Mtb. Subunit vaccines consist of  protein(s) and/or 
(poly)epitopes delivered using a viral vector system or as recombinant product together with an 
(Th1) adjuvant [16;107]. One of  the most advanced subunit vaccine is MVA85A, a recombinant 
(replication deficient) strain of  Modified Vaccinia Ankara (MVA) virus that expresses the Mtb 
Ag85A antigen. MVA85A was shown to be immunogenic and safe in use in children and adults 
located at multiple sites [108-111]. Unfortunately, although MVA85A was safe, the phase IIb trial, 
published in February 2013, resulted in insignificant efficacy against TB and Mtb infection in 
children [112]. Another vaccine, AdAg85A which is currently studied in phase I trial, resembles 
MVA85A in that it also expresses Ag85A but expressed in an (replication deficient) Adenovirus 
(type 5) [113;114]. Ad35 (AERAS-402) is a virus-based vaccine expressing both Mtb Ag85A, 
Ag85B and TB10.4 as a fusion protein using a replication deficient Adenovirus (type 35) vector. 
Again, this vaccine also showed strong immunogenic potential in BCG primed individuals and 
also at different test sites [115;116]. This Ad35 based vaccine is currently in a phase IIb trial 
[117]. Importantly, some concerns have been raised over the use of  adenovirus as vaccine vectors 
including the existence of  neutralizing host antibodies that can influence the functioning of  the 
vaccine, which can be avoided by using other viral vectors [118-120]. 
Also different subunit vaccines consisting of  protein and adjuvants are currently studied. 
M72/AS01, consisting of  Rv1196 (PPE18) and Rv0125 (serine protease, pepA) just finished phase 
IIa trial testing and showed to be safe and immunogenic [121;122]. Hybrid 1 (H1) (Ag85B and 
ESAT-6 fusion protein) administered using IC31 as adjuvant induced strong immunity in healthy 
donors and mycobacteria exposed individuals [123;124]. HyVac4 (or H4, consisting of  Ag85B 
and TB10.4 fusion protein) shows immunogenic and protective effects in various animal models, 
and has now entered clinical trials as H4 administered together with IC31 [125]. Of  note, H4 
was developed to avoid H1 vaccine induction of  ESAT-6 responses which interferes with IGRA 
outcome. Other potential subunit vaccines, including H56 (H1 backbone including Rv2660) [126] 
are still in pre-clinical phase e.g.: [127;128]. Instead of  proteins, immunogenic epitopes can be 
combined to form a polyepitope and this also shows vaccine potential [107]. These vaccines can 
be used in heterologous prime-boost settings, thus combining live or attenuated vaccines with 
subunit vaccines to induce optimal protection. 
Early secreted antigens such as ESAT-6 and Ag85 are often selected for TB subunit vaccines, 
based on expression in active replicating Mtb, secretion and strong (in vitro) immunogenicity 











































both ESAT-6 and Ag85B [130]. Nonetheless, the antigens chosen for vaccination should also 
be significantly expressed by Mtb during in vivo infection, preferably over extended periods of  
time, preferably in different phases of  Mtb infection and in both resistant and susceptible host 
backgrounds, such that the vaccine would induce T cells that directly recognize infected cells. This 
will be discussed in the next section.
Knowing Mtb’s lifestyle 
Phases of  Mycobacterium tuberculosis
As already indicated, after infection Mtb is able to reside for decades inside the host without 
causing any clinical symptoms. To accomplish this, Mtb has to evade host induced pressures 
such as nutrient and oxygen shortage, acidic environment, toxic products produced by host 
cells and immune pressure. Influenced by these factors, Mtb encounters a dormant state which 
is characterized by: lipid body loaded, (phenotypic) drug-resistant, non-replicating bacteria with 
low metabolic activity (dormant bacteria) [131;132]. The granuloma will function to contain 
the infection [31]. Most probably both active replicating and dormant bacteria will be present 
during infection [133], but only dormant bacteria are tolerant to drugs and therefore difficult 
to eliminate by antibiotic treatment [16]. For improved diagnosis of  latent Mtb infection and for 
optimal (therapeutic) vaccine development, a better understanding of  Mtb’s lifecycle is of  critical 
importance, particularly better insights in how Mtb adapts to in vivo environment upon infection. 
The change of  Mtb’s genetic and proteomic makeup could have major impact on what antigens 
can be used as vaccine candidates. 
In the beginning of  the 21st century, in vitro Mtb culture studies captured the first differences in 
Mtb’s transcriptomics response by comparing bacteria cultured under different stress conditions 
[134-136]. These studies focused on stress factors that Mtb is thought to encounter upon infection, 
including hypoxia, low pH, nutrient deprivation and free radicals. Oxygen tension is an important 
factor in the activation state of  Mtb as the bacteria prefer to inhabit aerated parts of  the host. 
[137]. Though, the transcriptional analysis showed that Mtb is able to adapt to oxygen depletion, 
to nitric oxide and to carbon monoxide [138-142], environmental conditions which are thought 
to occur within host cells and granulomas. Importantly, hypoxic regions were identified at the 
infection site in vivo [143]. Particularly interesting was the upregulation of  a cluster of  48 genes, 
known as the dormancy regulon (DosR), which is controlled by regulator Rv3133c (DosR or DevR) 
[144;145]. Interestingly, a second set of  genes is expressed at a later stage of  hypoxia, known as the 
enduring hypoxic response (EHR). This set includes ~230 genes (including several DosR genes), 
which are upregulated considerably longer than most of  the genes expressed by the DosR regulon 
[146].
Starvation conditions also trigger differential Mtb gene expression [140;147]. Here, Mtb has 










































carbon sources for energy [148]. Interestingly, a substantial number of  EHR genes overlap with 
genes associated with the starvation response [146]. Indeed, In vivo, Mtb will be exposed to multiple 
stress conditions at once. Dormancy was further simulated by Deb et al. [149] who cultured 
Mtb at low oxygen, high CO2 , acidic pH and low nutrient conditions. This resulted in dormant 
Mtb that had lost acid-fastness, contained lipid inclusion bodies and had become drug tolerant. 
Interestingly, genes encoding enzymes involved in the glyoxylate shunt were significantly expressed 
by Mtb cultured under multiple stress conditions. This cycle plays an essential role in the use of  
fatty acids as carbon source, and is essential for Mtb’s survival in vivo [150]. Thus, this study verified 
the role of  the glyoxylate shunt in stress conditions that Mtb may encounter in vivo [148;151;152]. 
All studies described here, however, mimicked the host environment in in vitro systems, but it would 
be more informative and relevant to directly analyze Mtb’s responses in vivo in infected lung tissue. 
Several studies were performed to analyze Mtb transcripts in vivo (reviewed by Waddell et al. [153]), 
however, no animal models exist that fully resemble human TB disease, although some models 
show several specific TB phenotypes such as hypoxia [143] and lesion/granuloma formation 
[154;155]. Intriguingly, multiple studies show a role for lipid metabolism in in vivo survival of Mtb 
[149;156;157].
Thus Mtb is able to adapt to host environmental conditions and appears to express particular sets 
of  genes in each condition, with some overlap in genes expressed between the different conditions 
identified and investigated. The proteins encoded by these sets of  genes can be considered to 
be expressed in an Mtb infection phase related way, and thus may be of  considerable interest as 
novel subunit vaccine candidates [16;158]. They may have an additional or even superior effect 
compared to antigens that are early secreted only. Indeed, the expression of  Mtb proteins in vivo is 
of  substantial significance as one study showed that upon Mtb infection the expression of  Ag85B 
decreased, resulting in reduced activation of  Ag85B specific T cells [29]. Thus Ag85B based 
vaccines might induce limited protection due to the loss of  Mtb Ag85B expression in chronic 
phase infection. This might also be an explanation for the low efficacy induced by MVA85A 
[112]. The phase related antigens can therefore also be of  use in therapeutic vaccines. A few novel 
Mtb phase related antigens are currently incorporated into TB vaccines. H56 contains next to 
ESAT-6 and Ag85B, also Rv2660, encoded by Rv2660, a gene highly expressed during starvation 
[126]. Furthermore, a polyepitope (consisting of  immunogenic epitopes from Hsp65, Ag85B, 
19Kda lipoprotein, HspX and Rv1733c) contains latency antigens HspX and Rv1733c [107]. 
Both studies revealed protective value of  the vaccines. Lastly, the protective value of  resuscitation 
promoting factor (Rpf) antigens as subunit vaccines was studied [159]. Rpfs are a set of  genes 
encoding proteins suggested to be involved in reactivation or resuscitation of  dormant bacteria. 
Five Rpfs are known in Mtb: RpfA-E (Rv0867c, Rv1009, Rv1884c, Rv2389c and Rv2450c). The 
proteins encoded by these genes resemble the Rpf  protein encoded by Micrococcus luteus, which is 
expressed and secreted by actively replicating M. luteus bacteria. This protein showed to be able to 











































the Mtb specific Rpfs also had a stimulating effect on the growth of  M. luteus and mycobacteria 
[161]. 
Thus understanding Mtb’s lifestyle opens doors to novel vaccine candidates that can be of  
value for both prophylactic and therapeutic vaccination strategies. 
 
Understanding TB immunity
Besides the aforementioned stress conditions, immune pressure is also a hurdle Mtb has to 
encounter. Understanding this is essential for future development of  novel TB vaccines. Vaccine 
induced humoral immunity is a well-known correlate of  protection for many viral vaccines such 
as hepatitis and influenza [162]. However, cell mediated immunity (CMI) is essential in protection 
against Mtb infection. Although the role of  B cells in TB immunity should not be neglected [163]. 
Mtb primarily resides in phagosomes which results in processing and presenting of  Mtb antigens 
via the MHC class II route. 
As previously mentioned, genetic defects in IFN-γ and IL-12 pathways, cytokines specific for 
Th1 differentiation, as well as depletion of  CD4+ T cells showed an increased risk of  tuberculosis 
[49-51;56], confirming that Th1 cells play an important role in TB protection. Analyzing 
Th1 immunity is currently the most common approach to study TB vaccine potential [164]. 
Furthermore, IGRAs are also based on Th1 T cell analysis as antigen-specific IFN-γ production 
is measured. An important role for IFN-γ in Mtb control is activation of  macrophages. Besides 
IFN-γ, other Th1 cytokines are of  importance in protection against TB. As mentioned above, 
patients receiving anti-TNF therapy as treatment against different inflammatory diseases such 
as psoriasis and rheumatoid arthritis, have a higher risk of  developing TB [52;53;165;166], 
indicating the need of  TNF-α in protection against TB. Both IFN-γ and TNF-α activate APC 
antimicrobial effector mechanisms. Although we now know that Th1 immunity is of  particular 
importance, exact insights in TB immune regulation remain limited. In contrast to Th1 cells, Th2 
cells are generally thought not to have protective value in TB infection, and helminth-induced 
Th2 responses can have a detrimental effect on protection against TB [90] and BCG vaccination 
efficacy. Interestingly, a recent mouse model showed that CD4+ T cells can exert protective 
functions even in the absence of  IFN-γ and/or TNF-α [167], indicating that other factors may 
play an important role in protection as well. Indeed, functional, IFN-γ deficient, CD4+ T cells still 
contribute to initial Mtb control [168], however, IFN-γ producing CD4+ T cells are required for 
long-term control [168]. 
The study of  novel T-cell subsets could shed further light upon the continued (though 
suboptimal) protection in the absence of  IFN-γ and/or TNF-α. Multiparameter flowcytometric 
analysis has enabled detection of  multiple markers on immune cells. Such analysis allows detection 
of  multiple T-cell subsets that might play a role in infection and vaccination induced immunity. 
Recent new subsets include Th17 and regulatory T cells [169]. Human IL-1β/IL-6/IL-23 induced 










































also IFN-γ production has been described [169-172]. Vaccine induced Th17 cells were involved 
in TB protection in mice [173]. Specifically, IL-17 plays a role in maturation of  granuloma 
formation [174]. Conversely, Th17 cells can be damaging as repeated antigen exposure results 
in IL-17-dependent lung pathology and enhanced neutrophil influx [175]. Thus, the net effect of  
Th17 cells on TB protection remains unclear. Regulatory T cells (Tregs) are also induced upon 
Mtb infection and are responsible for delayed priming of  CD4+ and CD8+ T cells in the MLN [18] 
and direct suppression of  effector T cell activity [176], thus having an anti-inflammatory effect. 
Therefore, they can be involved in bacterial persistence, next to limitation of  host tissue damage 
[177]. Interestingly, differentiation of  Th17 to Th1 and Treg to Th17 T cell subsets have been 
detected and indicate plasticity of  unstable T-cell subsets [172;178;179]. 
Importantly, Mtb not only resides in the phagosome, but can also translocate to the cytosol, a 
mechanism which is RD1 region dependent [180;181]. Translocation of  mycobacterial products 
to the cytosol enables loading of  immunogenic epitopes to MHC class I and presentation to CD8+ 
T cells, although many other mechanisms might also be involved in MHC-I loading such as 
cross-presentation and efferocytosis [40;182;183]. CD8+ T cells produce multiple cytokines upon 
activation but can exert direct cytotoxic functions as well [31]. In addition to CD4+ T cells, CD8+ 
T cells also contribute to TB protection [184-186]. 
The current belief  is that T cells producing multiple cytokines, chemokines and/or effector 
molecules are more effective compared to single cytokine producing cells. In more detail, T cells 
producing IFN-γ, TNF-α and IL-2 are believed to be of  higher quality compared to double or 
single cytokine producing Th1 T cells and provide optimal protection and effector function [187]. 
In this study, polyfunctional T cells expressing IFN-γ, TNF-α and IL-2 correlated with protection 
against the intracellular pathogen Leishmania major. Subsequently, this was confirmed in mouse 
TB vaccine studies [188-190]. Also, higher frequencies of  polyfunctional T cells were observed in 
LTBI compared to TB patients [191], based on mycobacterial load [192]. However, polyfunctional 
T cells correlated also to active TB disease [193;194]. In addition, several other studies showed 
no correlation of  these cells with vaccination induced protection [195;196]. Interestingly, the 
antigen dose may be of  importance for the development of  protective polyfunctional T cells 
[197]. Furthermore, the duration of  antigen stimulation and cytokine accumulation (due to Golgi 
transport inhibition) also influences the detection of  polyfunctional T cells [198]. Thus, overall, 
the role of  polyfunctional T cells in TB remains unclear. 
Outline of  this thesis
Efforts to decrease the number of  TB cases by using latest Mtb detection methods, treatments and 
BCG vaccination campaigns have failed to result in eradication of  the disease. TB remains one of  
the leading causes of  death on our planet. The main focus of  this thesis is to identify Mtb infection 











































Mtb Rpfs proteins are likely involved in reactivation of  dormant mycobacteria, and thus 
may play an important role in TB disease. We therefore hypothesized that immunity directed 
against Rpf  proteins could play a role in the control of  reactivating bacteria. In chapter 2 T-cell 
responses towards two Mtb resuscitation promoting factors (Rpfs), Rv0867c (RpfA) and Rv2389c 
(RpfD), are described in mycobacterium exposed individuals. 
A second group of  Mtb antigens, DosR antigens, previously was shown to be preferentially 
recognized by LTBI. From this perspective, we hypothesized that enhancing DosR specific 
immunity may be beneficial in controlling LTBI. However, only very few data on the Mtb DosR 
regulon encoded antigen-specific T-cell responses were available. We therefore analyzed the 
precise Mtb DosR antigen responding T cells and determined immunogenic peptide epitopes 
(chapter 3).
The thus far described phase related antigens are all selected from initial in vitro studies 
which tried to mimic environmental stress conditions that Mtb encounters upon infection. We 
hypothesized that Mtb vaccine candidates should be expressed by Mtb in vivo, in infected tissue, and 
therefore analyzed Mtb gene expression profiles in the lungs of  four genetically related but distinct 
mouse strains that represents a spectrum of  TB susceptibility controlled by the super-susceptibility to 
TB 1 locus. The immunogenicity of  a subset of  in vivo expressed Mtb (IVE-TB) antigens, associated 
to Mtb infection phenotypes, was subsequently determined (chapter 4). 
Besides the criterion that vaccine candidates should be expressed in vivo, they should also be 
immunogenic in vivo and provide protection against Mtb infection. To determine the immunogenic 
and protective value of  one of  the IVE-TB antigens, Rv2034, HLA transgenic mice were 
vaccinated with Rv2034 as an experimental TB vaccine as described in chapter 5. 
Studying the Rv2034 specific T-cell responses in more detail, we used a specific CD154 
T-cell cloning method that allows more detailed analysis of  these responses and in addition the 
development of  novel tools to dissect the precise nature of  the IVE-TB specific T-cell response 
(chapter 6). 
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The Mycobacterium bovis BCG vaccine is the only tuberculosis (TB) vaccine available, yet it provides 
limited protection against pulmonary TB in adults and fails to protect against TB reactivation. We 
hypothesized that immunity against Mycobacterium tuberculosis (Mtb) “resuscitation-promoting factors” 
(Rpfs), which are small bacterial proteins that promote proliferation of  dormant mycobacteria, 
may be relevant in the human immune response to Mtb. In previous unpublished work, we found 
that Rpfs Rv0867c and Rv2389c induced interferon gamma (IFN-γ) production in the blood of  
TB patients’ healthy household contacts in several different African populations. Here we examine 
these two dominant Rpf  antigens in more detail and define the nature of  the responding T-cell 
subsets. Multiparameter cytokine profiling showed that Rv2389c and, to a lesser extent, Rv0867c 
were recognized by mycobacterium-responsive healthy Dutch individuals; peptide-scanning 
revealed several epitopes, including a single immunodominant epitope in Rv2389c. Rv0867c and, 
to a lesser extent, Rv2389c Rpf-specific T-cell responses were maintained for decades in long-term 
Mtb non-progressors. Prominent Rv0867c-specific double- and single-cytokine-producing CD8+ 
T-cell subset responses were found, including a large population of  CD8+ effector memory and 
effector T-cell subsets. We conclude that Mtb Rpf  antigens are important targets in the human 












































It is estimated that over 2 billion people are latently infected with Mycobacterium tuberculosis (Mtb) 
and that 5 to 10% of  these individuals will develop active tuberculosis (TB) at one point in their 
lifetime whereas the remainder are able to contain infection long term without developing clinical 
symptoms [1]. During latency, the bacteria are thought to be in a dormant or slowly replicating 
state [2]. The vast reservoir of  individuals with latent infection is a major source of  new TB cases 
due to reactivation and resuscitation of  dormant bacilli [3;4]. 
The term “dormancy” was first introduced by Joseph Warwick Bigger, who discovered that 
a culture of  Staphylococcus pyogenes could not be sterilized after penicillin treatment since there was 
a small group of  antibiotic-resistant bacteria that could be re-grown from such cultures. Bigger 
proposed that these bacteria were dormant, nonreplicating, and thus insensitive to antimicrobials 
targeting bacterial metabolic pathways [5]. 
It is assumed that environmental factors are involved in inducing bacterial dormancy [6]. 
Mtb enters a state of  nonreplicating or slowly replicating persistence when grown under gradual 
oxygen depletion, which is thought to be one of  the stress factors that Mtb encounters upon 
infection [7]. Not only oxygen deprivation, but also low pH, NO, nutrient deprivation and host 
immune pressure are stress factors Mtb is subjected to in the lung granulomatous lesions. In 
response to these stress factors, Mtb decreases its metabolic activity and alters its gene expression 
pattern [6;8;9]. This adaptation results in increased resistance to environmental stress, by means 
of  entering the nonreplicating or slowly replicating persisting state [10].
While several studies have addressed bacterial transition from the replicating to the 
nonreplicating, slowly replicating or dormant state, little is known regarding the cues that induce 
bacteria to reactivate and resume growth from dormancy. Mukamolova et al. were the first to 
discover a resuscitation promoting factor (Rpf), a hormone-like protein secreted by Micrococcus 
luteus (M. luteus). Addition of  this Rpf  protein to dormant M. luteus resulted in resuscitation of  M. 
luteus bacteria [11;12]. Rpf genes were then found to be conserved throughout high-G+C Gram-
positive bacteria, including Mtb. Five such genes were identified in the Mtb genome, notably 
Rv0867c (rpfA), Rv1009 (rpfB), Rv1884c (rpfC), Rv2389c (rpfD) and Rv2450c (rpfE). Each Mtb Rpf  
protein contains an ~70 amino-acid rpf-like domain similar to the M. luteus rpf-encoded protein 
[13]. Mtb Rpfs showed similar properties to M. luteus Rpf, including their ability to resuscitate 
dormant mycobacteria [13;14]. Mtb Rpf  protein expression was observed in vitro in actively 
growing Mtb and in Mycobacterium bovis Bacillus Calmette-Guérin (BCG). Importantly, Mtb rpf gene 
expression was detected in infected murine and human tissue. Moreover, the presence of  Rpf-like 
proteins was shown in Mtb-infected human tissue [13;15-17]. Recently, rpf gene expression was 
analyzed in Mtb cells grown under different physiological stress conditions and growth factors. All 
five rpf  genes were expressed during actively replicating early log-phase growth of  Mtb, confirming 










































in cultures grown under hypoxia, nutrient starvation and acidic conditions and stationary-, 
nonculturable-, and resuscitation-phase-like conditions. These differential adaptive rpf expression 
profiles indicate that Mtb Rpfs likely play different roles [4]. 
While M. luteus Rpf  is essential for M. luteus growth, individual Mtb Rpfs were found to be 
redundant for growth in vitro and in vivo in single-gene-knockout mutants [17;18]. However, when 
multiple rpf deletions were introduced simultaneously in Mtb (∆Rv0867c/∆Rv1009/∆Rv1884c and 
∆Rv0867c/∆Rv1009/∆Rv2389c), a significant loss in the ability of  Mtb to resuscitate was found, 
accompanied by in vitro growth attenuation [19]. 
BCG vaccination is widely used and affords protection from severe forms of  TB in children, 
but it provides only limited and highly variable protection against pulmonary TB in adults and 
does not protect against reactivation. Better TB vaccines are clearly needed [20]. As the Mtb Rpf  
proteins are associated with resuscitation of  mycobacteria, we hypothesized that immunity directed 
against these proteins may play a role in sensing actively replicating Mtb organisms and possibly 
play a role in host immune control of  reactivating bacteria. Only two reports have investigated the 
immunogenicity of  the Mtb Rpf  antigens. One study with mice showed that Rv0867c, Rv1009, 
Rv2389c and Rv2450c were immunogenic [21]. Recently we identified the first human Mtb Rpf-
specific T-cell responses against a subset of  the five Mtb Rpfs in a larger antigen T-cell screening 
[22]. Interferon gamma (IFN-γ) production was detected in tuberculin skin test (TST)-positive 
individuals in response to Rv1009, Rv1884c and Rv2450c and, to a lesser extent, to Rv0867c, 
whereas limited to no IFN-γ was found in TST-negative individuals. Rv2389c, however, was not 
included in this study [22]. 
These two studies indicate a possible role for T-cell responses in detecting Mtb Rpf  antigen 
during Mtb infection. We have, therefore, performed a more detailed analysis studying the 
immunogenicity of  the Rv0867c and Rv2389c Mtb Rpf  proteins in several groups of  mycobacteria-
exposed individuals, including long-term non-progressors. These two antigens were selected based 
on highest recognition of  all 5 rpfs in a cross-sectional cohort study of  HIV-negative, TST- and/
or ESAT6/CFP10-positive household contacts from the Gambia, Uganda, and South Africa 
(BMGF GCGH GC6#74 Biomarkers for TB consortium; http://www.biomarkers-for-tb.net/; 
unpublished results). Of  interest, both Rv0867c and Rv2389c are predicted to be secreted proteins 
(SignalP and TMMHM server Technical University of  Denmark) [23], which may enhance 
availability of  the antigen to the innate immune system. Indeed, Rv0867c protein is present in Mtb 
culture filtrate [24]. Rv0867c and Rv2389c are both expressed in early log-phase-grown Mtb, but 
Rv2389c expression is induced in stationary and noncultivatable phases of  Mtb and during acidic 
conditions, whereas Rv0867c expression appears to be higher in nutrient-starved Mtb culture. 
Both genes are also highly induced during early resuscitation [4]. In the work reported here, 
we (i) identify frequent and significant human T-cell responses against Rv0867c and Rv2389c; 
(ii) identify a series of  novel Mtb rpf  epitopes, including a single dominant peptide epitope in 








































Immunogenicity of  Mtb Rpf  antigens
37
2
T-cell memory responses to Rv0867c and Rv2389c Mtb rpf  proteins in long-term naturally 
protected, Mtb nonprogressors. Based on these data, we propose that rpf  antigens are potentially 
interesting new TB vaccine candidates.
Materials and methods
Study subjects. Blood samples were collected by venipuncture from a group of  Dutch individuals 
including 9 tuberculosis (TB) patients, 10 tuberculin skin test (TST)-positive individuals (indurations 
of  ≥ 10 mm), 10 BCG-vaccinated individuals and 10 non-BCG-vaccinated, TST-negative, healthy 
individuals, as well as 12 Norwegian TST-positive individuals. The Norwegian donor group 
consisted of  elderly people (average 70 years) exposed to TB transmission several decades ago 
without developing any clinical disease and without receiving any treatment. Previously recorded 
TST indurations associated with natural conversion ranged from 12 to 60 mm (average 18 mm). 
Recent Interferon gamma (IFN-γ) release assay (IGRA) testing with the Quantiferon Gold in-tube 
test showed that 9 of  12 donors in this category were positive. All donors gave written consent 
before blood donation. The study protocol (P207/99) was approved by the Institutional Review 
Board of  the Leiden University Medical Center and the Regional Committees for Medical and 
Health Research Ethics in Norway. Peripheral blood mononuclear cells (PBMCs) were isolated 
from heparinized venous blood by Ficoll density gradient centrifugation and stored in liquid 
nitrogen until further use. 
Recombinant proteins. Recombinant proteins were produced as previously described [25]. 
Briefly, Mtb genes were amplified by PCR from genomic H37Rv DNA and cloned by Gateway 
technology (Invitrogen, Carlsbad, CA, USA) in a bacterial expression vector containing a histidine 
tag at the N-terminus. Vectors were over-expressed in Escherichia coli BL21(DE3) and purified. 
The size and purity of  recombinant proteins were analyzed by gel electrophoresis and Western 
blotting with an anti-His antibody (Invitrogen, Carlsbad, CA, USA) and an anti-E. coli polyclonal 
antibody (a kind gift from the Statens Serum Institute (SSI)). Endotoxin contents were below 50 
IU/mg recombinant protein, as tested using a Limulus Amebocyte Lysate (LAL) assay (Cambrex, 
East Rutherford, NJ). All proteins were tested in lymphocyte stimulation assays in order to exclude 
antigen-nonspecific T-cell stimulation and cellular toxicity by using PBMCs of  in vitro purified protein 
derivative (PPD)-negative healthy Dutch donors [26]. PPD of  M. tuberculosis was purchased from 
SSI, Copenhagen, Denmark. 
Synthetic peptides. Peptides (20-mers overlapping 10 amino acids) were produced at the 
Leiden University Medical Center (LUMC) facility by simultaneous multiple-peptide synthesis 
as described previously [27]. Homogeneity and purity were confirmed by analytical reversed-
phase high-pressure liquid chromatography, and mass spectrometry showed the expected masses. 










































Lymphocyte stimulation assay. PBMCs (1.5×105/ well) were cultured in triplicate in 96-wells 
round-bottom plates (Nunc, Roskilde, Denmark) and incubated with or without protein (10 μg/
ml) in AIM-V medium (Invitrogen, Breda, The Netherlands) at 37°C, 5% CO2. After 6 days 
supernatants were harvested and used for cytokine and chemokine profiling. 
Cytokine and chemokine profiling. Levels of  cytokines (IFN-γ, interleukin-1β (IL-1β), 
interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α)) were analyzed using the Lincoplex® 
kit (Millipore) according to the Milliplex™ Map protocol. Plates were analyzed using a BioPlex 
array reader with Bio-Plex software (Bio-Rad Laboratories, Veenendaal, The Netherlands).
Generation of  antigen-specific T-cell lines. T-cell lines were generated as previously 
described [28]. PBMCs (2x106 cells/well) from cured TB patients or TST-positive or BCG-
vaccinated individuals were cultured in 24-well plates in the presence of  protein (2 to 10 μg/
ml) in IMDM medium (Gibco, Paisley, UK) supplemented with 50 U/ml penicillin, 50 μg/ml 
streptomycin (Gibco, Paisley, UK) and 10% pooled human serum at 37 °C, 5% CO2. At day 6, 
recombinant-interleukin-2 (rIL-2) (Cetus, Emeryville, CA, USA) was added to the cell cultures in 
a final concentration of  25 U/ml. Cultures were maintained for an additional 2 to 3 weeks in the 
presence of  rIL-2. T cells were harvested and stored in liquid nitrogen until further use. 
T-cell proliferation of  antigen-specific T-cell lines. Thawed T-cell lines were cultured in 
triplicate in 96-wells flat-bottom plates (1.5×104/well) together with HLA-DR-matched irradiated 
(2000 rad) PBMCs (5×104/well) with or without protein (10 μg/ml) or peptide (10 μg/ml) at 37 °C 
5% CO2. After 3 days, supernatants were harvested and stored at -20 °C. Cells were pulsed for an 
additional 18 hours with [3H]thymidine (0.5 µCi/well), harvested, and counted on a Microbetaplate 
counter (Wallac Turku, Finland) [29]. A stimulation index (SI) of  ≥ 3 was considered positive.
IFN-g ELISA. The concentration IFN-g in supernatants was measured by enzyme-linked 
immunosorbent assay (ELISA) (U-CyTech, Utrecht, The Netherlands) according to the 
manufacturer’s instructions. The detection limit of  the assay was 20 pg/ml IFN-γ. Samples were 
tested in duplicate. An IFN-g response ≥ 100 pg/ml was considered positive.
Flow cytometric analysis. PBMCs were thawed and rested. After 24 hours, PBMCs were 
stimulated for 16 hours with protein (10 μg/ml) in the presence of  co-stimulatory antibodies anti-
CD28 and anti-CD49d (Sanquin, Netherlands and BD Biosciences, respectively). Brefeldin A (3 
μg/ml; Sigma) was added after the first 4 to 6 hours. Cells were stained for 30 minutes at 4 °C using 
the following surface markers; anti-CD3-Pacific blue (PB), anti-CD4-peridinin chlorophyll protein 
(PercP)-Cy5.5, anti-CD8-AmCyan, anti-CD25-allophycocyanin (APC)-Cy5, anti-CD45RA-
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anti-IFN-γ-Alexa 700, anti-TNF-α-APC, anti-IL-2-PE and anti-CD69-fluorescein isothiocyanate 
(FITC) (BD Biosciences) by using the Intrastain kit (Dako Cytomation, Denmark). Samples were 
acquired on an LSR II flow cytometer and analyzed using SPICE (software provided by Dr. M. 
Roederer, National Institute of  Allergy and Infectious Disease) and FlowJo software (Treestar Inc, 
Ashland, OR, USA). Cell populations should contain at least 100 events.
Statistical analyses. Differences between groups were analyzed with the non-parametrical 
Kruskal-Wallis test in GraphPad Prism (version 4). P values were corrected for multiple 
comparisons. The statistical significance level used was P <0.05.
Results
Recognition of  Mtb Rpf  antigens by T cells from Mtb-responsive individuals
To determine the immunogenicities of  both Rv0867c and Rv2389c, we investigated whether 
these two Mtb Rpf  proteins were recognized by PBMCs of  mycobacterium-exposed individuals. 
PBMCs from four groups of  Dutch individuals were tested: (i) HIV-negative, treated tuberculosis 
patients (TB; n = 9); (ii) tuberculin skin test (TST)-positive individuals (TST; n = 10); (iii) BCG-
vaccinated individuals (BCG; n = 10); and (iv) non-BCG-vaccinated, TST-negative and in vitro 
purified-protein-derivative (PPD)-negative healthy controls (HCs; n = 10). The secretion of  four 
cytokines (IFN-γ, IL1-β, IL-6 and TNF-α) was analyzed as a multiparameter read out of  antigen-
specific responses. 
As expected, IFN-γ production in response to PPD was low in healthy individuals, whereas the 
TST+ individuals and TB patients showed high responses to PPD, by both IFN-γ and the other 
cytokines analyzed. The BCG-vaccinated individuals showed intermediate levels of  responses 
(Figure 1A to D).
While minor IFN-γ levels were detectable in the three mycobacterium-exposed groups in 
response to Rv0867c, higher levels were found in response to Rv2389c (HCs and BCG; P < 
0.05). The healthy controls did not respond to Rv0867c and Rv2389c (Figure 1A). No IL-1β 
was produced upon Rv0867c stimulation in any of  the four groups analyzed; however, Rv2389c 
stimulation induced production of  IL-1β in all mycobacterium-exposed groups (HCs and TB; P 
< 0.05), but not in the healthy controls (Figure 1B). Rv0867c stimulation also induced IL-6 in all 
three mycobacterium-exposed groups, but not in the healthy individuals (HCs, TST, and TB P < 
0.05). In contrast to Rv0867c, Rv2389c induced high levels of  IL-6 in the HC group but much 
higher levels in the mycobacterium-exposed individuals (HCs and TB; P < 0.05) (Figure 1C). 
Rv2389c stimulation induced also high levels of  TNF-α, especially within the mycobacterium-
exposed groups (HCs and TB P < 0.05), while Rv0867c induced only limited levels of  TNF-α in 










































Figure 1. Cytokine and chemokine profiling. PBMCs from healthy individuals (HC; n = 10), BCG-
vaccinated individuals (BCG; n = 10), TST-positive individuals (TST; n = 10) and TB patients (TB; n = 9) 
were stimulated with Rv0867c and Rv2389c proteins and PPD for 6 days. Levels of  IFN-γ (A), IL-1β (B), IL-6 
(C) and TNF-α (D) were measured and corrected for background levels. Horizontal bars represent median 
cytokine production levels. Antigen stimuli: Rv0867c open circles (○), Rv2389c closed circles (●) and PPD 
inverted closed triangles (▼) * Background not corrected.
Overall, the mycobacterium-exposed individuals produced the highest levels of  cytokines upon 
Rv0867c and Rv2389c stimulation, and TB patients were often the highest responders to Rv2389c 
(HCs and TB; P < 0.05 for IL-1β, IL-6 and TNF-α). Rv2389c was more strongly recognized than 
Rv0867c, which induced no or low levels of  cytokines. 
 
Identification of  immunogenic peptides of  Mtb Rpf  proteins
To further characterize the Rpf-specific responses observed above, five CD4+ T-cell lines specific 
for Rv0867c and five CD4+ T-cell lines specific for Rv2389c were generated. These T-cell lines 
were tested for recognition of  all individual 20-mer peptides (overlapping by 10 amino acids) 
(see Supplementary Table S1A and B) and both IFN-γ production and T-cell proliferation were 
measured. Table 1 shows the recognition pattern of  the Rpf  peptides by the Rv0867c and Rv2389c 
antigen-specific T-cell lines examined. All T-cell lines responded to the corresponding Rpf  protein 
and to one or more of  the proteins’ corresponding individual peptides. The Rv0867c-specific 
T-cell lines recognized many different peptides ranging from 1/5 to 4/5 of  the donors. Four out of  
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peptide P761-80. In contrast to Rv0867c-specific T cells, all Rv2389c-specific T-cell lines recognized 
only a single peptide, P12111-130.
Table 1. CD4+ antigen-specific T-cell responses to single peptides of  Mtb Rpf  proteins a
rpf  protein 
peptide number of  responding T-cell lines
 p1 1-20   
 p2 11-30   
 p3 21-40   n = 0
 p4 31-50   n = 1
 p5 41-60     n = 2
 p6 51-70   n = 3
 p7 61-80    n = 4
 p8 71-90    n = 5
 p9 81-100   
 p10 91-110   
 p11 101-120   
 p12 111-130   
 p13 121-140   
 p14 131-150   
 p15 141-160  
 p16 151-170
 p17 161-180  
 p18 171-190  
 p19 181-200  
 p20 191-210  
 p21 201-220  
 p22 211-230  
 p23 221-240  
 p24 231-250  
 p25 241-260  
 p26 251-270






 p33 321-340  
 p34 331-350  
 p35 341-360  
 p36 351-370 
 p37 361-380
 p38 371-390  
 p39 381-400
 p40 388-407  



















































Characterization of  Mtb Rpf-specific polyfunctional T cells in long-term Mtb non-
progressors 
We next investigated T-cell responses to Rv0867c and Rv2389c antigens in a cohort of  long-
term Mtb non-progressors, which had been infected several decades ago but had never developed 
any signs of  active TB. We analyzed responsive CD4+ and CD8+ T-cell subsets producing 
IFN-γ, TNF-α and/or IL-2 by multiparameter flow cytometry. Polyfunctional T cells have been 
associated with protection following vaccination [30], but the situation in human infection is 
more complex, as polyfunctional T cells are also found in active TB patients [3]. In any case, the 
memory T-cell subsets responding to Rv0867c or Rv2389c was analyzed using PBMCs from long-
term nonprogressors (n = 12) and PPD-negative HCs (n = 11). 
Figure 2A shows that the Rv0867c protein induced polyfunctional T cells with different cytokine 
profiles (triple-positive (IFN-γ+ TNF-α+ IL-2+) or double-positive (IFN-γ+ TNFα+, TNFα+ IL-2+ 
and IFN-γ+ IL-2+) cells). Such polyfunctional T cells were detected in 9 out of  the 12 long-term 
latently infected individuals. Strikingly, higher frequencies of  polyfunctional CD8+ T cells (ranging 
between 0.20 and 9.72%) were observed, exceeding those of  CD4+ T cells (ranging between 0.21 
and 1.29%). Only 2 out of  12 donors showed polyfunctional CD8+ T cells recognizing Rv2389c, 
typically with a lower frequency (ranging between 0.24 and 0.82%) (Figure 2C). Single-cytokine-
producing CD4+ and CD8+ T cells were observed for both Rv0867c and Rv2389c, where IFN-γ+ 
CD4+ T cells are the most prominent T-cell subset of  all single-cytokine-producing T cells. No 
polyfunctional T cells were induced within the negative healthy control population upon Rv0867c 
stimulation, although for unknown reasons, low numbers of  IL-2+ single-positive cells were seen 
(Figure 2B). Some low frequencies of  polyfunctional and single-positive T cells were observed 
upon Rv2389c stimulation within the healthy control group (Figure 2D), but lower than those in 
the latently infected group. 
Figure 2E shows the proportions of  polyfunctional and single-positive CD4+ and CD8+ T 
cells for Rv0867c, as this antigen was the best recognized in this cohort. IFN-γ+ TNF-α+ double-
cytokine-producing CD8+ polyfunctional T cells were the most prominent polyfunctional T-cell 
subset identified. 
In addition, we analyzed the expression of  the T-cell memory markers CCR7 and CD45RA 
in these IFN-γ+ TNF-α+ double-cytokine-producing CD8+ T cells in the Rv0867c responders. 
After dividing the responding T-cells into central memory (Tcm) and effector memory (Tem) T-cell 
subsets (according to Seder et al. [31;32]), we found that Rv0867c-responding IFN-γ+ TNFα+ CD8+ 
T cells consisted mostly of  effector memory (CCR7- and CD45RA-) and effector (Teff) (CCR7- 
and CD45RA+) T-cell subsets (Figure 2F). These data show the presence of  Rv0867c-specific 
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Figure 2. Frequency of  antigen-specific polyfunctional T cells in long-term Mtb nonprogressors. 
Shown is the frequency of  antigen-specific CD4+ and CD8+ T cells in long-term latently infected elderly 
subjects (n = 12), producing combinations of  IFN-γ, TNF-α and IL-2 after stimulation for 16 hours with 
Rv0867c (A) or Rv2389c (C) protein. Healthy individuals were also analyzed for their polyfunctional responses 
to Rv0867c (B) and Rv2389c (D). CD4+ T cells are indicated as closed circles (●) and CD8+ T cells as open 
circles (○). Horizontal bars represent the median frequency of  antigen-specific CD4+ and CD8+ T cells. Slices 
in pie chart represent the fraction of  single (blue)-, double (green)-, or triple (red)-positive CD4+ and CD8+ T 
cells for Rv0867c (E). Expression of  T-cell memory markers CCR7 and CD45RA was analyzed and shown 
for the largest T-cell population identified: Rv0867c-specific IFN-γ and TNF-α double-positive CD8+ T cells 
(F). Effector memory T cells are CCR7- and CD45RA-, central memory T cells are CCR7+ and CD45RA-, 
naive T cells are CCR7+ and CD45RA+, and effector T cells are CCR7- and CD45RA+.
Besides the quantity of  the T-cell response, the quality of  the T-cell response plays an 
important role in protection. We therefore also measured the median fluorescence intensity (MFI) 
of  each cytokine produced by the Rv0867c-responsive T cells. Multiplication of  the frequency 
by the MFI results in an integrated MFI (iMFI) value, which was introduced previously as a 
quantitative parameter of  the overall functionality of  the T-cell response analysed [30]. The MFI 
values showed that the triple-positive T cells had the highest MFI values, followed by the double-










































not shown). However, when iMFI values were analyzed, the IFN-γ iMFI was the highest intensity 
within the IFN-γ+ TNF-α+ double-positive CD8+ T-cell population, followed by IFN-γ+ single-
cytokine-producing T cells (Figure 3A). This was also observed for TNF-α iMFI (Figure 3B). Taken 
together, these results indicate that double- and single-positive T cells contribute quantitatively 
more to the Mtb Rpf  Rv0867c antigen response in long-term non-progressors than triple-positive 
T cells. 
Figure 3. Integrated mean fluorescence intensity (iMFI) of  IFN-γ-, TNF-α- and/or IL-2-
producing CD8+ T cells. Shown is a box and whisker plot representing the iMFI values of  CD8+ T 
cells from long-term nonprogressors (n = 8) in response to Rv0867c protein. iMFI is the product value of  
multiplication of  the frequency of  CD8+ T cells with the indicated (poly- or mono-) cytokine profiles with the 
MFI of  IFN-γ (A) and TNF-α (B) produced by these T-cell subsets. The horizontal line represents the median, 
the lower boundary of  the box represents the 25th percentile, and the upper boundary represents the 75th 












































New TB vaccines are urgently needed to help control the TB pandemic. Both prophylactic and 
postexposure vaccines are considered important [33], but the antigens that can best be incorporated 
in such vaccines have been identified incompletely at best. Previously we have shown that 
dormancy-related or DosR regulon-encoded Mtb antigens, which are expressed during hypoxia 
and nitric oxide stress, were preferentially recognized by TST-positive individuals, suggesting an 
association with control of  infection [22;34;35]. Unexpectedly, BCG vaccination failed to induce 
responses to these antigens in humans and mice, even though BCG is able to express the DosR 
regulon under hypoxia conditions in vitro [26]. In contrast to the DosR regulon-encoded antigens, 
rpf genes Rv0867c and Rv2389c are expressed by actively replicating early log-phase-grown Mtb 
[4]. Rv0867c and Rv2389c share the M. luteus Rpf  protein’s property in being able to resuscitate 
dormant mycobacteria. We therefore hypothesized that immunity directed against these proteins 
may play a role in sensing and detecting actively resuscitating and replicating Mtb organisms and 
therefore possibly also in host immune control of  reactivating bacteria. 
We observed significant differences in levels of  Rv0867c and Rv2389c recognition between 
mycobacterium-exposed vs. PPD-negative individuals, yet some Rv2389c and, to a lesser extent, 
Rv0867c responses were found in the healthy PPD-nonresponding group. We have previously 
reported a similar recognition pattern for some Mtb dosR regulon-encoded antigens by PPD-
nonresponding donors. We explained these results by cross-reactive immunity to nontuberculous 
mycobacteria (NTM) which share large parts of  the DosR regulon with Mtb and M. bovis BCG 
[36]. Antigen contaminants (E.coli products) are less likely to be involved, since our recombinant 
proteins are standard quality control (QC) tested on cells from 4 to 5 PPD-negative donors and 
released only when no IFN-γ is produced. A BLAST search (http://www.ncbi.nlm.nih.gov/blast/) 
of  the Mtb Rv0867c and Rv2389c Rpf  protein sequences indeed showed protein sequence identity 
in several NTM and nonmycobacterial environmental bacteria (Table 2). Part of  the immunogenic 
peptides identified in our current study are indeed conserved in the identified protein sequences 
of  the species shown in Table 2 (P541-60 of  Rv0867c CE*GGNW*INT and P12111-130 of  Rv2389c 
TQG*GAWP*C), compatible with cross-reactivity at the polyclonal T-cell level.
To more precisely investigate the function and phenotype of  Rv0867c- and Rv2389c specific 
T-cell subsets, we analyzed the presence of  mono- and polyfunctional CD4+ and CD8+ T cells in 
PBMCs of  latently infected individuals who had been infected decades ago without developing 
TB. In the Dutch cohort above, we had identified Rv2389c as the best-recognized antigen, whereas 
in the long-term Mtb nonprogressors Rv0867c induced higher frequencies of  polyfunctional and 
single-positive T cells. This difference might be attributable to the type and/or longevity of  the 
infection as Mtb is more likely to be chronic than NTM infections, and Mtb might be a stronger 










































Table 2. Mtb rpf  protein sequence identity in NTM and nonmycobacterial environmental 
bacteria
Strain % protein sequence identity to 
Mtb Rpf  antigen a
Rv0867c Rv2389c
NTM
   Mycobacterium marinum M 88 55
   Mycobacterium ulcerans Agy99 88 54
   Mycobacterium avium subsp. Paratuberculosis K10 84 49
   Mycobacterium sp. strain MCS 76 55
   Mycobacterium vanbaalenii PYR-1 76 52
   Mycobacterium smegmatis MC2 155 78 57
   Mycobacterium avium 104 83 59
   Mycobacterium bovis BCG 100 100
Nonmycobacterial environmental bacteria
   Nocardia farcinica IFM 10152 62 58
   Rhodococcus jostii RHA1 61 56
   Streptomyces avermitilis MA-4680 56 45
   Streptomyces coelicolor A3(2) 70 43
   Corynebacterium jeikeium K411 54 52
   Corynebacterium diphtheriae NCTC 13129 55 45
   Corynebacterium glutamicum ATCC 13032 55 54
a H37Rv Rpf  protein sequences were compared to nontuberculous mycobacteria and nonmycobacterial 
environmental bacterial strains by BLAST searches (http://www.ncbi.nlm.nih.gov/blast/). The percentage 
of  protein sequence identity is given per antigen and species. For analysis, a cutoff value of  40% was used.
Among the polyfunctional antigen-specific T cells present in the long-term nonprogressors, 
predominantly Rv0867c-specific CD8+ were identified, particularly double-producing IFN-γ+ 
TNF-α+, Tem and Teff cells with high iMFI. This suggests that these two Rpf-specific CD8+ 
T-cell subsets may play a significant role in TB infection, next to triple-positive T cells. Of  
interest, IFN-γ+ TNFα+ double-positive CD8+ T cells were also found following vaccination with 
AERAS-402 vaccine, containing Ag85A, Ag85B, and TB10.4 antigens as a BCG boost, and these 
cells persisted over time [37]. Overall, CD8+ T cells are important in controlling Mtb infection, 
and the identification of  prominent populations of  Rv0867c-specific CD8+ T cells supports this 
notion. Nevertheless, relatively little is known about these antigen-specific polyfunctional CD8+ T 
cells and their role in protection [38]. 
Rv0867c-specific, IFN-γ+ TNF-α+ double-cytokine-producing CD8+ T cells were mainly Tem 
and Teff cells. These high CD8+ Tem en Teff subset responses to Rv0867c in the long-term Mtb 
nonprogressors do not seem to correspond to the hypothesis that after clearance of  infection Tem 
populations gradually wane, resulting mainly in long-lived Tcm cells [39]. A recent study showed 
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individuals may be continuously reexposed to Rpf  antigens expressed by either endogenous 
uncleared Mtb organisms or by other environmental bacteria expressing cross-reactive Rpf-like 
antigens, which boost Rv0867c-specific Tem cells [40]. Regardless, Rv0867c Mtb Rpf  antigen 
is recognized in long-term Mtb nonprogressors, indicating that Rpf-specific T-cell responses are 
maintained for decades after the initial Mtb infection. Of  note, the immune system changes with 
aging. Fewer naïve T-cells will be available during aging as a result of  thymic involution. However, 
CD8+ Tcm, Tem, and Teff cells accumulate with age [41;42]. These data are in agreement with 
our Tem and Teff findings in our elderly population (average age, 70 years). 
Besides CD8+ T cells, also a minor proportion of  polyfunctional CD4+ T cells was observed 
(Figure 2E). Although previous results have indicated that triple-positive polyfunctional CD4+ 
T cells can be induced by BCG vaccination, they are also clearly present in TB patients, such 
that they do not necessarily correlate with protection against developing disease [3]. Minor but 
significant proportions of  triple-positive CD4+ polyfunctional T cells were identified in our work 
reported here. 
We conclude that Mtb Rv0867c and Rv2389c Rpf  antigens are immunogenic in humans, 
as evidenced by antigen-specific cytokine production and high frequencies and iMFI values. 
Both single- and double-cytokine-producing Rv0867c-specific CD4+ and CD8+ T cells were 
identified in long-term latently infected individuals who did not develop TB. By directing T-cell 
responses to Mtb Rpf  antigens it may be possible to enhance immune surveillance of  reactivating 
and resuscitating Mtb bacilli, and thereby help to control TB reactivation, which is the major 
complication in latent TB that keeps fuelling the TB pandemic. 
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Supplementary Table 1. Overlapping peptide sets of  Mtb Rpf  antigens.
S1A Overlapping peptide set of  Rv0867c   S1B Overlapping peptide set of  Rv2389c   
Peptide Rv0867c Position Peptide Rv2389c Position
Number aa sequence start-end Number aa sequence start-end
1 MSGRHRKPTTSNVSVAKIAF 1-20 1 MTPGLLTTAGAGRPRDRCAR 1-20
2 SNVSVAKIAFTGAVLGGGGI 11-30 2 AGRPRDRCARIVCTVFIETA 11-30
3 TGAVLGGGGIAMAAQATAAT 21-40 3 IVCTVFIETAVVATMFVALL 21-40
4 AMAAQATAATDGEWDQVARC 31-50 4 VVATMFVALLGLSTISSKAD 31-50
5 DGEWDQVARCESGGNWSINT 41-60 5 GLSTISSKADDIDWDAIAQC 41-60
6 ESGGNWSINTGNGYLGGLQF 51-70 6 DIDWDAIAQCESGGNWAANT 51-70
7 GNGYLGGLQFTQSTWAAHGG 61-80 7 ESGGNWAANTGNGLYGGLQI 61-80
8 TQSTWAAHGGGEFAPSAQLA  71-90 8 GNGLYGGLQISQATWDSNGG 71-90
9 GEFAPSAQLASREQQIAVGE 81-100 9 SQATWDSNGGVGSPAAASPQ 81-100
10 SREQQIAVGERVLATQGRGA 91-110 10 VGSPAAASPQQQIEVADNIM 91-110
11 RVLATQGRGAWPVCGRGLSN 101-120 11 QQIEVADNIMKTQGPGAWPK 101-120
12 WPVCGRGLSNATPREVLPAS 111-130 12 KTQGPGAWPKCSSCSQGDAP 111-130
13 ATPREVLPASAAMDAPLDAA 121-140 13 CSSCSQGDAPLGSLTHILTF 121-140
14 AAMDAPLDAAAVNGEPAPLA 131-150 14 LGSLTHILTFLAAETGGCSG 131-150
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More than 2 billion individuals are latently infected with Mycobacterium tuberculosis (Mtb). Knowledge 
of  the key Mtb antigens and responding T-cell subsets mediating protection against Mtb is critical 
for developing improved tuberculosis (TB) vaccines. We previously reported that Mtb DosR-
regulon-encoded antigens are recognized well by human T cells in association with control of  Mtb 
infection. The characteristics of  the responding T-cell subsets, however, remained unidentified. 
We have therefore studied the cytokine production and memory phenotypes of  Mtb DosR-regulon 
encoded antigen-specific T cells from individuals who had been infected with Mtb decades ago, 
yet never developed TB (long-term latent Mtb-infected individuals). Using multi-parameter flow 
cytometry and intracellular cytokine staining for IFN-γ, TNF-α and IL-2, we found double 
and single cytokine producing CD4+ as well as CD8+ T cells to be the most prominent subsets, 
particularly IFN-γ+ TNF-α+ CD8+ T cells. The majority of  these T cells comprised effector 
memory and effector T cells. Furthermore, CFSE labeling revealed strong CD4+ and CD8+ T-cell 
proliferative responses induced by several ”immunodominant” Mtb DosR antigens and their 
specific peptide epitopes. These findings demonstrate the prominent presence of  double- and 
monofunctional CD4+ and CD8+ T-cell responses in naturally protected individuals and support 












































Host defense against mycobacteria critically depends on effective innate and adaptive immunity, 
culminating in the activity of  Mycobacterium tuberculosis (Mtb)- specific T cells and in the formation 
of  granulomas that contain Mtb bacilli. Both CD4+ and CD8+ T-cell responses are involved, and it 
is undisputed that Th1- and Th17-like cytokines (IL-12, IFN-γ, TNF-α and IL-17) are crucial for 
optimal host immunity [1;2]. Tuberculosis (TB) continues to claim almost 2 million lives each year, 
and causes active (infectious) TB disease in over 9 million new cases per annum. Control of  TB is 
further impeded by the strong increase in TB morbidity and mortality due to HIV co-infection, 
and the rise of  multi-drug resistant and extensively drug-resistant Mtb strains [3]. At least 2 billion 
people are latently infected with Mtb, representing a huge reservoir of  latently infected individuals 
from which most new TB cases arise. While 90-98% of  all Mtb-infected individuals are able to 
contain infection asymptomatically in a latent state, 2-10% of  these Mtb-infected individuals will 
progress towards developing TB during their lifetime.
Despite strong international efforts in TB vaccine development, Mycobacterium bovis Bacillus 
Calmette-Guérin (BCG) continues to be the only available TB vaccine. BCG vaccination induces 
effective protection against severe TB in young children and protects against leprosy, but does 
not provide sufficient protection against the severe and contagious form of  TB; pulmonary TB 
in adults [4;5]. Moreover, BCG does not protect against TB reactivation later in life. Ideally, not 
only improved preventive vaccines with pre-exposure activity but also therapeutic vaccines with 
post-exposure activity during late-phase infection are urgently required [2;6]. Such vaccines 
should prevent reactivation of  TB from latency by inducing and maintaining robust immunity 
to Mtb antigens that are expressed by persisting Mtb bacilli during latent infection. Such immune 
responses may not only help controlling but perhaps also eradicating persisting bacilli. 
Work from our group has shown that several genes from the recently identified Mtb DosR 
(Rv3133c) regulon encode particular antigens that induce significant T-cell responses in Mtb-
infected individuals (latently infected or active TB disease) [7]. This 48-gene DosR-regulon is 
expressed by Mtb during in vitro exposure to hypoxia, low-dose nitric oxide and carbon monoxide, 
conditions thought to be encountered by Mtb in vivo when persisting in immunocompetent hosts 
[8]. Approximately half  of  the Mtb dosR-regulon genes are also expressed over prolonged periods 
of  time in a related stress model, the enduring hypoxia response model [9]. Of  note, immunity 
to Mtb DosR-regulon-encoded antigens is associated with control of  latent Mtb infection, as 
several DosR-regulon-encoded antigens are preferentially recognized by individuals with latent 
Mtb infection [7;10;11]. Thus, enhancing immune responses to these antigens might contribute 
towards controlling persistent Mtb infection with the potential to help preventing reactivation TB 
disease. 
The precise nature of  the human T-cell response to Mtb DosR-regulon-encoded antigens has 










































to Mtb DosR antigens, but the major cellular source(s) of  the produced IFN-γ have not been 
identified, neither was concomitant production of  other cytokines assessed [7;12-14]. 
In this study we show that Mtb DosR-regulon-encoded antigens induce antigen and peptide 
specific, double and single cytokine producing CD4+ and CD8+ T cells in elderly persons who had 
been infected with Mtb decades ago in the pre-antibiotic era, yet never developed TB (designated 
here as long-term latent Mtb-infected individuals, (ltLTBIs)). Among the responding cells, IFN-
γ+TNF-α+ CD8+ T cells were highly prevalent, the majority being effector memory (CCR7-
CD45RA-) or effector (CCR7-CD45RA+) T cells. Furthermore, a register of  peptide epitopes 
recognized by both CD4+ and CD8+ T cells was identified for several Mtb DosR-regulon-encoded 
antigens, which are potently recognized in humans [7]. Collectively, these results underscore the 
importance of  Mtb DosR antigens and their association with control of  latent Mtb infection. 
Materials and methods 
Study subjects. We studied PBMCs derived from a Norwegian group that had been exposed to 
Mtb decades ago, but had never developed TB despite lack of  any treatment. This population was 
designed as long-term LTBI (ltLTBIs) (n = 13). Their ages ranged from 62 to 74 years (average 70 
years) with tuberculin skin test indurations ranging from 12 to 60 mm (average 18 mm). About 77% 
(10/13) of  the Norwegian donors tested positive for Quantiferon® TB Gold (Cellestis Carnegie, 
Victoria, Australia). PBMCs of  healthy PPD negative (PPD-) blood bank donors were used as 
negative controls. Donors were considered PPD- when IFN-g responses to PPD was < 100 pg/
ml. For the second study, buffy coats from 21 in vitro PPD responsive (PPD+) healthy anonymous, 
HLA-typed blood bank donors were included. PPD responding donors were considered positive 
when IFN-g responses (corrected for background values) to PPD exceeded 100 pg/ml, in line 
with our previous studies [7;15;16]. Buffy coats were used since the number of  cells derived from 
that source allowed us to perform experiments in which the Mtb DosR antigen and all single 
peptides could be tested simultaneously. All donors were HIV-negative and written informed 
consent was obtained prior venipuncture. The study protocol (P207/99) was approved by the 
Regional Committees for Medical and Health Research Ethics in Norway and the Institutional 
Review Board of  the Leiden University Medical Center. PBMCs were isolated by standard Ficoll 
density gradient centrifugation using Leucosep® tubes (Greiner Bio-one, Alphen aan den Rijn, 
The Netherlands). PBMCs were collected and stored in liquid nitrogen until use. 
Mtb recombinant antigens and synthetic peptides. Recombinant proteins were produced 
as described previously [17]. In short, PCR was used to amplify the selected Mtb H37Rv genes from 
genomic H37Rv DNA. The PCR products were cloned using Gateway Technology (Invitrogen, 
San Diego, CA, USA) and were subsequently sequenced. Escherichia coli strain BL21 (DE3) was 
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previously [17]. All recombinant proteins were tested in quality control assays including, size and 
purity check, determination of  residual endotoxin levels as well as non-specific T-cell stimulation 
and cellular toxicity in lymphocyte stimulation assays [16]. PPD (batch RT49) was purchased from 
Statens Serum Institute (Copenhagen, Denmark).
Synthetic peptides were synthesized as previously described [18]. Peptides from Mtb DosR 
antigens Rv1733c, Rv2029c, Rv2031c and control antigen Ag85B were 20-mers peptides with 10 
aa overlap, except peptides 20-22 of  Ag85B which were 15-mers with 10 aa overlap (Supplementary 
Table S1A-D). The 20-mer peptides of  Rv1733c and Rv2029c were elongated with two lysine (K) 
residues at the C-terminal to improve solubility. The HLA-A*0201-restricted, HIV-1 p17 Gag77–85
 
epitope (SLYNTVATL) was used as control peptide [19]. 
Functional T-cell analysis. T-cell phenotype analysis was performed as previously described 
[20]. In brief, PBMCs were stimulated for 16 hours with protein (10 μg/ml) or peptide pools 
(5 μg/ml) in the presence of  co-stimulatory antibodies anti-CD28/anti-CD49d (Sanquin, The 
Netherlands and BD Biosciences respectively). After 4-6 hours, Brefeldin A (3 μg/ml; Sigma) was 
added to the culture. Cell surface staining was performed for the following markers; CD3-PB, 
CD4-PercP/Cy5.5, CD8-AmCyan, CD45RA-PE/Cy5, CD25-APC/Cy7 and CCR7-PE/Cy7. 
Subsequently, intracellular markers were stained with IFN-γ-Alexa700, TNF-α-APC, IL-2-PE and 
CD69-FITC (BD Biosciences) using Intrastain kit (Dako Cytomation, Denmark). Samples were 
acquired on an LSRII. CD4+ and CD8+ populations of  ≥ 2 x 105 events were analyzed using 
FlowJo (Treestar, Ashland, OR, USA) and SPICE software (provided by Dr. Mario Roederer, 
Vaccine Research Center, NIAID, NIH, USA). Boolean gate analysis was used to study the 
different single, double and polyfunctional CD4+ and CD8+ T cells. 
T-cell proliferation. Proliferation was measured using carboxy-fluorescein diacetate, 
succinimidyl ester (CFSE) dilution and flow cytometry. PBMCs from study subjects were 
thawed, washed and labeled with CFSE (Molecular Probes, Leiden, The Netherlands) at a final 
concentration of  5 mM for 10 minutes at 37 °C. Washed, counted and viable cells were seeded in 
triplicates in 96-well round-bottom plates at a concentration of  1.5 x 105 cells/well in the presence 
of  control antigens (PPD 5 µg/ml, PHA 2 µg/ml (Remel, Oxoid, Haarlem, The Netherlands)) or 
test antigens and peptides (all at final concentrations of  10 µg/ml). Cells were cultured in IMDM 
supplemented with glutamax, 100 U/ml penicillin, 100 mg/ml streptomycin (Invitrogen, Breda, 
The Netherlands), and 10% human serum at 37°C and 5% CO2. After 7 days of  incubation, cells 
were stained for further analysis on the flow-cytometer.
Cells were stained for the following surface markers; CD8-APC (DakoCytomation, Heverlee, 
Belgium), CD3-PerCP and CD4-PE (BD Biosciences), washed in PBS 0.1% BSA (Sigma 
Aldrich, Zwijndrecht, The Netherlands), fixed in 1% paraformaldehyde (Pharmacy LUMC, The 










































performed using FACS DIVA software (BD Biosciences). Live lymphocyte gated cells combined 
with gating of  CD3+ CD4+ and CD3+ CD8+ T cells were analyzed for proliferation using CFSE 
dye dilution. The D geometric mean was used as a measure of  proliferation and calculated as 
follows: D geometric mean = geometric mean (non-proliferated cells) - geometric mean (total 
cells). The D geometric mean was then used to calculate the ‘relative proliferation’, which is 
the percentage of  maximal proliferation (PHA) corrected for spontaneous proliferation (HIV-1 
p17 Gag77-85) ((Δ geometric mean sample - Δ geometric mean control medium) / (Δ geometric mean 
PHA - Δ geometric mean control medium)) x 100% = % of  maximal proliferation. The cut-off 
value for a positive proliferative response was arbitrarily set at 10% relative proliferation in order 
to limit the number of  candidate epitopes to be evaluated in subsequent experiments [21].
IFN-g ELISA. IFN-g concentration in cellular supernatants was detected using ELISA (U-CyTech, 
Utrecht, The Netherlands) as previously described [20]. 
Results
Selection of  recombinant Mtb DosR antigens 
Our previous work showed that Mtb DosR-regulon-encoded antigens are efficiently recognized by 
Mtb-exposed individuals, particularly asymptomatic TST positive individuals [7;12;13]. To study 
the nature of  the response against these antigens in more detail, we selected Rv1733c and Rv2029c 
as two Mtb DosR proteins consistently ranking among the top ten most frequently recognized 
Mtb DosR antigens in Mtb exposed individuals across different ethnic populations [7;12;13]. The 
secreted protein Ag85B and the Mtb DosR antigen Rv2031c (HspX, hsp16, α-crystallin) were 
included as control antigens [22-24]. Besides recombinant proteins (Table 1) overlapping sets of  
synthetic peptides of  all four antigens were produced and tested as well (Supporting Information 
Table S1A-D).
Table 1. Selected Mycobacterium tuberculosis antigens tested in present study




 product a  References
DosR genes Rv1733c 22,4 conserved transmembrane protein [7;11-13]
Rv2029c pfkB 35,4 phosphofructokinase PfkB [7;11;12]
Rv2031c hspX 16,3 heat shock protein HspX (alpha-
crystallin)
[7;10;22-24]
Reference gene Rv1886c fbpB 34,6 secreted antigen 85-B fbpB 
(mycolyltransferase 85B, Ag85B)
[37]
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Single, double and polyfunctional T-cell responses against Mtb DosR antigens in 
ltLTBIs 
Mtb DosR antigen-specific T-cell recognition described previously in Mtb-exposed donors was 
based mostly on the production of  IFN-g. Previously, polyfunctional T cells producing IFN-g, 
TNF-α and IL-2 have been suggested as possible markers of  protective immunity, based on 
observations that vaccine-induced triple positive T cells correlated well with protection [25-31]. 
However, other studies reported that such T cells were associated with active TB disease [32-35]. 
The nature of  Mtb DosR antigen-responsive CD4+ and CD8+ T-cell subsets in untreated Mtb-
exposed donors who had been infected several decades ago, yet never developed any signs or 
symptoms of  active TB (ltLTBIs), was studied here. In vitro purified protein derivative of  Mtb (PPD) 
negative (PPD-) donors were included as uninfected controls. PBMCs of  ltLTBIs and PPD- donors 
were stimulated with Mtb DosR-regulon-encoded antigens or corresponding peptide pools and the 
responses were analyzed using multi-parameter flow cytometry (Supplementary Figure S1A and 
S1B). Donors were considered positive when the frequency of  a double or polyfunctional T-cell 
subset population was ≥ 0.2 %, which is equivalent to ≥ 200 events. 
In ltLTBIs high percentages of  IFN-γ, TNF-α and/or IL-2 cytokine producing CD4+ and 
CD8+ T cells were found in response to PPD (0.23-7.91% and 0.25-7.55%, respectively), Rv2031c 
protein (0.21-19.71% and 0.25-20.35%, respectively) and the Rv2031c peptide pool (0.2-16.28% 
and 0.23-32.92%, respectively), whereas no such responses were observed in PPD- controls (Figure 
1A). The highest frequencies were consistently found within the single cytokine producing CD4+ 
and CD8+ T-cell populations. Interestingly, many double producing T cells were identified 
within the CD8+ T-cell population, as shown by Figure 1B, which depicts the proportions of  
polyfunctional as well as double and single cytokine-producing T cells. For Mtb DosR antigen 
Rv1733c, two peptide pools were tested (Figure 1C). Again high CD4+ and CD8+ T-cell responses 
were observed (0.43-14.41% and 0.2-14.25%, respectively), with single positive cells being the most 
frequent. In addition, substantial numbers of  double cytokine-producing CD4+ and CD8+ T cells 
were present in both peptide pool responsive CD4+ and CD8+ T-cells populations, IFN-g+ TNF-α+ 
CD8+ T cells being the most frequent (Figure 1D). Low to no Rv1733c-specific responses were 
identified within the PPD- controls (Figure 1C). A comparable pattern was observed for Rv2029c 
(0.29-8.41% CD4+ T cells and 0.36-9.55% CD8+ T cells). Unlike Rv1733c, the Rv2029c protein 
induced a considerable fraction of  IFN-g+ TNF-α+ CD8+ T cells. Some responses to Rv2029c 
peptide pool 1 were also observed in the PPD- group, but no responses were seen to peptide pools 
2 and 3 (Figure 1E and 1F). Of  note, stimulation of  PBMCs with Staphylococcus enterotoxin B 
induced high percentages of  CD4+ and CD8+ T cells producing single (0.3-26.44% CD4+ T cells 
and 0.29-12.6% CD8+ T cells), double (0.23-22.26% CD4+ T cells and 0.24-20.17% CD8+ T cells) 
and triple (0.29-5.37% CD4+ T cell and 0.54-6.91% CD8+ T cells) cytokines in both ltLTBIs and 
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Figure 1. Frequency of  antigen-specific polyfunctional T cells in ltLTBIs. Frequency of  antigen-
specific CD4+ and CD8+ T cells in ltLTBIs (upper panel) and PPD- control donors (lower panel), producing 
combinations of  IFN-γ, TNF-α or IL-2 after stimulation for 16 hours with control antigens as determined by 
flow cytometry. (A) Stimulation with PPD, Rv2031c protein and Rv2031c peptide pool 1, n = 13 and n = 11, 
(C) stimulation with Rv1733c protein and corresponding peptide pools 1 and 2, n = 11 and (E) stimulation 
with Rv2029c protein and corresponding peptide pools 1-3, n = 11. CD4+ T cells are indicated as closed 
circles (●) and CD8+ T cells as open circles (○). Horizontal bars represent the median frequency of  antigen-
specific CD4+ and CD8+ T cells. (B, D and F) Pie chart representation of  the proportion of  single-, double- or 
triple-positive CD4+ and CD8+ T cells for each antigen. Only CD4+ and CD8+ populations of  ≥ 2 x 105 
events were analyzed. Donors were considered positive when the frequency of  a double or polyfunctional 
T-cell subset population was ≥ 0.2 %, which corresponds to ≥ 200 events. Range total CD4+ T cells: 0-3694 
events and total CD8+ T cells: 0-3937 events. 
Interestingly, the IFN-γ+ TNF-α+ CD8+ T-cell population consistently was the most frequent 
multiple cytokine-producing T-cell subset identified (Figure 1B, D and F). To assess the memory 
phenotype of  these cells, we measured expression of  memory markers CCR7 and CD45RA by 
Mtb antigen or peptide responsive cells from the ltLTBI population (Figure 2A and B). T-cell subsets 
were classified according to the model described by Seder et al. [36]. Only a minor fraction of  the 
IFN-γ+ TNF-α+ CD8+ T cells appeared to be “naïve” (CCR7+CD45RA+) or central memory T 
cells (CCR7+CD45RA-), while most were found to be effector memory (CCR7-CD45RA-) T cells, 
followed by effector (CCR7-CD45RA+) T cells (percentages ranged between 36 and 62% (SD ± 










































Figure 2. T-cell memory subset distribution of  IFN-γ+ TNF-α+ CD8+ T cells. Expression of  T-cell 
memory markers CCR7 and CD45RA was analyzed by flow cytometry in IFN-γ+ TNF-α+ CD8+ T cells of  
(A) PPD responders (n = 4) and (B) Mtb antigen or peptide pool responders from the ltLTBI donors. Rv2031c 
protein (n = 3), Rv2031 peptide pool 1 (n = 2), Rv1733c protein (n = 2), Rv1733c peptide pool 1 (n = 2), 
Rv1733c peptide pool 2 (n = 3), Rv2029c protein (n = 3), Rv2029c peptide pool 1 (n = 4), Rv2029c peptide 
pool 2 (n = 3) and Rv2029c peptide pool 3 (n = 3). CD8+ populations with ≥ 2 x 105 events were analyzed. 
Effector memory T cells are CCR7- and CD45RA-, central memory T cells are CCR7+ and CD45RA-, naive 
T cells are CCR7+ and CD45RA+ and effector T cells are CCR7- and CD45RA+. 
Taken together, our results show the presence of  Mtb DosR-regulon-encoded antigen-specific 
double- and monofunctional CD4+ and CD8+ T-cell responses in ltLTBIs. IFN-γ+ TNF-α+ CD8+ 
T cells were the most prominently present multiple cytokine-producing T cells, and comprised 








































Double- and monofunctional T-cell responses to Mtb latency antigens
63
3
Peptide epitope mapping of  Mtb DosR antigens by CFSE proliferation and flow 
cytometry
Next, we analyzed single peptide-induced responses in PPD positive (PPD+) individuals in order to 
identify immunogenic Mtb DosR antigen epitopes. In view of  the number of  cells required for these 
analyses, we used buffy coat derived PBMCs. PBMCs of  PPD+ individuals were incubated with 
each single peptide of  Mtb DosR Rv1733c, Rv2029c and Rv2031c and the control protein Ag85B. 
Proliferative responses were measured using CFSE labeling, an assay that we have described 
previously [21;34]. Figure 3 demonstrates typical proliferation profiles of  CD4+ and CD8+ T cells 
in response to Mtb antigens and control conditions in one PPD+ donor. Following stimulation of  
PBMCs with PPD, Rv1733c or its corresponding peptides, significant CD4+ and to a lesser extent 
CD8+ T-cell proliferation were observed (Figure 3A and B, respectively). No proliferation was 
observed to the irrelevant control peptide HIV-gag77–85 or for medium only (data not shown). A 
relative proliferation (see Material and methods for calculation) of  10% was considered positive 
in this assay, in line with previous studies [21;34]. Responses to previously published HLA class 
I and class II restricted epitopes of  Ag85B [37] and Rv2031c [24;35;38-40] could be confirmed, 
validating this approach (Figure 3A and B).
Results for CFSE-labeled PBMCs from all 15 PPD+ donors in response to PPD, Mtb DosR-
regulon encoded proteins Rv1733c, Rv2029c and Rv2031c and Ag85B protein and all respective 
single peptides from each of  the four antigens are given in Figure 4A and B, showing comprehensive 
epitope maps for CD4+ (Figure 4A) or CD8+ (Figure 4B) T cells. Notwithstanding the expected 
inter-individual differences in antigen and peptide recognition patterns, all 15 PPD+ donors 
responded to at least one of  the recombinant proteins and/or peptides investigated. Recombinant 
antigens Rv1733c, Rv2029c and Rv1886c (Ag85B) were recognized efficiently: 7/15 PPD+ donors 
recognized Rv2029c (CD4+: 15-97.2%, CD8+: 10.6-66.6%), 5/15 recognized Rv1733c (CD4+: 
20.3-40%, CD8+: 12.2-31.1) and 4/15 recognized Ag85B (CD4+: 13.8-53.4%, CD8+: 12.6-
97.7%). Corresponding to our previous observations, Rv2031c/hspX/acr was recognized by a 


























































































































































































































































































































































































































Mtb  antigen donor protein 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Rv1733c 1 23 2 0 0 6 7 3 0 1 1 0 0 12 0 0 13 8 7 4 2 6
2 2 0 0 0 0 0 1 0 8 0 0 2 3 7 7 1 2 4 1 0 1
3 0 0 28 2 0 0 0 1 19 1 0 0 0 0 0 0 4 0 0 0 1
4 0 0 0 2 0 2 1 2 8 2 18 2 0 2 0 2 8 0 0 0 0
5 0 0 0 0 0 1 0 0 0 0 0 12 0 0 3 0 0 0 0 3 0
6 0 76 77 0 0 0 0 75 0 0 0 0 0 0 0 0 0 1 0 0 0
A
7 5 1 1 1 0 5 0 1 0 1 0 1 9 0 1 2 17 0 1 4 0
8 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
9 22 10 2 2 3 4 1 5 7 0 16 2 2 1 16 27 2 61 1 30 18
10 22 0 0 0 0 0 0 0 0 0 0 5 0 0 0 0 0 14 0 0 0
11 20 0 46 45 35 1 3 0 3 3 12 3 0 6 12 7 0 0 1 8 4
12 40 0 0 0 0 0 18 1 0 16 0 2 45 0 0 70 0 0 0 12 0
13 1 0 0 13 0 0 0 0 5 0 0 0 0 0 10 0 0 4 0 0 0
14 1 0 1 1 0 0 1 1 0 1 1 1 2 0 0 0 0 3 0 1 0
15 1 0 10 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7
Rv2029c 1 2 17 4 3 21 4 10 8 12 6 9 15 25 1 7 4 2 4 5 19 16 6 0 5 23 2 16 7 3 5 10 3 2 2
2 5 2 0 1 0 1 0 3 2 0 0 0 4 0 1 1 0 1 8 0 1 1 4 3 2 3 0 0 0 2 2 2 1 8
3 6 0 1 0 0 0 0 0 1 0 0 3 0 0 0 0 0 0 0 0 11 0 0 0 0 0 0 0 1 0 0 0 1 0
4 15 12 4 0 12 6 1 3 7 0 5 1 5 15 1 7 5 5 2 8 15 4 0 6 6 1 0 4 2 0 2 11 12 5
5 0 0 2 4 0 7 3 0 0 5 0 0 0 4 30 1 0 2 0 1 1 0 0 0 0 0 0 0 5 0 0 0 0 0
6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
7 0 0 0 0 1 0 1 2 1 27 1 0 4 1 1 2 1 6 7 6 1 1 0 4 0 2 1 3 0 1 3 2 8 1
8 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 18 0 2 0 0 0 0 1 0 0 0 1 0 1 0 0 1 0
9 47 1 21 1 5 9 33 3 1 2 6 64 44 2 0 0 0 1 20 2 2 1 0 2 0 1 9 0 8 4 2 1 30 0
10 38 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0
11 43 1 0 10 2 17 11 2 0 2 1 4 46 12 0 7 0 4 0 9 0 0 23 4 12 1 21 0 6 0 0 0 2 0
12 97 0 29 0 14 0 0 47 0 0 0 0 0 0 0 30 0 0 0 0 0 0 0 -3 0 0 19 0 101 22 5 23 0 0
13 68 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 9 0 0 0 0 0
14 22 1 0 0 0 0 0 6 4 0 2 1 3 0 3 1 1 2 4 0 1 1 1 0 1 0 1 0 7 1 1 1 1 0
15 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
Rv2031c 1 2 2 4 6 2 9 1 2 3 2 6 3 4 12 1
2 1 0 5 0 0 7 0 5 0 0 1 2 3 2 7
3 0 0 9 3 3 0 0 3 3 0 0 0 0 2 0
4 1 7 42 3 28 0 8 22 13 7 35 9 16 24 23
5 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0
6 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
7 1 10 1 6 26 1 0 1 4 1 1 2 4 2 0
8 0 0 0 0 0 1 1 0 0 0 0 1 1 0 0
9 15 1 8 3 8 17 1 20 5 24 54 1 38 1 0
10 16 0 1 0 0 0 0 0 0 0 10 0 0 3 0
11 4 0 8 1 1 5 0 17 24 39 48 0 4 5 0
12 5 0 28 0 0 0 2 0 0 0 0 0 12 54 12
13 11 0 0 18 0 0 0 0 5 0 1 0 0 1 0
14 2 1 2 1 2 0 2 2 3 1 1 0 1 0 0
15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Rv1886c 1 2 1 0 3 0 1 6 8 0 9 1 3 0 2 0 0 1 1 19 1 7 0 0 0 5 3 0 14 1 1 9
(Ag85B) 2 0 0 3 4 10 1 0 20 4 11 2 2 6 4 5 3 20 2 28 8 11 1 9 2 0 2 0 1 7 0 1
3 0 0 2 3 0 0 3 6 2 0 0 8 0 5 2 0 6 0 0 0 0 3 0 0 0 0 0 4 1 0 0
4 7 8 10 11 10 25 3 7 3 11 11 27 6 28 11 8 8 2 7 5 20 3 11 15 11 8 10 1 0 5 1
5 1 0 0 0 0 0 0 2 0 15 0 0 0 0 0 0 4 0 0 0 0 2 3 0 0 0 0 0 0 0 0
6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
7 0 3 3 2 0 11 3 0 3 5 1 1 3 2 5 8 10 7 0 1 0 0 0 0 0 0 1 1 0 0 6
8 3 1 2 0 4 1 0 0 5 0 0 0 3 1 2 0 4 1 0 0 5 0 0 0 0 0 0 2 6 0 0
9 14 4 0 1 1 12 8 31 14 64 27 6 14 71 34 69 16 103 1 2 61 134 37 9 2 62 3 7 17 5 8
10 19 0 0 17 7 9 40 35 29 74 18 34 31 30 15 30 13 5 0 24 8 12 42 0 0 15 22 7 32 0 20
11 30 0 0 0 2 57 12 0 0 12 0 2 3 15 5 0 14 28 0 7 8 1 5 15 0 0 1 6 0 15 0
12 53 0 0 0 0 49 75 0 0 3 25 55 13 24 0 9 0 207 0 0 0 148 32 0 0 0 0 9 109 0 0
13 4 0 0 4 5 0 36 8 17 2 6 1 28 33 0 2 0 0 0 0 9 0 6 0 0 0 0 2 0 0 0
14 3 1 0 7 1 0 23 1 1 1 1 5 4 1 0 1 1 3 1 1 1 0 1 1 1 2 1 1 1 0 1
15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0
  rel. proliferation < 3%   rel. proliferation 3-10%   rel. proliferation >10%
peptide
Mtb  antigen donor protein 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
B
Rv1733c 1 31 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 0 0 0
2 2 0 0 0 1 1 0 0 13 6 5 2 0 0 0 1 0 0 0 0 1
3 1 0 71 3 0 1 1 0 56 0 1 0 0 0 1 0 2 6 1 2 3
4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
5 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
6 3 100 101 0 0 0 0 98 19 1 2 2 4 0 5 2 0 12 0 0 1
7 0 0 0 0 1 5 0 0 0 0 3 0 0 0 0 0 5 0 0 3 0
8 0 15 0 1 4 3 2 2 0 0 0 0 0 0 0 0 0 59 0 57 1
9 5 1 4 1 0 0 0 1 1 1 0 0 0 0 6 6 0 18 0 28 1
10 12 0 0 0 0 0 0 0 0 0 0 6 0 0 0 0 0 7 0 0 0
11 3 0 52 13 32 0 0 0 3 3 4 0 1 2 5 1 0 0 0 0 0
12 9 0 0 27 0 0 47 0 0 3 0 55 3 0 2 24 0 1 0 0 0
13 5 1 0 2 6 0 0 0 5 2 0 0 1 0 3 0 0 65 0 20 0
14 0 4 0 0 0 0 0 1 0 0 0 3 0 0 0 0 0 27 0 34 0
15 9 29 59 45 20 13 10 18 3 11 2 7 1 6 2 7 1 1 0 4 2
Rv2029c 1 0 0 0 0 36 5 5 12 2 0 0 11 4 7 0 0 0 15 0 36 30 0 0 4 3 0 2 0 0 3 0 2 0 15
2 1 1 0 3 0 2 0 1 0 0 0 0 0 3 0 0 0 1 0 0 2 0 0 1 1 2 1 0 4 2 6 2 0 0
3 0 2 0 1 0 0 0 1 0 0 2 0 0 0 0 0 11 0 0 0 1 0 0 0 0 2 0 0 0 0 0 2 0 0
4 0 0 0 0 0 0 0 0 0 2 0 1 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0
5 0 0 3 0 0 10 0 0 0 5 0 0 0 0 52 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
6 0 1 1 0 0 1 0 0 0 0 0 0 1 0 8 0 1 0 0 0 4 1 4 6 1 0 0 1 0 3 5 1 0 0
7 0 0 0 0 0 0 1 3 0 24 0 0 0 0 0 4 0 2 8 3 0 1 0 0 0 0 0 4 0 0 0 0 5 0
8 0 0 3 5 0 0 1 0 0 0 0 0 0 0 1 0 23 0 1 36 0 0 0 0 0 0 0 2 0 0 0 0 0 0
9 67 0 16 0 3 5 16 2 0 1 0 42 8 5 1 -1 0 3 4 1 1 0 0 0 0 2 9 0 3 3 0 0 22 1
10 18 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
11 11 0 0 0 0 0 1 0 0 0 0 0 2 1 0 2 0 0 0 5 0 0 1 0 0 0 0 0 0 0 0 0 0 0
peptide 
Mtb  antigen donor protein 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Rv1733c 1 23 2 0 0 6 7 3 0 1 1 0 0 12 0 0 13 8 7 4 2 6
2 2 0 0 0 0 0 1 0 8 0 0 2 3 7 7 1 2 4 1 0 1
3 0 0 28 2 0 0 0 1 19 1 0 0 0 0 0 0 4 0 0 0 1
4 0 0 0 2 0 2 1 2 8 2 18 2 0 2 0 2 8 0 0 0 0
5 0 0 0 0 0 1 0 0 0 0 0 12 0 0 3 0 0 0 0 3 0
6 0 76 77 0 0 0 0 75 0 0 0 0 0 0 0 0 0 1 0 0 0
A
7 5 1 1 1 0 5 0 1 0 1 0 1 9 0 1 2 17 0 1 4 0
8 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
9 22 10 2 2 3 4 1 5 7 0 16 2 2 1 16 27 2 61 1 30 18
10 22 0 0 0 0 0 0 0 0 0 0 5 0 0 0 0 0 14 0 0 0
11 20 0 46 45 35 1 3 0 3 3 12 3 0 6 12 7 0 0 1 8 4
12 40 0 0 0 0 0 18 1 0 16 0 2 45 0 0 70 0 0 0 12 0
13 1 0 0 13 0 0 0 0 5 0 0 0 0 0 10 0 0 4 0 0 0
14 1 0 1 1 0 0 1 1 0 1 1 1 2 0 0 0 0 3 0 1 0
15 1 0 10 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7
Rv2029c 1 2 17 4 3 21 4 10 8 12 6 9 15 25 1 7 4 2 4 5 19 16 6 0 5 23 2 16 7 3 5 10 3 2 2
2 5 2 0 1 0 1 0 3 2 0 0 0 4 0 1 1 0 1 8 0 1 1 4 3 2 3 0 0 0 2 2 2 1 8
3 6 0 1 0 0 0 0 0 1 0 0 3 0 0 0 0 0 0 0 0 11 0 0 0 0 0 0 0 1 0 0 0 1 0
4 15 12 4 0 12 6 1 3 7 0 5 1 5 15 1 7 5 5 2 8 15 4 0 6 6 1 0 4 2 0 2 11 12 5
5 0 0 2 4 0 7 3 0 0 5 0 0 0 4 30 1 0 2 0 1 1 0 0 0 0 0 0 0 5 0 0 0 0 0
6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
7 0 0 0 0 1 0 1 2 1 27 1 0 4 1 1 2 1 6 7 6 1 1 0 4 0 2 1 3 0 1 3 2 8 1
8 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 18 0 2 0 0 0 0 1 0 0 0 1 0 1 0 0 1 0
9 47 1 21 1 5 9 33 3 1 2 6 64 44 2 0 0 0 1 20 2 2 1 0 2 0 1 9 0 8 4 2 1 30 0
10 38 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0
11 43 1 0 10 2 17 11 2 0 2 1 4 46 12 0 7 0 4 0 9 0 0 23 4 12 1 21 0 6 0 0 0 2 0
12 97 0 29 0 14 0 0 47 0 0 0 0 0 0 0 30 0 0 0 0 0 0 0 -3 0 0 19 0 101 22 5 23 0 0
13 68 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 9 0 0 0 0 0
14 22 1 0 0 0 0 0 6 4 0 2 1 3 0 3 1 1 2 4 0 1 1 1 0 1 0 1 0 7 1 1 1 1 0
15 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
Rv2031c 1 2 2 4 6 2 9 1 2 3 2 6 3 4 12 1
2 1 0 5 0 0 7 0 5 0 0 1 2 3 2 7
3 0 0 9 3 3 0 0 3 3 0 0 0 0 2 0
4 1 7 42 3 28 0 8 22 13 7 35 9 16 24 23
5 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0
6 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
7 1 10 1 6 26 1 0 1 4 1 1 2 4 2 0
8 0 0 0 0 0 1 1 0 0 0 0 1 1 0 0
9 15 1 8 3 8 17 1 20 5 24 54 1 38 1 0
10 16 0 1 0 0 0 0 0 0 0 10 0 0 3 0
11 4 0 8 1 1 5 0 17 24 39 48 0 4 5 0
12 5 0 28 0 0 0 2 0 0 0 0 0 12 54 12
13 11 0 0 18 0 0 0 0 5 0 1 0 0 1 0
14 2 1 2 1 2 0 2 2 3 1 1 0 1 0 0
15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Rv1886c 1 2 1 0 3 0 1 6 8 0 9 1 3 0 2 0 0 1 1 19 1 7 0 0 0 5 3 0 14 1 1 9
(Ag85B) 2 0 0 3 4 10 1 0 20 4 11 2 2 6 4 5 3 20 2 28 8 11 1 9 2 0 2 0 1 7 0 1
3 0 0 2 3 0 0 3 6 2 0 0 8 0 5 2 0 6 0 0 0 0 3 0 0 0 0 0 4 1 0 0
4 7 8 10 11 10 25 3 7 3 11 11 27 6 28 11 8 8 2 7 5 20 3 11 15 11 8 10 1 0 5 1
5 1 0 0 0 0 0 0 2 0 15 0 0 0 0 0 0 4 0 0 0 0 2 3 0 0 0 0 0 0 0 0
6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
7 0 3 3 2 0 11 3 0 3 5 1 1 3 2 5 8 10 7 0 1 0 0 0 0 0 0 1 1 0 0 6
8 3 1 2 0 4 1 0 0 5 0 0 0 3 1 2 0 4 1 0 0 5 0 0 0 0 0 0 2 6 0 0
9 14 4 0 1 1 12 8 31 14 64 27 6 14 71 34 69 16 103 1 2 61 134 37 9 2 62 3 7 17 5 8
10 19 0 0 17 7 9 40 35 29 74 18 34 31 30 15 30 13 5 0 24 8 12 42 0 0 15 22 7 32 0 20
11 30 0 0 0 2 57 12 0 0 12 0 2 3 15 5 0 14 28 0 7 8 1 5 15 0 0 1 6 0 15 0
12 53 0 0 0 0 49 75 0 0 3 25 55 13 24 0 9 0 207 0 0 0 148 32 0 0 0 0 9 109 0 0
13 4 0 0 4 5 0 36 8 17 2 6 1 28 33 0 2 0 0 0 0 9 0 6 0 0 0 0 2 0 0 0
14 3 1 0 7 1 0 23 1 1 1 1 5 4 1 0 1 1 3 1 1 1 0 1 1 1 2 1 1 1 0 1
15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0
  rel. proliferation < 3%   rel. proliferation 3-10%   rel. proliferation >10%
peptide
Mtb  antigen donor protein 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
B
Rv1733c 1 31 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 0 0 0
2 2 0 0 0 1 1 0 0 13 6 5 2 0 0 0 1 0 0 0 0 1
3 1 0 71 3 0 1 1 0 56 0 1 0 0 0 1 0 2 6 1 2 3
4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
5 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
6 3 100 101 0 0 0 0 98 19 1 2 2 4 0 5 2 0 12 0 0 1
7 0 0 0 0 1 5 0 0 0 0 3 0 0 0 0 0 5 0 0 3 0
8 0 15 0 1 4 3 2 2 0 0 0 0 0 0 0 0 0 59 0 57 1
9 5 1 4 1 0 0 0 1 1 1 0 0 0 0 6 6 0 18 0 28 1
10 12 0 0 0 0 0 0 0 0 0 0 6 0 0 0 0 0 7 0 0 0
11 3 0 52 13 32 0 0 0 3 3 4 0 1 2 5 1 0 0 0 0 0
12 9 0 0 27 0 0 47 0 0 3 0 55 3 0 2 24 0 1 0 0 0
13 5 1 0 2 6 0 0 0 5 2 0 0 1 0 3 0 0 65 0 20 0
14 0 4 0 0 0 0 0 1 0 0 0 3 0 0 0 0 0 27 0 34 0
15 9 29 59 45 20 13 10 18 3 11 2 7 1 6 2 7 1 1 0 4 2
Rv2029c 1 0 0 0 0 36 5 5 12 2 0 0 11 4 7 0 0 0 15 0 36 30 0 0 4 3 0 2 0 0 3 0 2 0 15
2 1 1 0 3 0 2 0 1 0 0 0 0 0 3 0 0 0 1 0 0 2 0 0 1 1 2 1 0 4 2 6 2 0 0
3 0 2 0 1 0 0 0 1 0 0 2 0 0 0 0 0 11 0 0 0 1 0 0 0 0 2 0 0 0 0 0 2 0 0
4 0 0 0 0 0 0 0 0 0 2 0 1 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0
5 0 0 3 0 0 10 0 0 0 5 0 0 0 0 52 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
6 0 1 1 0 0 1 0 0 0 0 0 0 1 0 8 0 1 0 0 0 4 1 4 6 1 0 0 1 0 3 5 1 0 0
7 0 0 0 0 0 0 1 3 0 24 0 0 0 0 0 4 0 2 8 3 0 1 0 0 0 0 0 4 0 0 0 0 5 0
8 0 0 3 5 0 0 1 0 0 0 0 0 0 0 1 0 23 0 1 36 0 0 0 0 0 0 0 2 0 0 0 0 0 0
9 67 0 16 0 3 5 16 2 0 1 0 42 8 5 1 -1 0 3 4 1 1 0 0 0 0 2 9 0 3 3 0 0 22 1
10 18 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
11 11 0 0 0 0 0 1 0 0 0 0 0 2 1 0 2 0 0 0 5 0 0 1 0 0 0 0 0 0 0 0 0 0 0
peptide 
Mtb  antigen donor protein 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Rv1733c 1 23 2 0 0 6 7 3 0 1 1 0 0 12 0 0 13 8 7 4 2 6
2 2 0 0 0 0 0 1 0 8 0 0 2 3 7 7 1 2 4 1 0 1
3 0 0 28 2 0 0 0 1 19 1 0 0 0 0 0 0 4 0 0 0 1
4 0 0 0 2 0 2 1 2 8 2 18 2 0 2 0 2 8 0 0 0 0
5 0 0 0 0 0 1 0 0 0 0 0 12 0 0 3 0 0 0 0 3 0
6 0 76 77 0 0 0 0 75 0 0 0 0 0 0 0 0 0 1 0 0 0
A
7 5 1 1 1 0 5 0 1 0 1 0 1 9 0 1 2 17 0 1 4 0
8 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
9 22 10 2 2 3 4 1 5 7 0 16 2 2 1 16 27 2 61 1 30 18
10 22 0 0 0 0 0 0 0 0 0 0 5 0 0 0 0 0 14 0 0 0
11 20 0 46 45 35 1 3 0 3 3 12 3 0 6 12 7 0 0 1 8 4
12 40 0 0 0 0 0 18 1 0 16 0 2 45 0 0 70 0 0 0 12 0
13 1 0 0 13 0 0 0 0 5 0 0 0 0 0 10 0 0 4 0 0 0
14 1 0 1 1 0 0 1 1 0 1 1 1 2 0 0 0 0 3 0 1 0
15 1 0 10 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7
Rv2029c 1 2 17 4 3 21 4 10 8 12 6 9 15 25 1 7 4 2 4 5 19 16 6 0 5 23 2 16 7 3 5 10 3 2 2
2 5 2 0 1 0 1 0 3 2 0 0 0 4 0 1 1 0 1 8 0 1 1 4 3 2 3 0 0 0 2 2 2 1 8
3 6 0 1 0 0 0 0 0 1 0 0 3 0 0 0 0 0 0 0 0 11 0 0 0 0 0 0 0 1 0 0 0 1 0
4 15 12 4 0 12 6 1 3 7 0 5 1 5 15 1 7 5 5 2 8 15 4 0 6 6 1 0 4 2 0 2 11 12 5
5 0 0 2 4 0 7 3 0 0 5 0 0 0 4 30 1 0 2 0 1 1 0 0 0 0 0 0 0 5 0 0 0 0 0
6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
7 0 0 0 0 1 0 1 2 1 27 1 0 4 1 1 2 1 6 7 6 1 1 0 4 0 2 1 3 0 1 3 2 8 1
8 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 18 0 2 0 0 0 0 1 0 0 0 1 0 1 0 0 1 0
9 47 1 21 1 5 9 33 3 1 2 6 64 44 2 0 0 0 1 20 2 2 1 0 2 0 1 9 0 8 4 2 1 30 0
10 38 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0
11 43 1 0 10 2 17 11 2 0 2 1 4 46 12 0 7 0 4 0 9 0 0 23 4 12 1 21 0 6 0 0 0 2 0
12 97 0 29 0 14 0 0 47 0 0 0 0 0 0 0 30 0 0 0 0 0 0 0 -3 0 0 19 0 101 22 5 23 0 0
13 68 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 9 0 0 0 0 0
14 22 1 0 0 0 0 0 6 4 0 2 1 3 0 3 1 1 2 4 0 1 1 1 0 1 0 1 0 7 1 1 1 1 0
15 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
Rv2031c 1 2 2 4 6 2 9 1 2 3 2 6 3 4 12 1
2 1 0 5 0 0 7 0 5 0 0 1 2 3 2 7
3 0 0 9 3 3 0 0 3 3 0 0 0 0 2 0
4 1 7 42 3 28 0 8 22 13 7 35 9 16 24 23
5 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0
6 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
7 1 10 1 6 26 1 0 1 4 1 1 2 4 2 0
8 0 0 0 0 0 1 1 0 0 0 0 1 1 0 0
9 15 1 8 3 8 17 1 20 5 24 54 1 38 1 0
10 16 0 1 0 0 0 0 0 0 0 10 0 0 3 0
11 4 0 8 1 1 5 0 17 24 39 48 0 4 5 0
12 5 0 28 0 0 0 2 0 0 0 0 0 12 54 12
13 11 0 0 18 0 0 0 0 5 0 1 0 0 1 0
14 2 1 2 1 2 0 2 2 3 1 1 0 1 0 0
15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Rv1886c 1 2 1 0 3 0 1 6 8 0 9 1 3 0 2 0 0 1 1 19 1 7 0 0 0 5 3 0 14 1 1 9
(Ag85B) 2 0 0 3 4 10 1 0 20 4 11 2 2 6 4 5 3 20 2 28 8 11 1 9 2 0 2 0 1 7 0 1
3 0 0 2 3 0 0 3 6 2 0 0 8 0 5 2 0 6 0 0 0 0 3 0 0 0 0 0 4 1 0 0
4 7 8 10 11 10 25 3 7 3 11 11 27 6 28 11 8 8 2 7 5 20 3 11 15 11 8 10 1 0 5 1
5 1 0 0 0 0 0 0 2 0 15 0 0 0 0 0 0 4 0 0 0 0 2 3 0 0 0 0 0 0 0 0
6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
7 0 3 3 2 0 11 3 0 3 5 1 1 3 2 5 8 10 7 0 1 0 0 0 0 0 0 1 1 0 0 6
8 3 1 2 0 4 1 0 0 5 0 0 0 3 1 2 0 4 1 0 0 5 0 0 0 0 0 0 2 6 0 0
9 14 4 0 1 1 12 8 31 14 64 27 6 14 71 34 69 16 103 1 2 61 134 37 9 2 62 3 7 17 5 8
10 19 0 0 17 7 9 40 35 29 74 18 34 31 30 15 30 13 5 0 24 8 12 42 0 0 15 22 7 32 0 20
11 30 0 0 0 2 57 12 0 0 12 0 2 3 15 5 0 14 28 0 7 8 1 5 15 0 0 1 6 0 15 0
12 53 0 0 0 0 49 75 0 0 3 25 55 13 24 0 9 0 207 0 0 0 148 32 0 0 0 0 9 109 0 0
13 4 0 0 4 5 0 36 8 17 2 6 1 28 33 0 2 0 0 0 0 9 0 6 0 0 0 0 2 0 0 0
14 3 1 0 7 1 0 23 1 1 1 1 5 4 1 0 1 1 3 1 1 1 0 1 1 1 2 1 1 1 0 1
15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0
  rel. proliferation < 3%   rel. proliferation 3-10%   rel. proliferation >10%
peptide
Mtb  antigen donor protein 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
B
Rv1 33c 1 31 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 0 0 0
2 2 0 0 0 1 1 0 0 13 6 5 2 0 0 0 1 0 0 0 0 1
3 1 0 71 3 0 1 1 0 56 0 1 0 0 0 1 0 2 6 1 2 3
4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
5 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
6 3 100 101 0 0 0 0 98 19 1 2 2 4 0 5 2 0 12 0 0 1
7 0 0 0 0 1 5 0 0 0 0 3 0 0 0 0 0 5 0 0 3 0
8 0 15 0 1 4 3 2 2 0 0 0 0 0 0 0 0 0 59 0 57 1
9 5 1 4 1 0 0 0 1 1 1 0 0 0 0 6 6 0 18 0 28 1
10 12 0 0 0 0 0 0 0 0 0 0 6 0 0 0 0 0 7 0 0 0
11 3 0 52 13 32 0 0 0 3 3 4 0 1 2 5 1 0 0 0 0 0
12 9 0 0 27 0 0 47 0 0 3 0 55 3 0 2 24 0 1 0 0 0
13 5 1 0 2 6 0 0 0 5 2 0 0 1 0 3 0 0 65 0 20 0
14 0 4 0 0 0 0 0 1 0 0 0 3 0 0 0 0 0 27 0 34 0
15 9 29 59 45 20 13 10 18 3 11 2 7 1 6 2 7 1 1 0 4 2
Rv2029c 1 0 0 0 0 36 5 5 12 2 0 0 11 4 7 0 0 0 15 0 36 30 0 0 4 3 0 2 0 0 3 0 2 0 15
2 1 1 0 3 0 2 0 1 0 0 0 0 0 3 0 0 0 1 0 0 2 0 0 1 1 2 1 0 4 2 6 2 0 0
3 0 2 0 1 0 0 0 1 0 0 2 0 0 0 0 0 11 0 0 0 1 0 0 0 0 2 0 0 0 0 0 2 0 0
4 0 0 0 0 0 0 0 0 0 2 0 1 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0
5 0 0 3 0 0 10 0 0 0 5 0 0 0 0 52 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
6 0 1 1 0 0 1 0 0 0 0 0 0 1 0 8 0 1 0 0 0 4 1 4 6 1 0 0 1 0 3 5 1 0 0
7 0 0 0 0 0 0 1 3 0 24 0 0 0 0 0 4 0 2 8 3 0 1 0 0 0 0 0 4 0 0 0 0 5 0
8 0 0 3 5 0 0 1 0 0 0 0 0 0 0 1 0 23 0 1 36 0 0 0 0 0 0 0 2 0 0 0 0 0 0
9 67 0 16 0 3 5 16 2 0 1 0 42 8 5 1 -1 0 3 4 1 1 0 0 0 0 2 9 0 3 3 0 0 22 1
10 18 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
11 11 0 0 0 0 0 1 0 0 0 0 0 2 1 0 2 0 0 0 5 0 0 1 0 0 0 0 0 0 0 0 0 0 0
12 12 0 1 0 0 0 0 5 0 1 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 4 5 5 0 18 0
13 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0
14 2 0 1 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 5 3 0 0 0 0 0 0 1 0 0 0
15 1 2 0 0 0 0 4 0 0 0 0 0 0 0 2 0 0 1 0 0 0 1 2 0 0 0 1 0 0 1 0 0 0 0
Rv2031c 1 0 0 0 0 0 7 0 0 1 0 0 0 6 0 0
2 2 1 0 0 0 1 0 5 0 0 2 0 1 1 1
3 0 0 0 0 0 0 1 0 1 0 0 1 1 0 0
4 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
6 4 0 5 0 1 0 0 1 1 0 0 2 0 0 0
7 0 2 4 3 1 0 0 0 4 1 0 0 3 0 0
8 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0
9 10 1 1 0 11 3 0 18 2 3 14 0 18 1 0
10 43 1 0 0 0 0 2 0 0 0 0 0 0 0 0
11 0 0 1 0 0 0 0 0 1 0 3 0 0 0 0
12 0 0 1 7 0 0 0 32 3 0 13 0 23 13 0
13 3 0 0 5 0 0 0 0 0 0 0 0 0 0 0
14 1 0 2 0 0 0 0 0 7 0 0 1 0 0 0
15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Rv1886c 1 0 21 0 0 0 0 0 0 0 23 0 0 0 0 0 1 3 2 0 0 0 0 0 0 0 0 0 0 0 0 0
(Ag85B) 2 0 0 1 1 0 0 0 2 2 5 0 3 1 21 9 5 11 7 0 1 5 0 2 19 0 1 0 0 2 1 0
3 1 0 0 1 0 1 0 0 0 0 0 9 0 0 2 0 1 0 2 0 0 0 0 0 0 0 0 0 1 0 0
4 0 0 6 12 0 0 0 0 0 0 0 40 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
6 3 0 7 0 12 1 6 0 0 0 2 0 3 4 1 1 1 0 0 0 0 0 1 0 0 0 0 5 3 0 0
7 0 0 0 0 0 0 0 0 4 0 0 4 0 0 0 0 74 0 0 0 0 0 0 0 0 0 0 0 0 0 0
8 0 0 0 1 1 0 0 0 0 0 7 0 0 0 0 1 1 0 0 0 0 0 7 0 0 1 0 2 1 0 7
9 13 0 2 1 0 31 36 11 15 45 8 1 3 54 17 30 4 50 1 3 36 38 14 2 1 24 2 0 24 0 22
10 98 -10 11 26 29 45 0 13 0 67 31 0 57 3 0 1 0 0 0 2 0 0 0 0 0 0 26 0 54 0 0
11 6 0 1 4 0 59 1 0 0 1 1 0 0 2 0 0 0 3 0 0 0 0 0 7 0 0 0 1 0 1 0
12 35 0 0 2 0 12 24 0 0 0 21 20 6 30 8 1 22 152 0 0 0 25 5 1 0 3 4 5 93 0 0
13 1 0 0 1 0 0 2 1 2 6 4 1 32 16 1 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0
14 1 0 0 4 0 0 4 0 0 1 0 1 2 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0
15 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0
  rel. proliferation < 3%   rel. proliferation 3-10%   rel. proliferation >10%
peptide ®
Mtb  antigen cell subsprotein 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
CD4 5 1 4 2 1 0 1 1 1 1 3 1 2 0 3 3 1 2 0 2 1
CD8 2 3 4 3 2 1 2 2 3 1 0 1 0 0 0 1 0 5 0 4 0
CD4 7 2 2 1 3 1 3 1 1 1 0 2 3 2 1 1 1 0 1 1 3 0 1 0 2 0 3 0 1 1 0 2 2 0
CD8 4 0 1 0 1 1 1 1 0 1 0 2 0 0 1 0 2 1 0 2 1 0 0 0 0 0 0 0 0 0 0 0 2 1
CD4 3 1 2 1 2 1 0 3 2 2 3 0 3 3 2




CD4 1 1 0 0 1 0 1 2 1 2 4 1 1 1 2 1 1 3 1 5 3 2 2 2 2 3 2 3 3 0 3 1 4 1
CD8 0 0 0 0 0 1 2 0 0 1 0 0 0 3 2 0 1 0 1 2 1 1 0 1 0 0 1 1 0 0 1
CD4 4 0 1 2 0 5 5 3 3 6 4 3 4 6 3 2 4 3 2 1 3 3 4 2 1 2 2 1 3 1 1
CD8 3 1 1 2 2 4 2 2 1 3 2 2 2 4 1 1 3 2 0 0 1 2 1 1 0 1 1 0 3 0 1
not tested  ≤ 1 responder  2 responders  3 responders  4 responders
peptide ®
Mtb  antigen cell subsprotein 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
CD4 1 0 2 0 0 0 0 0 1 0 0 0 1 0 0 1 1 0 0 0 0
CD8 0 1 1 1 0 0 1 1 2 0 0 1 0 0 0 1 0 2 0 1 0
CD4 0 1 0 0 1 0 1 0 1 1 0 1 1 0 0 0 0 0 0 1 2 0 0 0 1 0 1 0 0 0 0 0 0 0





CD4 0 1 0 0 1 0 0 0 0 0 0 0 0 1 0
CD8 0 0 0 0 1 0 0 2 0 0 2 0 2 1 0
CD4 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 0
CD8 0 0 0 0 0 0 0 1 0 1 0 0 1 0 0 0 2 2 0 0 0 1 2 1 1 0 1 0 0 1 1 0 0 1
CD4 0 0 0 0 0 1 0 1 0 1 0 0 0 0 0 0 1 0 2 0 1 0 0 0 0 0 0 1 0 0 0
CD8 2 0 0 1 1 2 2 1 1 1 1 2 0 3 1 1 3 2 0 0 1 2 1 1 0 1 0 0 2 0 1





Figure 4. Proliferative CD4+ and CD8+ T-cell responses to Mtb DosR antigen epitopes among 
PPD+ individuals. PBMCs of  15 PPD+ donors were stimulated with either Mtb DosR antigen protein, 
corresponding single peptides or control antigen and peptides of  Ag85B. Relative proliferation of  (A) CD4+ 
and (B) CD8+ T cells is indicated in grey tones. Relative proliferation was calculated as follows; ((Δ geometric 
mean sample - Δ geometric mean control medium) / (Δ geometric mean PHA - Δ geometric mean control 
medium)) x 100% = % of  maximal proliferation. Light grey; less than 3% proliferation, grey; between 3 
and 10% proliferation, dark grey; over 10% proliferation. A relative proliferation of  ≥ 10% was considered 
positive.
A substantial number of  peptides was recognized by CD4+ and CD8+ T cells for Rv17 3c 
(CD4+: 17/2  (10.1-76.9%) CD8+: 12/2  (1 .4-1 0%)), Rv2029c (CD4+: 25/33 (10.4-100%) 
CD8+: 14/33 (10.3-66.6%)), Rv2 31c (CD4+: 12/14 (1 .2-53.8%) CD8+: 5/14 (11.3-42.7%)) and 
Ag85B (CD4+: 28/30 (10.1-75.3%) CD8+: 25/30 (10.9-97.7%)). Some peptides were recognized 
by CD4+ T cells from more than one third of  the donors (e.g. 6/15 donors in case of  Ag85B 
peptides 9 and 13, and 5/15 for Ag85B peptides 5, 6), whereas other peptides were recognized by 
CD4+ T cells in 4/15 donors, such as Rv1733c peptide 2 and Ag85B peptides 10, 12, 16 and 22. 
CD8+ T-cell responses were particularly observed against Rv1733c and Ag85B, these responses 
were found in four to five donors; Rv1733c peptides 17 (5/15), 2 and 19 (4/15), and Ag85B 
peptides 5 and 13 (4/15). Notably, some peptides were recognized by both CD4+ and CD8+ T cells 
(Rv1733c peptide 2, Ag85B peptides 5 and 13). Table 2 shows the cumulative epitope recognition 










































tested. Interestingly, the results suggest enrichment of  epitopes in certain immunogenic regions, 
for example Rv1733c(1-40), Rv1733c(161-200) and Ag85B(81-180), which harbour Rv1733c peptides 1-3, 
17-19 and Ag85B peptides 5-14.
The above-described Mtb DosR antigen-encoded peptide epitopes were recognized by 
donors with varying HLA-genotypes. Many of  the in vitro responses given in Figure 4A and B 
matched with in silico epitope motif  searches for the relevant HLA-genotypes (data not shown) 
[41]. This suggests that responses to Mtb dosR-regulon-encoded antigens occur in a wide range 
of  HLA backgrounds. In order to better characterize the molecular interactions of  Mtb DosR 
antigenic epitope presentation, we examined peptide recognition in the context of  the highly 
frequent HLA-A*0201 genotype (New allele frequency database: http://www.allelefrequencies.
net [42]) and found that Rv1733cp181-189 specific CD8
+ T cells were able to lyse peptide loaded 
and endogenously processed Rv1733c-antigen loaded target cells in the context of  HLA-A*0201 









































































































































































































































































































































































































































































































































































































We have proposed that Mtb DosR-regulon-encoded antigens [7] that are expressed by Mtb during 
in vitro conditions mimicking intracellular infection represent rational targets for TB vaccination. 
Immune responses to Mtb DosR-regulon-encoded antigens are prominently found in latently 
infected individuals, and are associated with latent Mtb infection (LTBI) in several ethnically 
and geographically distinct populations [7;11;13]. Additional work showed that the Mtb DosR-
regulon-encoded antigen Rv2628 was strongly recognized by individuals with remote Mtb infection 
[13;14]. Thus far, the precise mechanisms and T-cell subsets responsible for the responses against 
Mtb DosR-regulon-encoded antigens have not been studied in detail; and virtually all studies have 
relied on measuring IFN-γ production by polyclonal cells. Here we report peptide reactivity and 
memory phenotypes of  Mtb DosR-regulon-encoded antigen-specific T cells in long-term LTBI, 
and moreover, document a large series of  specific peptide epitopes recognized by specific CD4+ 
and CD8+ T cells. 
Three Mtb DosR antigens, Rv1733c, Rv2029c and Rv2031c (HspX, a-crystallin) were tested 
in this study. Strong Mtb DosR antigen-specific CD4+ and CD8+ polyfunctional T-cell responses 
were detected in ltLTBIs. The highest responses were observed among single cytokine-producing 
CD4+ and CD8+ T-cell subsets (either TNF-α+, IL-2+ or IFN-γ+, depending on the stimulus) 
followed by double producing CD4+ and particularly CD8+ T cells. Of  interest, the most frequent 
multiple cytokine-producing T cells were IFN-γ+ TNF-α+ CD8+ T cells. These cells were further 
characterized as effector memory (CCR7- and CD45RA-) or effector (CCR7- and CD45RA+) T 
cells, which have the ability to perform immediate effector functions. This is compatible with an 
important role for CD8+ T cells in Mtb infection [43;44]. 
Mtb antigen specific polyfunctional T cells have been studied intensely the last few years, 
both in vaccination and in observational studies in Mtb infected individuals [25-36;45]. There is 
currently no consensus whether polyfunctional T cells represent a marker of  protective immunity 
or of  disease activity. The vaccine MVA85A (recombinant replication-deficient vaccinia Ankara, 
expressing Ag85A) induced polyfunctional CD4+ and CD8+ T cells producing IFN-γ, TNF-α and 
IL-2 as well as IFN-γ and TNF-α in mice, which correlated with TB protection [26]. This vaccine 
also induced increased CD4+ T cells expressing IFN-γ, TNF-α and IL-2 in humans when given 
as a booster to previous BCG vaccination [27;28]. Similar results were reported following human 
vaccination with the BCG booster AERAS-402 (recombinant replication-deficient Adenovirus 
(Ad35) virus, expressing a polyprotein of  Ag85A, Ag85B and TB10.4) [29]. Finally, mice vaccinated 
with hybrid subunit vaccines H1 (Ag85-ESAT6) and H56 (H1+Rv2660) also had high numbers of  
triple cytokine-producing CD4+ T cells [30;31]. However, observational studies in humans have 
associated polyfunctional CD4+ T cells with TB disease [32;33]. Although limited information 
is available on Mtb-specific polyfunctional CD8+ T cells, two of  our recent studies showed that 








































Double- and monofunctional T-cell responses to Mtb latency antigens
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cured TB patients and that IFN-γ+/IL-2+ CD8+ T cells are a biomarker of  protective host defense 
against Mtb [34;35]. Moreover, no difference in polyfunctional CD4+ T-cell profiles could be 
identified between BCG-vaccinated children from a high endemic area that either developed TB 
or did not, indicating that polyfunctional T cells are not a biomarker of  BCG-induced protection 
against TB [45]. In our study here we show the presence of  mostly single and double positive 
T cells, the latter mainly present in CD8+ T cells, supporting previous findings that single and 
double positive T cells are prominent in LTBI [32;35]. This suggests that these double and single 
cytokine-producing T cells play a significant role in Mtb immunity, although their precise nature 
and mechanisms of  action requires more detailed studies. 
While most studies on polyfunctional T cells have focused on highly expressed Mtb early 
phase proteins such as ESAT6 and Ag85B, instead, we here have analyzed Mtb antigens that are 
expressed during dormancy. It remains possible that antigens expressed during different phases of  
infection may preferentially induce different patterns of  single, double and polyfunctional T cells. 
A striking observation was the wealth of  epitopes that could be identified in Mtb DosR-
regulon-encoded antigens, in accordance with the significant immunogenicity of  Mtb DosR-
regulon-encoded antigens in a wide variety of  HLA backgrounds [46]. The donors used to detect 
single peptide responses were anonymous Dutch blood bank donors. Although we have no precise 
information about their mycobacterial exposure status, we have shown previously that over 50% 
of  blood bank donors respond to PPD; furthermore, responses to Mtb DosR antigens were also 
observed in nontuberculous mycobacteria-exposed donors, probably due to the high conservation 
of  these antigens [47]. 
Within several Mtb DosR-regulon-encoded antigens highly immunogenic regions could be 
identified and a substantial number of  peptides elicited both CD4+ and CD8+ T-cell responses. 
Although HLA-class I presented peptides are typically 8-11 amino acids long, whereas HLA-
class II ligands can be between 10-25 amino acids [41;48;49], we nevertheless found efficient 
CD8+ T-cell responses using 20-mers and confirmed Rv1733c-specific lysis of  target cells by 
Rv1733cp181-189 specific CD8
+ T cells. It has been suggested that apoptosis, induced by the cytotoxic 
activity of  CTL, can inhibit Mtb growth or even kill Mtb bacteria [50-52]. Granulysin may play 
a role in this mycobactericidal activity [53]. In addition, vaccine-induced CD8+ T cells in mice 
indeed can reduce bacterial load in vivo [54]. Again, this suggests a protective role for CD8+ T cells 
in Mtb infection. 
Our 6-10 day incubation period may have allowed internalization and processing of  peptides 
for HLA-class I presentation or allowed cross-presentation via alternative antigen presentation 
pathways [55;56]. Peptides appeared to be more sensitive tools for detecting CD4+ or CD8+ T-cell 
responses compared to recombinant proteins; this is likely due to the preprocessed nature of  
peptides, facilitating highly efficient antigen presentation. Second, peptides were present at much 
higher molar concentrations since proteins and peptides were tested at 10 μg/ml, regardless of  










































in recombinant proteins, may also have permitted identification of  subdominant epitopes using 
peptides. Thus, peptide-based epitope mapping also offers the potential to elucidate subdominant 
epitopes, which might be exploited in designing improved vaccines by inducing immunity to a 
broader epitope repertoire than would be seen following natural infection or protein vaccination 
[57;58]. Of  note, previous work has shown the efficacy of  vaccines containing subdominant 
epitopes in protection against infection with Mtb [59] .
In conclusion, we report the presence of  Mtb DosR-regulon-encoded peptide antigen-specific 
single and double functional CD4+ and CD8+ T-cell responses in ltLTBIs. We show that the 
majority of  multiple cytokine-producing T cells comprise IFN-γ+ TNF-α+ CD8+ T cells; these 
cells were characterized as mainly effector memory or effector T cells. Furthermore, we describe a 
large series of  new peptide epitopes expressed by Mtb DosR-regulon-encoded antigens, which are 
recognized by CD4+ and/or CD8+ T cells of  PPD+ donors. These results significantly enhance 
our understanding of  the human immune response to Mtb phase-dependent antigens in long-term 
control of  infection, and pave the way for designing Mtb DosR antigen and/or peptide-based 
vaccination approaches to TB.
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The peptides recognized by HLA-A2 positive donors were subjected to further in silico minimal 
epitope motif  searches in the context of  HLA-A2 to select the precise epitopes embedded in the 
recognized 20-mer peptides. 25 candidate epitopes were identified and subsequently synthesized 
as 9-mer peptides. Their ability to bind HLA-A2 was measured using an HLA-A2 binding assay 
which resulted in a set of  epitopes that had an intermediate or high binding affinity (IC50 < 
10 μM) for HLA-A*0201 and epitopes that had low (IC50 > 10 μM) or no measurable (IC50 
> 100 μM) affinity, this despite high prediction scores and in vitro CD8+ T-cell recognition of  
the corresponding 20-mer peptide (Table S2). In addition to the binding assay, all 25 candidate 
HLA-A2 epitopes were tested in a lymphocyte stimulation test to examine their recognition in 
the context of  HLA-A2 molecules. Five HLA-A2 candidate peptides were recognized solely by 
HLA-A2+ but not HLA-A2- donors as assessed by CFSE proliferation (Table S2). 
A polyclonal CD8+ T-cell line directed against Rv1733cp181-189 and Rv2031cp96-104 was generated 
from an HLA-A2 positive donor that responded to both Rv1733cp181-189 and Rv2031cp96-104 epitopes. 
Effector CD8+ T cells showed specific peptide dependent lysis of  allogenic EBV-BLCL JY target-
cells (HLA-A*0201) when pulsed with peptide Rv1733cp181-189 (but not with Rv2031cp96-104). Killing 
was observed at different effector-to-target ratios (E: T) (Figure S2A). CD8+ T cells also recognized 
and lysed EBV-BLCL JY target cells that had been transduced with a plasmid encoding Rv1733c, 
while not recognizing EBV-BLCL JY target cells similarly transduced with control plasmid (Figure 
S2A). Specific peptide dependent lysis of  EBV-BLCL JY target cells loaded with HLA-candidate 
epitopes Rv1733cp181-189 could be inhibited partly (~30 %) by the addition of  a pan anti-HLA-class 
I antibody whereas no decrease in lysis was observed following addition of  pan anti-HLA-class II 
antibody (Figure S2B). As expected, the use of  allogeneic EVB-BLCL target cells in combination 
with polyclonal effector cells resulted invariably in some background activity, even in such short 
term assays (5-35 % lysis of  control targets). Nevertheless, peptide dependent lysis was clearly 
evident. Collectively these results show that CD8+ T cells can (i) recognize Mtb dosR antigen 
peptide Rv1733cp181-189 presented by HLA- A*0201 restricted target cells and (ii) lyse peptide 
loaded- and endogenously processed antigen loaded- target cells in the context of  HLA-A*0201 
molecules. These results further document the presence of  functional Mtb dosR regulon encoded 












































Generation of  CD8+ T-cell lines. CD8+ T-cell line was generated from PBMC from an 
HLA-A2+ TB patient (HLA-A2, A3, and DR11) that was directed against Rv1733cp181-189 and 
Rv2031cp96-104 peptides. Lines were generated using (autologous) dendritic cells (DC) as antigen 
presenting cell (APC) as previously described [60].  
Chromium release assay. EBV-BLCL JY (HLA-A*0201, -B7, -Cw7), EBV-BLCL JY-
Rv1733c-GFP (EBV-BLCL JY transduced with an expression vector encoding the Mtb dosR gene 
Rv1733c and the GFP marker [61;62] and EBV-BLCL JY-GFP (EBV-BLCL JY transduced with 
an empty control vector encoding GFP only) were used as target cells and incubated at 37°C for 
1 hr with 0.1 μCi Na2
51CrO4 (Amersham, United Kingdom), washed, and plated in triplicate 
in 96-well round-bottom plates (2500 cells/well). Effector CD8+ T cells were added in different 
effector-to-target (E:T) ratios, 12:1, 25:1 and 50:1 together with either medium, peptide (25 mg/
ml), or 5% Triton X-100 and with or without pan HLA-class I or HLA-class II antibodies. After 
five hours the supernatants were harvested, and the percentage lysis was calculated as follows: 
[(release - spontaneous release)/(maximum release- spontaneous release)] * 100%.
Table S1A. Overlapping peptide set of  Mtb dosR antigen Rv1733c
peptide  dosR antigen Rv1733c  position
number  aa sequence  start-end
1  MIATTRDREGATMITFRLRLKK  1-20
2  ATMITFRLRLPCRTILRVFSKK  11-30
3  PCRTILRVFSRNPLVRGTDRKK  21-40 
4  RNPLVRGTDRLEAVVMLLAVKK  31-50 
5  LEAVVMLLAVTVSLLTIPFAKK  41-60
6  TVSLLTIPFAAAAGTAVQDSKK  51-70
7  AAAGTAVQDSRSHVYAHQAQKK  61-80
8  RSHVYAHQAQTRHPATATVIKK  71-90
9  TRHPATATVIDHEGVIDSNTKK  81-100
10  DHEGVIDSNTTATSAPPRTKKK  91-110
11  TATSAPPRTKITVPARWVVNKK  101-120
12  ITVPARWVVNGIERSGEVNAKK  111-130
13  GIERSGEVNAKPGTKSGDRVKK  121-140
14  KPGTKSGDRVGIWVDSAGQLKK  131-150
15  GIWVDSAGQLVDEPAPPARAKK  141-160 
16  VDEPAPPARAIADAALAALGKK  151-170
17  IADAALAALGLWLSVAAVAGKK  161-180
18  LWLSVAAVAGALLALTRAILKK  171-190
19  ALLALTRAILIRVRNASWQHKK  181-200











































Table S1B. Overlapping peptide set of  Mtb dosR antigen Rv2029c
peptide  dosR antigen Rv2029c  position
number  aa sequence  start-end
1  MTEPAAWDEGKPRIITLTMNKK  1-20
2  KPRIITLTMNPALDITTSVDKK  11-30
3  PALDITTSVDVVRPTEKMRCKK  21-40
4  VVRPTEKMRCGAPRYDPGGGKK  31-50
5  GAPRYDPGGGGINVARIVHVKK  41-60
6  GINVARIVHVLGGCSTALFPKK  51-70
7  LGGCSTALFPAGGSTGSLLMKK  61-80
8  AGGSTGSLLMALLGDAGVPFKK  71-90
9  ALLGDAGVPFRVIPIAASTRKK  81-100
10  RVIPIAASTRESFTVNESRTKK  91-110
11  ESFTVNESRTAKQYRFVLPGKK  101-120
12  AKQYRFVLPGPSLTVAEQEQKK  111-130
13  PSLTVAEQEQCLDELRGAAAKK  121-140
14  CLDELRGAAASAAFVVASGSKK  131-150
15  SAAFVVASGSLPPGVAADYYKK  141-160
16  LPPGVAADYYQRVADICRRSKK  151-170
17  QRVADICRRSSTPLILDTSGKK  161-180
18  STPLILDTSGGGLQHISSGVKK  171-190
19  GGLQHISSGVFLLKASVRELKK  181-200
20  FLLKASVRELRECVGSELLTKK  191-210
21  RECVGSELLTEPEQLAAAHEKK  201-220
22  EPEQLAAAHELIDRGRAEVVKK  211-230
23  LIDRGRAEVVVVSLGSQGALKK  221-240
24  VVSLGSQGALLATRHASHRFKK  231-250
25  LATRHASHRFSSIPMTAVSGKK  241-260
26  SSIPMTAVSGVGAGDAMVAAKK  251-270
27  VGAGDAMVAAITVGLSRGWSKK  261-280
28  ITVGLSRGWSLIKSVRLGNAKK  271-290
29  LIKSVRLGNAAGAAMLLTPGKK  281-300
30  AGAAMLLTPGTAACNRDDVEKK  291-310
31  TAACNRDDVERFFELAAEPTKK  301-320
32  RFFELAAEPTEVGQDQYVWHKK  311-330
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Table S1C. Overlapping peptide set of  Mtb dosR antigen Rv2031c
peptide  dosR antigen Rv2031c  position
number  aa sequence  start-end
1  MATTLPVQRHPRSLFPEFSE  1-20
2  PRSLFPEFSELFAAFPSFAG  11-30
3  LFAAFPSFAGLRPTFDTRLM  21-40
4  LRPTFDTRLMRLEDEMKEGR  31-50
5  RLEDEMKEGRYEVRAELPGV  41-60
6  YEVRAELPGVDPDKDVDIMV  51-70
7  DPDKDVDIMVRDGQLTIKAE  61-80
8  RDGQLTIKAERTEQKDFDGR  71-90
9  RTEQKDFDGRSEFAYGSFVR  81-100
10  SEFAYGSFVRTVSLPVGADE  91-110
11  TVSLPVGADEDDIKATYDKG  101-120
12  DDIKATYDKGILTVSVAVSE  111-130
13  ILTVSVAVSEGKPTEKHIQI  121-140
14  SVAVSEGKPTEKHIQIRSTN  125-144










































Table S1D. Overlapping peptide set of  Mtb early secreted antigen Ag85B (Rv1886c)
peptide   antigen Ag85B  position
number  aa sequence  start-end*
1  FSRPGLPVEYLQVPSPSMGR    41-60
2  LQVPSPSMGRDIKVQFQSGG  51-70
3  DIKVQFQSGGNNSPAVYLLD      61-80
4  NNSPAVYLLDGLRAQDDYNG      71-90
5  GLRAQDDYNGWDINTPAFEW     81-100
6  WDINTPAFEWYYQSGLSIVM      91-110
7  YYQSGLSIVMPVGGQSSFYS      101-120
8  PVGGQSSFYSDWYSPACGKA      111-130
9  DWYSPACGKAGCQTYKWETF     121-140
10  GCQTYKWETFLTSELPQWLS     131-150
11  LTSELPQWLSANRAVKPTGS      141-160
12  ANRAVKPTGSAAIGLSMAGS      151-170
13  AAIGLSMAGSSAMILAAYHP      161-180
14  SAMILAAYHPQQFIYAGSLS      171-190
15  QQFIYAGSLSALLDPSQGMG      181-200
16  ALLDPSQGMGPSLIGLAMGD      191-210
17  PSLIGLAMGDAGGYKAADMW      201-220
18  AGGYKAADMWGPSSDPAWER      211-230
19  GPSSDPAWERNDPTQQIPKL       221-240
20  NDPTQQIPKLVANNT #           231-245
21  QIPKLVANNTRLWVY #  236-250
22  VANNTRLWVYCGNGT #  241-255
23  VANNTRLWVYCGNGTPNELG            241-260
24  CGNGTPNELGGANIPAEFLE           251-270
25  GANIPAEFLENFVRSSNLKF            261-280
26  NFVRSSNLKFQDAYNAAGGH           271-290
27  QDAYNAAGGHNAVFNFPPNG            281-300
28  NAVFNFPPNGTHSWEYWGAQ             291-310
29  THSWEYWGAQLNAMKGDLQS              301-320
30  YWGAQLNAMKGDLQSSLGAG           306-325
# 15-mers, 10 aa overlap   
* sequence Ag85B consists of  325 aa. First 40 aa is leader sequence;


































































































































































































































































































































































































































































































































































































































































































































































































































Figure S1. Multi-parameter flow cytometry analysis. The gating strategy of  CD4+ T cells from one 
donor in response to PPD as a representative of  all analyzed CD4+ and CD8+ T-cell populations. Lymphocytes 
were gated using the forward scatter (FSC) and side scatter (SSC) profile. CD3 positive lymphocytes were 
then plotted against CD4 and CD8. CD3+CD4+ T-cell populations were plotted against CD8 to obtain the 
CD3+CD4+CD8- T-cell population (CD4+ T cells) (A). The same approach was used for the selection of  
CD3+CD8+CD4- T cells (CD8+ T cells). Subsequently, IFN-g, TNF-α and IL-2 producing T cells were gated 
(B). Cytokine and surface marker combinations produced and expressed by single, double and polyfunctional 
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Figure S2. Cytotolytic activity of  a CD8+ polyclonal T-cell line against the candidate HLA-A2 
restricted Mtb epitope Rv1733cp181-189. The results show specific recognition of  peptide epitope 
Rv1733cp181-189 by CD8
+ T cells when peptide was loaded onto EBV-BLCL JY target cells (compared to 
medium control). CD8+ T cells also recognized EBV-BLCL JY target cells that had been transduced with an 
expression plasmid encoding Rv1733c, thus facilitating endogenous expression and presentation of  Rv1733c 
in the context of  HLA-A*0201. In contrast, EBV-BLCL JY target cells which were transduced with an empty 
plasmid (A) were not efficiently killed. Specific lysis of  EBV-BLCL JY target cells loaded with Rv1733cp181-189 
could be inhibited partly by addition of  anti-HLA-Class-I antibody but not by addition of  anti-HLA-Class-II 
antibody (B). The % specific lysis was calculated as follows [(release-spontaneous release)/(maximum release-
spontaneous release)] x 100%.
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Mycobacterium tuberculosis (Mtb) is responsible for almost 2 million deaths annually. Mycobacterium 
bovis bacillus Calmette-Guérin, the only vaccine available against tuberculosis (TB), induces highly 
variable protection against TB, and better TB vaccines are urgently needed. A prerequisite for 
candidate vaccine antigens is that they are immunogenic and expressed by Mtb during infection 
of  the primary target organ, that is, the lungs of  susceptible individuals. In search of  new TB 
vaccine candidate antigens, we have used a genome-wide, unbiased antigen discovery approach 
to investigate the in vivo expression of  2170 Mtb genes during Mtb infection in the lungs of  mice. 
Four genetically related but distinct mouse strains were studied, representing a spectrum of  TB 
susceptibility controlled by the supersusceptibility to TB 1 locus. We used stringent selection approaches 
to select in vivo-expressed Mtb (IVE-TB) genes and analyzed their expression patterns in distinct 
disease phenotypes such as necrosis and granuloma formation. To study the vaccine potential 
of  these proteins, we analyzed their immunogenicity. Several Mtb proteins were recognized by 
immune cells from tuberculin skin test-positive, ESAT6/CFP10-responsive individuals, indicating 
that these antigens are presented during natural Mtb infection. Furthermore, TB patients also 
showed responses towards IVE-TB antigens, albeit lower than tuberculin skin test-positive, 
ESAT6/CFP10-responsive individuals. Finally, IVE-TB antigens induced strong IFN-γ+/TNF-α+ 
CD8+ and TNF-α+/IL-2+ CD154+/CD4+ T-cell responses in PBMC from long-term latently 
Mtb infected individuals. In conclusion, these IVE-TB antigens are expressed during pulmonary 
infection in vivo, are immunogenic, induce strong-T cell responses in long-term latently Mtb-












































Tuberculosis (TB) remains a leading cause of  death, particularly in low and middle income 
countries [1]. One third of  the world population is estimated to be latently infected with 
Mycobacterium tuberculosis (Mtb), and 3-10% of  these will develop active TB during their lifetime. 
In HIV-infected individuals this proportion increases to 7-10% per life year. The emergence of  
multidrug-resistant, extensively drug-resistant and more recently also totally drug-resistant Mtb 
strains is further aggravating the TB epidemic. Currently, Mycobacterium bovis Bacille Calmette-
Guérin (BCG) is the only available vaccine against TB. Although BCG vaccination can prevent 
severe childhood TB [2], it induces highly variable and inconsistent protection against pulmonary 
TB, the contagious form of  TB in adults [3]. A more recently identified drawback of  live BCG 
vaccination is the occurrence of  disseminating BCG infections in HIV infected children [4], 
similar to severe BCG infections in individuals with genetic defects in the IL-12/IL-23/IFN-γ axis 
[5;6]. Thus, new TB vaccines are needed that are more effective and safer than BCG. 
Understanding the intracellular behavior of  Mtb during in vivo infection is important not only 
for understanding its infection biology, but it is also essential for the identification of  possible novel 
TB vaccine candidate antigens. Infection stage and site-related differences in in vivo Mtb gene 
expression patterns can clearly affect the repertoire of  potential Mtb antigens that is available for 
immune recognition in the primary infected organ, the lung. Antigens expressed in the lungs of  
Mtb infected, susceptible individuals could represent interesting new candidate antigens for TB 
vaccination, because they would induce responses capable of  recognizing in situ Mtb infected cells.
Mtb has a remarkable ability to adapt to environmental changes by altering its metabolic state. 
A major environmental stress factor that Mtb is thought to encounter during host infection is the 
deprivation of  oxygen and nutrients. In vitro hypoxia induces the expression of  the Mtb dormancy 
regulon [7], which is controlled by the master regulator DosR (Rv3133c). The expression of  the Mtb 
DosR regulon is also induced by low-dose NO, carbon monoxide exposure, and during infection in 
IFN-g-activated macrophages [7;8]. Previously, we have reported broad human T-cell responses to 
Mtb DosR regulon-encoded antigens, and showed that responses to these antigens were prominent 
and associated with latent tuberculosis infection (LTBI) in ethnically and geographically distinct 
populations [9-13]. Other work has shown that nutrient limitation can induce the expression of  
specific Mtb genes such as Rv2660c [14]. This gene was found to encode a “starvation” antigen 
with promising long-term vaccine efficacy in preclinical TB infection models, both in mice [15] 
and in nonhuman primates [16]. The more recently described enduring hypoxic response (EHR) 
genes represent an alternative hypoxia-induced response model, which includes most of  the DosR 
regulon-encoded genes complemented with an additional number (> 200) of  Mtb stress response 
genes [17]. This model has also helped to identify new Mtb antigens [18].  
A limitation of  the models discussed above is that the identification of  differentially regulated 










































that Mtb encounters upon host infection. First, however, many of  these environmental stress factors 
may not be known as yet, limiting the value of  such hypothesis-driven studies. Second, there may 
be additive or synergistic effects between multiple stress factors in vivo which may easily be missed 
when studied in isolation in vitro. Thirdly, and perhaps more importantly, certain key features 
of  host response-induced stress cannot readily be recapitulated in vitro, including granuloma 
formation and TB necrosis, both being cardinal features of  TB. To overcome these limitations 
several laboratories have started to analyze the gene expression profiles of  intracellular Mtb, either 
in infected human or murine macrophages [8;19], in the infected tissue of  different mouse strains 
(BALB/c, SCID [20]) or in artificial granuloma mouse models [21]. However, none of  these 
mouse models developed granulomatous necrotic TB lesions [22]. We therefore have studied 
Mtb genome-wide gene expression patterns in mice strains carrying different genotypes of  the 
supersusceptibility to TB 1 (sst1) locus. This genetic locus is located on chromosome 1 and controls the 
progression of  Mtb infection to severe and necrotic lesions in a lung-specific manner: C3HeB/FeJ 
(C3H) mice carrying the susceptible sst1 allele develop TB pneumonia with strong inflammatory 
responses with exudation throughout the lung and early onset of  massive necrosis, whereas 
C57BL/6J (B6) mice carrying the resistant sst1 allele develop smaller, interstitial granulomas 
without necrotic lesions that control bacterial multiplication. C3H.B6-sst1 congenic mice carrying 
the (B6-derived) resistant sst1 locus on the C3H background showed increased survival after Mtb 
infection compared with the susceptible C3H mice, but less prominently than did the resistant 
B6 mice. Finally, Mtb-infected B6.C3H-sst1 mice, carrying the susceptible C3H-sst1 locus on the 
B6 background, develop robust granulomas that are fenced from the healthy tissue where lesions 
contain foamy macrophages and develop late-onset necrosis, resembling pulmonary TB in human 
adults. In contrast, the B6 strain does not display this phenotype, confirming the specific role for 
sst1 in the control of  cell death [23].
The sst1 locus carries 22 genes, 1 of  which was highly expressed in Mtb infected lungs of  C3H.
B6-sst1 but not of  hypersusceptible C3H mice. Interestingly, the expression of  this gene, termed 
intracellular pathogen resistance 1 (Ipr1), decreased Mtb multiplication in susceptible macrophages and 
induced a switch from necrotic to apoptotic cell death [24]. The lack of  Ipr1 expression in C3H-
susceptible sst1 locus is therefore responsible for the development of  lung-specific necrosis upon 
Mtb infection [25]. The closest human homologue of  Ipr1 is SP110b. The expression of  both 
Ipr1 and SP110b is regulated by IFNs, indicating a role in immunity [26-28]. Genetic association 
studies performed in West Africa identified three polymorphisms in the SP110b gene that were 
associated with genetic susceptibility to TB [29]. However, a number of  other studies performed 
in Ghana, Russia, South Africa and Indonesia did not replicate this finding [30-33]. A SP110b 
homologue was also identified in cattle, which correlated to susceptibility to Mycobacterium avium 
ssp. paratuberculosis [34].
These four (congenic) mouse models we have studied here show a spectrum of  TB susceptibility 








































Novel Mtb antigens expressed in pulmonary infection
89
4
necrotic lesions depending on the sst1 locus and the modifying genetic background in which 
the locus is expressed. This mouse model replicates key features of  human Mtb infection. In this 
study, we have taken advantage of  this disease spectrum and 1) analyzed quantitative real-time 
expression patterns of  all Mtb genes predicted to be the first gene in each operon, in the lungs of  
Mtb-infected mice, aiming to identify the Mtb genes that are highly or differentially expressed in 
the lung during in vivo infection (in vivo-expressed Mtb (IVE-TB) genes); 2) compared these Mtb 
gene expression patterns between susceptible (B6.C3H-sst1 and C3H) and resistant (C3H.B6-sst1 
and B6) mouse strains in an attempt to correlate expression patterns to infection phenotype, and 
3) selected a set of  the most consistently expressed Mtb genes, produced these as recombinant 
proteins, and analyzed their immunogenicity in tuberculin skin test (TST)+ healthy, TB-affected 
individuals as well as long-term LTBI (ltLTBI) as a first step towards their validation as new TB 
vaccine candidate antigens. 
Materials and methods
Mouse strains. C3HeB/FeJ (C3H) and C57BL/6J (B6), mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME). Congenic C3H.B6-sst1 and B6.C3H-sst1 mouse strains carrying 
the resistant and susceptible alleles of  the sst1 locus, respectively, were generated as previously 
described [24;35]. Briefly, an ~ 20-cM segment of  chromosome 1, containing the sst1 locus, was 
introgressed in the opposite background strain via > 10 backcrosses. Mice were bred and housed 
under specific pathogen-free conditions at the Harvard Medical School of  Public Health.
Bacterial strains. Mtb suspensions were used as previously described [36]. In short, Mtb (Erdman 
strain; Trudeau Institute, Saranac Lake, NY) cultures were grown to midlog phase in Middlebrook 
7H9 medium (BD Biosciences, Franklin Lakes, NJ) ((10% oleic acid/albumin/dextrose/catalase 
(OADC; Difco), 0.05% Tween 80 (Sigma-Aldrich), and 0.5% glycerol (Sigma-Aldrich)). Bacteria 
were washed and stored at -80 ºC. Prior to infection, bacteria were thawed, sonicated, and diluted 
in PBS to 106 CFU/ml.
Infection of  mice. Mice were infected by aerosol with 25 - 50 CFU Mtb using a Madison 
chamber (College of  engineering shops at the University of  Wisconsin, Madison, WI) with n = 2 
per time point [24]. B6 and C3H mice were sacrificed both 6 and 9 weeks postinfection, whereas 
B6.C3H-sst1 and C3H.B6-sst1 mice were sacrificed 9 and 6 weeks postinfection, respectively. For 
the reactivation model, B6 and B6.C3H-sst1 mice were infected i.v. via the tail vein with 5 x 104 
CFU Mtb per mouse as previously described [23].Twelve weeks after challenge the mice were 
given isoniazid (INH) supplied via the drinking water (10 mg/100 ml) for 90 days. Mice were 










































Genome-Wide Mtb transcription profiling via a Two-Step Multiplex Real-Time RT-
PCR. Quantification of  Mtb mRNA gene expression was performed as previously described 
[15;37;38]. The protocol is based on first-strand cDNA synthesis and controlled multiplex 
amplification of  cDNAs, which is followed by individual real-time PCR (Taqman) quantification 
of  Amplified cDNAs in a 384-well format using a LightCycler 480. 
Total Mtb RNA was isolated from the infected mouse lung tissue by homogenization in 
TRIzol and bacillary disruption by bead beating (MP Biomedicals, Solon, OH). Total RNA was 
isolated using RNeasy columns (Qiagen, Valencia, CA). RNA was precipitated, cleaned with two 
consecutive off-column RQ1 DNase digestions (Promega, Madison, WI) and resuspended in 50 ml 
of  RNase-free water (Applied Biosystems/Ambion, Austin, TX). 
cDNA synthesis was performed using 50 ng total RNA, which was separated in reverse 
transcriptase (RT)+ and RT- reactions to control for DNA contamination. Exo-resistant random 
primer (0.5 µl), 1 µl 10 mM dNTPs, and nuclease-free water was added and incubated for 3 minutes 
at 70 ºC in a thermal cycler. Subsequently, 4 µl 5X Maxima RT Buffer, 0.5 µl RiboLock RNase 
inhibitor, 0.5 µl Maxima RT enzyme (replaced by water for RT- control samples) (all Fermentas, 
Gen Burnie, MD), and nuclease-free water were added and incubated at 50 ºC for 1 hour, 95 ºC 
for 2 minutes to inactivate, and then kept at 4 ºC. 
The generated cDNAs were further amplified via controlled multiplex preamplification with a 
mix of  2179 Mtb gene-specific primers (23.8 µl primer mix: ~50 nM per amplification reaction), 
2 µl cDNA, 3 µl 10X Advantage 2 buffer (Clontech, Mountain View, CA), 0.6 µl 1X Advantage 
2 Polymerase Mix (Clontech, CA), and 0.6 µl 10 mM dNTPs (Fermentas) to a volume of  30 µl 
(ftp://smd-ftp.stanford.edu/tbdb/rtpcr/taqman_oligos.fa) [15]. Sequences and design of  PCR 
primer/probe sets are available at http://genes.stanford.edu/technology.php and http://www.
tbdb.org/rtpcrData.shtml. A comparative control of  100 pg (2 x 104 gene copy number) genomic 
H37Rv DNA was also included. As an additional control, 25 Mtb reference genes were used to 
control for variation across amplification mixes. The gene primer sets were designed using Primer 
Express software (Perkin Elmer, Foster City, CA) to cover at least one gene of  each predicted Mtb 
operon. Each reaction was heated at 95 oC for 5 minutes, followed by 15 cycles with 95 oC for 30 
seconds, 60 oC for 20 seconds, and 68 oC for 1 minute. Previously we have validated conditions 
for multiplex PCR preamplification via linearity of  amplification assay using all the genes used in 
the assay. We also validated all individual TaqMan assays from our collection for sensitivity and 
linearity before we started using them in gene expression profiling in this study.
Individual gene transcript quantification was carried out using TaqMan primer/probe sets 
(Biosearch Technologies). Quantitative real-time PCR mix contained 0.07 µl preamplified cDNA, 
2 µl TaqMan primer/probe mix, 5 µl 2X LightCycler 480 Probes Master Mix, and 2.93 µl Probes 
Master PCR-grade water (Roche) to a final volume of  10 µl. Reactions were heated at 95 oC for 5 
minutes, followed by 40 cycles at 95 oC for 30 seconds and 60 oC for 20 seconds. A cool down step 
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gene copy numbers (RGCN) based on logarithmic transformation/linear regression equations 
devised from calibration curves. The dataset is available at http://www.tbdb.org/pubdata/tbdb/
publications/Raw-Data-Harvard-Mice.xls.  
Correction for some biological heterogeneity between the different mice and mouse strains 
such as differences in bacterial load was not possible because these were inherent to the extensive 
differences in genetic TB susceptibility.
In vivo expressed Mtb (IVE-TB) gene selection procedure. First, genes were selected that 
were expressed in one data set (>1000 RGCN) but not in the other data set (+/-), thus selecting 
Mtb genes that are differentially expressed owing to genetic host susceptibility and/or infection 
phenotype variations. 
The second approach was to select genes that were highly expressed in both data sets from two 
different mouse strains in the chosen comparison (+/+), selecting for Mtb genes that are expressed 
independent of  the genetic makeup of  the host. For this selection, the RGCN data were ranked 
from the highest to the lowest value and overlapping genes were selected from the top 100 highest 
expressed genes of  both data sets. This number of  100 genes was arbitrarily chosen to limit the 
number of  candidates to be analyzed further. 
The third and last approach included genes that were expressed in data set 2 (>1000 RGCN) 
but not in data set 1 (-/+), following the same rationale as approach 1. Hence, approach 1 and 
3 included differentially expressed genes. There was no number restriction limit (because fewer 
genes were identified compared with the second approach (+/+)) (Figure 1 and 2). 
Recombinant proteins. Recombinant proteins were produced from the selected Mtb genes as 
described previously [39]. Briefly, Mtb genes were amplified by PCR from genomic H37Rv DNA 
and cloned by Gateway technology (Invitrogen, Carlsbad, CA) in a bacterial expression vector 
containing a histidine tag at the N-terminus. Vectors were overexpressed in Escherichia coli BL21 
(DE3) and purified. Size and purity of  recombinant proteins were analyzed by gel electrophoresis 
and Western blotting with an anti-His Ab (Invitrogen) and an anti-E. coli polyclonal Ab (gift of  
Statens Serum Institute, Copenhagen, Denmark). Rv2380c, Rv2435c and Rv2737c proteins were 
prepared as two or three recombinant protein fragments owing to their large sizes (C, Middle 
(M), and N termini). Endotoxin contents were < 50 IU/ mg as tested using a Limulus Amebocyte 
Lysate assay (Cambrex, East Rutherford, NJ). All recombinant proteins were tested in lymphocyte 
stimulation assays to exclude antigen nonspecific T-cell stimulation and cellular toxicity using PBMC 
of  in vitro-purified protein derivative of  Mtb-negative healthy Dutch donors (Sanquin Blood Bank, 
Leiden, The Netherlands) [12;40-42]. Purified protein derivative of  Mtb was purchased from 










































Mtb lysate. Mtb H37Rv organisms were grown to a late log phase in a culture flask at 37 °C and 
collected in a V-bottom shaped tube. The pellet was washed twice with PBS and heat killed for 
30 minutes at 80 oC. The cell suspension was subsequently collected in a BioSpec tube containing 
0.1-mm glass beads. The bacteria were disrupted using a Mini-BeadBeater (BioSpec Products). 
Concentrations of  lysates were measured using the BCA assay (Thermo scientific Pierce).
Study subjects. One hundred and thirty-three donors were selected that responded to Mtb-
purified protein derivative by TST (weak positive 5-11 mm (n = 26); positive ≥ 12 (n = 90); not 
determined (n = 17), ranging from 6 to 32 mm (average 16 mm)), and that had documented 
exposure to a TB index case (n = 63) and/or had traveled to high endemic countries (n = 76). TST+ 
individuals entered a follow-up study and at recruitment a QuantiFERON-TB Gold In-Tube test 
(QFT-GIT) was performed (Cellestis, Carnegie, VIC, Australia). The test was considered positive 
when there were ≥ 0.3 IU/ml. Blood samples were collected by venipuncture and PBMC isolated 
by standard Ficoll density gradient centrifugation using Leucosep® tubes (Greiner Bio-one, Alphen 
aan den Rijn, The Netherlands). Mtb-unexposed donors were included as healthy control (HC) 
donors (n = 11). PBMC from TST+ donors and treated TB patients (n = 7) were used in lymphocyte 
stimulation assays. PBMC from ltLTBI [41;42] (n = 6) were used for polychromatic flow cytometry 
assays. Informed consent was obtained prior to venipuncture. The study protocols (P07.048 and 
P207/99) were approved by the Institutional Review Board of  the Leiden University Medical 
Center and the Regional Committees for Medical and Health Research Ethics in Norway.
Whole blood assay (WBA). Blood was diluted 1:10 in AIM-V medium (Invitrogen, Breda, 
The Netherlands), incubated in 48-wells plates (Nunc, Roskilde, Denmark) and cultured with or 
without recombinant protein (10 μg/ml), PHA (2 µg/ml), or Mtb lysate (5 µg/ml) at 37°C, 5% 
CO2. After 6 days supernatant was harvested and stored at -20 °C for use at a later stage.
Lymphocyte stimulation test. PBMC (1.5 × 10^5/well) were cultured in triplicate in 96-well 
round-bottom plates (Nunc) and incubated with or without protein (10 μg/ml) in IMDM (Life 
Technologies/Invitrogen) containing 10% pooled human serum (Invitrogen) at 37 °C in 5% CO2. 
After 6 days, supernatants were harvested, pooled, and stored at -20 °C for future use in IFN-γ 
ELISAs.
IFN-γ ELISA. IFN-γ concentrations in supernatants were measured with a standard ELISA 
technique (U-CyTech, Utrecht, The Netherlands). ELISA samples were tested in duplicate and 
the assay was performed according to the manufacturer’s guidelines. Detection limit of  the assay 
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Flow cytometric analysis. PBMC (1-2 × 10^6 per tube) were thawed and rested overnight 
and subsequently stimulated for 16 h with protein (10 μg/ml) in the presence of  costimulatory 
Abs anti-CD28 and anti-CD49d (Sanquin and BD Biosciences, respectively). Brefeldin A (3 μg/
ml; Sigma-Aldrich) was added after the first 4-6 h. Cells were stained with Live/Dead fixable 
violet dead cell stain (ViViD; Invitrogen) to discriminate between live and dead cells according to 
manufacturer’s instructions. Cells were stained for 1 h at 4 °C with the following surface markers: 
anti-CD3 PE-Cy5 (BD Biosciences), anti-CD4 Texas Red (Caltag) and anti-CD8 V500 (BD 
Biosciences). Additionally, anti-CD14 Pacific Blue and anti-CD19 Pacific Blue (both Invitrogen) 
were included to select for CD14- and CD19- live cells. Intracellular staining was performed with 
anti-IFN-γ Alexa 700 (BD Pharmingen), anti-TNF-α PE-Cy7 (BD Biosciences), anti-IL-2 PE (BD 
Pharmingen), and CD154 APC-Alexa 780 (eBioscience) using the ADG Fix&Perm kit (An Der 
Grub Bio Research, Vienna, Austria). Data were acquired on a BD LSRFortessa (BD Biosciences) 
and analyzed using FlowJo version 7.6.5 (Tree Star, Ashland, OR). Single CD14-/CD19-/CD3+ 
live cells were gated to analyze CD4+ and CD8+ cytokine responses. Final antigen-specific CD4+ 
and CD8+ T-cell subset populations all contained at least 200 events. For comparative purposes, 
medium background values were subtracted for each response in each donor.
Statistical analysis. Statistical analysis was performed using GraphPad Prism (version 5.1). A 
Mann-Whitney U test was used to analyze 1) the difference between cumulative IFN-γ responses 
for the ESAT6/CFP10 hybrid (E/C)+ , E/C- and HC individuals and 2) the difference between 
PHA-induced IFN-γ responses measured in E/C+ and E/C- donors. A p value ≤ 0.05 was 
considered significant. 
Results
Identification of  IVE-TB genes in the lungs of  genetically resistant and/or 
susceptible mice
To start identifying novel candidate Mtb antigens in an unbiased and Mtb genome-wide fashion, 
we analyzed the gene expression patterns of  2170 Mtb genes, most of  which represent the first 
gene of  each predicted Mtb operon, in the lungs of  four different Mtb infected mouse strains (B6, 
C3H, C3H.B6-sst1 and B6.C3H-sst1) that show a spectrum of  TB susceptibility (Table I). The 
RGCN were determined using quantitative PCR [15]. This allows for absolute quantization of  
the level of  transcripts per sample, because the data are normalized against a standard reference 















































Sst1 allele Inflammation Lung 
necrosis
Clinical TB correlate
C3H C3H Susceptible +++ + (early) Caseous pneumonia
C3H.B6-sst1 C3H Resistant +++ - Progressive interstitial granuloma 
without necrosis
B6.C3H-sst1 B6 Susceptible ++ + (late) Caseous granuloma
B6 B6 Resistant + - Chronic persistent interstitial 
granuloma without necrosis
+, ++, and +++ indicate intensity of  inflammation
a Pichugin et al. (23) and Pan et al. (24)
In this IVE-TB gene selection screen we used the following criteria to select candidate genes 
for further analysis: first, we used the most strongly upregulated Mtb genes in all four analyzed 
mouse models. This group of  genes includes genes that are expressed independently of  the host 
susceptibility background. Second, we used Mtb genes specifically upregulated in either B6, C3H, 
B6.C3H-sst1 or C3H.B6-sst1. The expression of  these genes is influenced by the host genetic 
background and may therefore include genes whose expression is associated to particular TB 
disease characteristics such as granuloma formation and necrosis. The obtained RGCN of  all 
four mouse models were independently compared with each other as visualized in Figure 1A. All 
four mouse models were infected with a low-dose aerosol Mtb inoculum. Additionally, a subset of  
B6.C3H-sst1 was infected using a previously described TB relapse model to study features of  gene 
expression during Mtb reactivation [23]. 
Figure 1. Overview of  IVE-TB gene selection procedure. (A) The Mtb RGCN profiles of  each mouse 
model were independently compared with each other. (B) Three gene selection procedures were used to 
select genes for each comparison: genes that were expressed in data set 1 (>1000 RGCN) but not in data set 
2 (+/-); genes highly expressed in both data sets (top 100 highest expressed genes in both models and select 
overlapping genes) (+/+); and genes not expressed in data set 1 but expressed in data set 2 (>1000 RGCN) 
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Every individual Mtb gene’s expression data (e.g., B6 versus C3H, B6 versus B6.C3H-sst1) 
was subjected to three different selection approaches as indicated in Figure 1B and described 
in detail in Materials and Methods. The gene selection results for each comparison are visualized 
in Figure 2 and Supplementary Table I (available online at http://www.jimmunol.org/
content/190/4/1659/suppl/DC1). The results shown in Figure 2 were then used to select IVE-
TB genes whose expression was associated with particular disease characteristics as indicated in 
Figure 3. These included 1) Mtb genes highly expressed independently of  host genetic background 
(expressed in all four mouse models; these Mtb genes included esxA encoding ESAT6 and other esx 
genes); 2) Mtb genes expressed in association with necrosis (expressed in both C3H and B6.C3H-
sst1, but not in B6 or C3H.B6-sst1); 3) Mtb genes expressed in association with severe necrotic 
infection (sni) or susceptibility (expressed in C3H, but not in B6, C3H.B6-sst1 or B6.C3H-sst1); 
4) Mtb genes expressed in association with dense granuloma development (only expressed in 
B6.C3H-sst1 but not in C3H, B6 or C3H.B6-sst1); 5) Mtb genes expressed in association with 
diffuse granuloma development (expressed in C3H but not in B6.C3H-sst1, B6 or C3H.B6-sst1); 
6) Mtb genes expressed in association with resistance (expressed in every more resistant mouse 
strain per comparison); 7) Mtb genes expressed in association with low inflammation (expressed 
in B6, but not in C3H.B6-sst1); 8) inflammation (expressed in C3H.B6-sst1, but not in B6) and 9) 
relapse (expressed in i.v. Mtb infected, INH treated B6.C3H-sst1, but not low-dose aerosol-infected 
B6.C3H-sst1). An overview of  the resulting IVE-TB genes is presented in Supplementary Table II 
(available online at http://www.jimmunol.org/content/190/4/1659/suppl/DC1). 
Figure 2. Selection of  IVE-TB genes. Numbers of  Mtb genes obtained after each comparison of  two 










































Figure 3. Selection of  IVE-TB genes associated with particular TB disease characteristics. 
Flowchart of  analysis to identify IVE-TB genes related to TB disease phenotypes is shown. Letters in graphs 
refer to the specific selections indicated in Figure 2. Mtb genes highly expressed independent of  host genetic 
background are presented in Figure 2A(b), 2B(e), 2C(h), 2D(k), 2E(n) and 2F(q). Mtb genes highly expressed in 
association with necrosis are presented in; Figure 2A(c), 2B(f), 2D(j), and/or 2F(p). Mtb genes highly expressed 
in association with severe necrotic infection or susceptibility are presented in; Figure 2A(c), 2D(j) and/or Figure 
2C(i). Mtb genes highly expressed in association with dense granuloma are presented in Figure 2C(g), Figure 
2B(f) and/or Figure 2F(p). Mtb genes highly expressed in association with diffuse granuloma are presented in 
Figure 2C(i), but also 2A(c) and 2D(j). Mtb genes highly expressed in association with resistance are presented 
in one or more of  the following selections: Figure 2A(a), 2B(d), 2D(l), 2E(m) (although not related to the 
susceptible sst1 locus), 2F(r) and/or 2G(s). Mtb genes highly expressed in association with low inflammation 
are presented in Figure 2E(m). Mtb genes highly expressed in association with inflammation are presented in 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Immunogenicity of  newly identified IVE-TB antigens 
Further down selection of  IVE-TB genes. The goal of  the above selection of  IVE-TB genes was to 
identify potentially interesting new vaccine candidate antigens. Thus, we next determined their 
immunogenicity. To this end, a number of  Mtb genes were further selected that were either 
present in more than one group or were among the top number of  genes in the IVE-TB selections 
performed (Table II). Some Mtb genes identified using our unbiased genome-wide approach were 
also identified in previous studies as environmental stress induced proteins [7;14;17]. 
A subsequent literature search revealed that almost all further selected IVE-TB proteins (14 of  
the 16) have been identified previously in Mtb proteomic studies, confirming the protein expression 
of  the Mtb genes identified in our study [43-56] (Table III). Indeed, we observed that Mtb-infected 
C3H mice recognized most of  the selected IVE-TB antigens as measured by antigen-specific IFN-γ 
production by splenocytes (Supplementary Figure 1). Furthermore, we analyzed the conservation 
of  these IVE-TB proteins using protein BLAST searches on different Mtb strains as well as other 
mycobacterial species. This showed that the Mtb IVE-TB protein sequences are strongly conserved 
among all tested Mtb, M. bovis and M. africanum strains. Strong conservation was observed also for 
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Recognition of  IVE-TB proteins by TST+ positive donors. To assess the immunogenicity of  the 16 selected 
IVE-TB proteins, recombinant proteins of  the IVE-TB genes were generated and analyzed for 
the induction of  IFN-γ responses in 133 TST+ individuals. Approximately one third of  the TST+ 
individuals responded to Mtb specific E/C protein (32%, 61-9980 pg/ml). ESAT6 and CFP10 
Mtb-specific proteins are frequently used as immunodiagnostic antigens to identify Mtb exposure 
[12]. One third of  our population also responded to these diagnostic antigens (ESAT6, CFP10 
complemented with TB7.7 (p4) peptides) using the commercial QFT-GIT. The responses in the 
QFT-GIT correlated very well with responses to our E/C protein measured in WBA (84%). 
Division of  the group into WBA E/C+ and WBA E/C- donors showed that 74% of  the E/C+ 
donors responded to Mtb lysate (87-3112 pg/ml) and 40% to Ag85B antigen (97-735 pg/ml) 
(Figure 4A). Importantly, high levels of  recognition of  the newly identified Mtb proteins were 
seen within this population, with responses ranging from 10 to 60% of  the donors. To identify the 
antigens that are well recognized, we first examined which ones were recognized by ≥ 25% of  the 
E/C+ donors. From all 20 proteins and protein fragments (derived from the 16 selected antigens) 
tested, 13 were recognized by ≥ 25% (n ≥ 3 of  10 and ≥ 11 of  43) of  the donors. Six of  13 antigens 
induced only intermediate levels of  IFN-γ (60-600 pg/ml) after stimulation, whereas high levels of  
IFN-γ were produced after stimulation with Rv1363c (102-1053 pg/ml), Rv1956 (100-1861 pg/
ml), Rv2034 (77-1256 pg/ml), Rv2324 (63-2130 pg/ml), Rv2380c-C (80-1159 pg/ml), Rv3353c 
(70-899 pg/ml) and Rv3420c (88-660 pg/ml), representing the seven best recognized proteins. 
Of  the TST+ E/C- donors still 47% responded to Mtb lysate and 20% to Ag85B (Figure 4B). 
Additionally, HC were analyzed for possible IVE-TB responses (Figure 4C). Most importantly, 
limited to no responses against the IVE-TB proteins were detected in the TST+ E/C- and HC 
groups, demonstrating clear specificity of  recognition, presumably linked to Mtb exposure. 
To further verify that the IVE-TB antigens are specifically recognized by E/C+ donors, the 
cumulative IFN-γ response to the 20 tested antigens per individual was calculated, as described 
before [9]. A highly significant difference between the E/C+ and E/C- population was observed (p 
< 0.0001). As expected, a significant difference was also observed between E/C+ and HC donors (p 
= 0.049) (Figure 5), confirming the association between antigen recognition and E/C test positivity. 
Interestingly, of  the seven best recognized proteins, Rv3420c was the most discriminatory between 
the E/C+ (≥25%) and E/C- group (≤ 1%) (p < 0.0001) and was not recognized by HC donors (p = 
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Figure 4. IFN-γ responses to IVE-TB antigens in E/C+ (A), E/C- (B), and HC donors (C). A 
total of  43 E/C+ donors (A), 90 E/C- donors (B) and 11 HC donors (C) were analyzed for their IFN-γ WBA 
responses to antigens and controls; the antigens were Mtb Rv1284, Rv1956, Rv2034, Rv2324, Rv3353c and 
Rv3420c. Ten E/C+ donors (A), 36 E/C- donors (B) and 9 HC donors (C) were also analyzed for responses 
to Mtb antigens Rv0079, Rv1363c, Rv2225, Rv2380c, Rv2435c, Rv2465c, Rv2737c, Rv2828c, Rv2982c 
and Rv3515c IFN-γ. The proportion of  responders for each antigen is indicated at the top of  the graph. 
For comparative purposes, medium background values were subtracted for each response in each donor. 
Horizontal bars represent the median IFN-γ responses. The dotted line indicates the cut-off value for positivity, 
arbitrarily calculated as 3 x medium value.
Figure 5. Cumulative IFN-γ responses induced by IVE-TB antigens, calculated per individual 
in the E/C+, E/C- and HC groups. Cumulative IFN-γ responses to all 20 IVE-TB protein and protein 
fragments in E/C+ (n = 43), E/C- (n = 90), and HC donors (n = 11). Squares indicate cumulative IFN-γ 
response of  all 20 IVE-TB antigens, and circles indicate cumulative IFN-γ response of  Rv1284, Rv1956, 











































Recognition of  IVE-TB proteins by PBMC from TB patients. We next investigated whether TB patients 
could also recognize these antigens. PBMC from WBA E/C+ TST+ donors (Figure 6A) and TB 
patients (Figure 6B) were therefore stimulated with the 20 proteins and protein fragments and 
IFN-γ production was measured. High IFN-γ responses (123-3391 pg/ml) to the IVE-TB antigens 
were observed in the PBMC cultures from the WBA E/C+ TST+ population, confirming the results 
obtained in the WBA assay above. Nine of  the tested antigens were recognized by ≥50% of  the 
donors and eight antigens by 38% of  the donors. Only one protein fragment was not recognized in 
this assay (Rv2380c-M). In contrast, seven of  the tested IVE-TB antigens did not induce detectable 
IFN-γ production in PBMC from TB patients, whereas most of  the IVE-TB antigens induced only 
low levels of  IFN-γ compared with the WBA E/C+ TST+ individuals (107-1825 pg/ml). Only 
two antigens induced high levels of  IFN-γ in the TB patients. Additionally, only one antigen was 
recognized by 50% of  the TB patients, whereas the remainder of  the antigens were recognized by 
relatively fewer TB patients (14-43%). Thus, IVE-TB antigens seem to be less immunogenic in TB 
patients than in TST+ individuals. 
T-cell responses towards IVE-TB antigens in long-term latent Mtb infected individuals. Because the IVE-TB 
antigens were strongly recognized by TST+ individuals, we subsequently analyzed the immune 
responses toward the seven best recognized antigens in more detail using PBMC from donors 
that had been exposed to Mtb decades ago, but had never developed TB despite the lack of  any 
preventive treatment, designated ltLTBI [41;42]. Of  additional importance, the availability of  
several vials of  PBMC also allowed more detailed cell subset analysis.
Interestingly, high frequencies of  TNF-α- and IL-2-producing CD4+ T cells were observed after 
stimulation with the IVE-TB antigens, whereas only intermediate frequencies of  IFN-γ-producing 
CD4+ T cells were detected (Figure 7A). In contrast, high frequencies of  IFN-γ-producing as well 
as TNF-α+ CD8+ T cells were present in these donors, whereas fewer IL-2+ T cells were detected 
compared with CD4+ T cells. Besides IFN-γ, TNF-α and IL-2, also the antigen-induced CD4+ 
T-cell activation marker CD154 [57] was expressed. 
More detailed analysis of  the multifunctional Th1 responses among CD4+ and CD8+ T 
cells showed that CD154+CD4+ T cells were mostly TNF-α+/IL-2+ and TNF-α+ (Figure 7B). 
Furthermore, intermediate frequencies of  IFN-γ+/TNF-α+/IL-2+ CD154+CD4+ T cells were 
detected. Finally, a CD154+ population was detected, producing none of  the IFN-γ, TNF-α and 
IL-2 cytokines. Intriguingly, the same pattern was observed for every IVE-TB antigen or E/C 
control antigen. Furthermore, interindividual variation of  antigen recognition was observed. 
Remarkably, few TNF-α+/IL-2+ CD8+ T cells were detected compared with TNF-α+/IL-2+ CD4+ 
T cells. IFN-γ+/TNF-α+ CD8+ T cells were the most prominent population present, followed by 
TNF-α+ CD8+ T cells. Also intermediate IFN-γ+/TNF-α+/IL-2+ and IFN-γ+ CD8+ T cells were 
observed. Again, as mentioned for CD4+ T cells, the same patterns were observed for every antigen 
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Figure 6. PBMC IFN-γ responses towards IVE-TB antigens in TB patients and WBA E/C+ TST+ 
donors. PBMC of  WBA E/C+ TST+ donors (n = 8) (A) and TB patients (n = 7) (B) were stimulated with IVE-
TB antigens and control conditions for 6 days. Levels of  IFN-γ were measured and medium background values 
were subtracted for each response in each donor for comparative purposes. The proportion of  responders for 
each antigen is indicated at the top of  the graph. Horizontal bars represent the median IFN-γ responses. The 










































Figure 7. Polychromatic flow cytometric analysis of  IVE-TB-specific T-cell responses in long-
term latent Mtb infected individuals. PBMC from ltLTBI (n = 6) were stimulated for 16 hours with 
the seven best recognized antigens as determined in Figure 4. Frequencies of  IFN-γ-, TNF-α-, IL-2- and 
CD154-producing CD4+ and CD8+ T cells were determined (A). Subsequently, “multifunctional” responses 
were determined by analyzing combinations of  IFN-γ, TNF-α, IL-2 and CD154 responses for CD4+ T cells 
and IFN-γ, TNF-α and IL-2 responses for CD8+ T cells. Results for two representative IVE-TB antigens are 
shown (Rv2034 and Rv3420c) (B). For comparative purposes, medium background values were subtracted for 
each response in each donor. Horizontal bars represent the median frequency of  cytokine-producing CD4+ 
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The integrated median fluorescence intensity (iMFI) was calculated to determine the 
quantitative contribution of  cytokines produced by the different multiple and single cytokine 
producing CD154+/CD4+ and CD8+ T cells (Figure 8). IFN-γ+/TNF-α+/IL-2+ CD154+/CD4+ 
T cells had the highest iMFI, which gradually declined for double producing and single IFN-γ+ 
CD154+/CD4+ T cells. IFN-γ+/TNF-α+ CD8+ T cells contributed the most to IFN-γ production, 
directly followed by the IFN-γ+/TNF-α+/IL-2+ CD8+ T cells. IFN-γ+/TNF-α+ CD8+ T cells are 
also the main contributors for TNF-α, whereas IFN-γ+/TNF-α+/IL-2+ CD8+ T cells showed a 
higher IL-2 iMFI. TNF-α and IL-2 iMFI were also the highest for TNF-α+/IL-2+ CD154+/CD4+ 
T cells, followed by the IFN-γ+/TNF-α+/IL-2+ CD154+/CD4+ T cells. Thus the TNF-α+/IL-2+ 
CD4 and IFN-γ+/TNF-α+ CD8 T cells contribute strongly to the production of  Th1 cytokines, 
followed by the triple positive T cells. Single cytokine producing cells only showed a relatively 
minor contribution.
In conclusion, seven of  the identified IVE-TB antigens are strongly immunogenic, triggering 
specific and high cellular immune responses in E/C+ TST+ individuals and ltLTBI individuals, but 
not in E/C- TST+ individuals, healthy mycobacterial naive individuals, and TB patients. The strong 
IVE-TB responses that were measured in the ltLTBI group were identified as IFN-γ+/TNF-α+ 
CD8+ T cells and TNF-α+/IL-2+ CD4+ T cells, which were the most prominent contributors to the 































































































































































































































































































































































































































Using quantitative genome-wide Mtb transcriptional profiling we have identified a series of  Mtb 
genes that are expressed during in vivo Mtb infection in the lungs of  resistant and susceptible mice, 
which we term IVE-TB. Most of  the genes identified have previously been found to be expressed 
in the Mtb proteome, and thus encode bona fide Mtb proteins. This is further supported by their 
immunogenicity profiles, as many of  these proteins triggered IFN-γ production in human WBA 
and lymphocyte stimulating assays in Mtb ESAT6/CFP10-responsive patients, but not in ESAT6/
CFP10- TST+ individuals, HC donors, or TB patients. This is particularly relevant in the case 
of  Rv2435c and Rv3353c as their protein products have not been identified yet; however IFN-γ 
responses were demonstrated in E/C+ TST+ individuals, indirectly showing that these Mtb proteins 
are presented to the human immune system during mycobacterial infection. 
Many of  the IVE-TB genes we identified have been described previously in relationship to 
the adaptive response of  Mtb to environmental stress conditions, especially those that Mtb likely 
encounters during host infection. We identified one Mtb DosR regulon-encoded gene (Rv0079) [7] 
as well as six genes that are part of  the EHR regulon (Rv1284, Rv1956, Rv2034, Rv2324, Rv2465 
and Rv3515) [17]. Three of  these have also been described as starvation/nutritional stress genes 
(Rv1284, Rv1956 and Rv2034) [14]. This function of  the IVE-TB genes in responding to host-
induced stress conditions during in vivo pulmonary infection enhances the biological plausibility of  
our findings and lends validity to our approach. 
Of  further interest, nine of  the Mtb genes identified in this study have not been described 
previously in relation to Mtb host infection, although some of  their functions have been linked to 
possible adaptation to in vitro host-induced stress conditions (Supplementary Table III). Several 
of  these genes have a role in metal transport, metallo-regulatory transcriptional regulation, or 
represent metalloenzymes. Furthermore genes were identified that play a role in lipid metabolism. 
This is in agreement with the documented shift towards using fatty acids as an alternative carbon 
source instead of  carbohydrates under nutrient-limiting conditions. Altogether, many of  the IVE-
TB genes we have identified appear to be related to the adaptation of  Mtb to environmental stress 
conditions encountered in the host. Of  additional importance, the identification of  these genes 
in our in vivo model supports previous findings mostly obtained in in vitro models, by showing that 
they are induced during pulmonary Mtb infection in vivo. On a cautionary note, however, our data 
do not allow us to discriminate whether the observed differential Mtb gene expression patterns are 
cause or consequence of  variations in host susceptibility (background and/or sst1 locus).
As already mentioned, Mtb gene expression profiling has been performed in the past, mostly 
focusing on in vitro-cultured bacteria grown under a variety of  different conditions. Subsequent 
work assessed Mtb gene expression profiles following infection of  host cells [8;19;58] and some 
recent studies have analyzed Mtb gene expression patterns also in vivo [20;59]. Ward et al. [59] 










































studies reporting on Mtb intracellular infection, likely as a result of  methodological differences. 
Nonetheless, the two studies Ward et al. described [8;60] indicate that similar functional categories 
of  Mtb genes are expressed during intracellular infection. In line with this notion, when comparing 
our data to previous reports there are few overlapping individual Mtb genes, but we nevertheless do 
identify genes with previous described functional categories. These differences are probably due 
to differences in selection criteria, in experimental settings such as infection route, and the specific 
mouse models we have used, which have not been analyzed previously. 
Despite these differences, several of  our selected IVE-TB genes do overlap with Mtb genes 
identified in other studies as indicated in Table II. The Mtb gene Rv2225 whose expression was 
TB granuloma associated was also significantly expressed in the artificial granuloma model of  
Karakousis et al. [21]. This strengthens their association with host granuloma formation. Our 
in vivo pulmonary TB granuloma-associated Mtb-expressed genes did not overlap with the 
granuloma associated genes or macrophage associated genes described by Ramakrishnan and 
colleagues [61;62] for M. marinum, which might be due to differences between the mycobacterial 
species studied. Moreover, several of  the IVE-TB genes we identified to be highly expressed have 
also been described previously, including Rv0467 (icl), which encodes an enzyme in the glyoxylate 
pathway which is important for Mtb persistence of  Mtb [63;64], and Rv0991c, which is part of  the 
so-called in vivo expressed genomic island [20]. 
The new Mtb antigens we have identified here may represent interesting targets for vaccination, 
as they are expressed during Mtb infection in the (genetically susceptible) lung, which we consider a 
critical parameter for appropriate antigen selection. Moreover, successful vaccine antigens should 
be conserved between multiple Mtb strains. All protein sequences examined were conserved 
among the tested Mtb strains. Additionally, for almost all IVE-TB genes multiple proteome studies 
have documented their expression as proteins in Mtb (Table III). A subset of  the analyzed IVE-TB 
proteins was shown to be strongly immunogenic as judged by Th1 responses in WBA, lymphocyte 
stimulation assays, and polychromatic flow cytometry. Indeed, the highest IFN-γ responses were 
identified within the E/C+ population of  our TST+ cohort, whereas no differences in mitogen-
induced responses were seen. No responses were seen in Mtb nonresponder healthy individuals, 
suggesting that T-cell recognition of  IVE-TB antigens is indeed antigen specific and is correlated 
with Mtb exposure based on TST and QFT-GIT conversions. Interestingly, TB patients showed 
relatively low recognition of  the IVE-TB antigens, suggesting that they did not develop strong Th1 
immunity against these antigens. 
Importantly, IVE-TB antigen specific responses could be detected in ltLTBI, which have 
been exposed to Mtb many years ago and never developed TB symptoms despite not having had 
preventive treatment. The most prominent T-cell subsets with activity against IVE-TB antigens 
included IFN-γ+/TNF-α+ CD8+ T cells and TNF-α+/IL-2+ CD154+CD4+ T cells. Thus, CD8+ T 
cells were the major contributors of  IFN-γ production. Interestingly, also a population of  antigen-
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2. These cells may exert alternative functions, which could include IL-17 production, immune 
regulation, or yet other functions, which need further study. Finally, we previously reported 
multifunctional CD4+ and CD8+ T-cell responses towards resuscitation promoting factor and 
DosR proteins and showed that IFN-γ+/TNF-α+ CD8+ T cells were also the most prominent 
subset in the response to these antigens, suggesting that the development of  specific differential 
T-cell subsets may be unrelated to the nature of  the specific protein antigen involved. 
CD8+ T cells are activated upon recognition of  epitopes presented via MHC-I molecules, 
indicating that the antigens are present and processed via the canonical cytosolic pathway or via 
alternative (e.g. cross priming) pathways [65]. Both CD4+ and CD8+ T cells are important in Mtb 
control, and CD4+ and CD8+ T cell-deficient mice, for example, have increased susceptibility 
to Mtb [66]. CD4+ T cells were recently shown to play an important (IFN-γ-independent) role 
in the indirect activation of  IFN-γ+ CD8+ T cells [67]. In any case, our data obtained in the 
ltLTBI individuals show that the Mtb antigen-specific CD4+ and CD8+ T cells recognizing IVE-
TB antigens must be long lived. 
The immunogenicity of  some of  the IVE-TB antigens has been analyzed previously. The 
immunogenicity of  the DosR Rv0079 protein was analyzed in TST+ (endemic) individuals as well 
as (cured) TB patients [9;12;68]. In these studies Rv0079 protein was recognized by a minority of  
individuals, in agreement with our results in this study. The immunogenicity of  EHR and starvation 
antigens Rv1284 and Rv1956 was previously analyzed in M. bovis-exposed cattle [17] [69]. Rv1284 
was one of  the five best recognized antigens, whereas Rv1956 was also highly recognized. In 
contrast to the responses observed in M. bovis-exposed cattle, Rv1284 was moderately recognized 
in our study, whereas Rv1956 was better recognized. 
In conclusion, by combining Mtb genome-wide transcriptional profiling in the lungs of  infected 
mice with strikingly differing host susceptibility backgrounds, we have identified Mtb genes that are 
specifically expressed in resistant or susceptible animals during pulmonary infection. These genes 
reveal a signature of  the Mtb stress response in vivo depending on the genetic host background and 
host susceptibility. From these genes we selected 16 proteins, of  which seven proved to be highly 
immunogenic in E/C+ TST+ donors and ltLTBI and therefore represent interesting TB vaccine 
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Supplementary Figure 1. IFN-g production in response to IVE-TB proteins by splenocytes of  
Mtb infected C3H mice. C3H mice were infected intranasally with Mtb (104 CFU), and after 6 weeks their 
splenocytes were harvested and stimulated with control antigens (hsp65, Rv2031c, TB10.4, Ag85B, ESAT-
6/CFP10, Mtb lysate and PPD), IVE-TB antigens (Rv1284, Rv2034, Rv4320c, Rv3515c, Rv0079, Rv2324, 
Rv2737c, Rv2838c, Rv1956, Rv2225, Rv2982c, Rv3353c and Rv2435c all in final concentration of  10µg/
ml), mitogen (conA; 1 mg/ml; positive control), or HPV16E6 recombinant protein (10 mg/ml; negative protein 
control). Rv2737c and Rv2435c protein fragments were pooled. All groups included three mice. All mice were 
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The newly identified Mycobacterium tuberculosis antigen 
Rv2034 induces CD4+ T cells that protect against pulmonary 
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Tuberculosis (TB) remains one of  the most serious infectious diseases worldwide. Mycobacterium bovis 
BCG, the current vaccine against TB, provides insufficient protection against adult pulmonary 
TB, indicating the need for improved TB vaccines. Besides being immunogenic, Mycobacterium 
tuberculosis (Mtb) antigens that represent potential vaccine candidates should also be expressed in 
vivo during Mtb infection. We have analyzed the in vivo immunogenicity and protective efficacy of  
Rv2034, a novel potential vaccine candidate that is expressed in lungs of  Mtb-infected susceptible 
mice and that was recognized by T cells from tuberculin skin test-positive individuals. The Rv2034 
protein was highly immunogenic in HLA-DR3-immunized tg mice, but not in HLA-DR3-negative 
littermates. Rv2034 protein immunization induced IFN-γ+/TNF+ and IFN-γ+ CD4+ T cells specific 
for an HLA-DR3-restricted epitope, Rv2034 peptide 31-50. CD4+ T-cell responses were optimally 
induced when using TLR9 and TLR3 ligand-adjuvants, whereas Rv2034-specific antibodies were 
observed using ligands for TLR2, TLR3, TLR4, TLR5, TLR7 and TLR9. Finally, Rv2034/CpG 
immunization reduced the number of  bacilli in the lungs after Mtb challenge specifically in HLA-
DR3 mice indicating the potential of  Rv2034 in TB vaccines.












































8.7 million new tuberculosis (TB) cases and 1.4 million deaths due to TB were recorded for 2011, 
illustrating the enormous global burden of  TB on human health [1]. BCG, the only registered TB 
vaccine, does protect against severe forms of  childhood TB but not sufficiently against pulmonary 
TB in adults, nor does protect against reactivation from latent TB [2;3]. There is wide consensus 
that better TB vaccines are urgently needed. 
In search of  new TB vaccine candidate antigens, we have recently used a genome-wide 
unbiased antigen discovery approach in which we investigated the expression of  2170 Mycobacterium 
tuberculosis (Mtb) genes during infection in the lungs of  four genetically related but distinct mouse 
strains, which ranged in TB susceptibility and TB disease manifestations. We identified a series 
of  in vivo expressed Mtb (IVE-TB) genes and showed that several of  these IVE-TB gene encoded 
proteins were efficiently recognized by human T cells and thus qualify as candidate TB vaccine 
antigens [4]. One of  the IVE-TB genes identified, Rv2034, encodes for an arsenic repressor (ArsR) 
protein that belongs to the Synechococcus metallothionein regulator (SmtB)/ArsR family of  metallo-
regulatory transcriptional repressors [5]. Rv2034 is suggested to be involved in the regulation of  
lipid metabolism and the hypoxic stress response of Mtb [6-8]. This is further supported by studies 
showing Rv2034 gene expression by Mtb cultures grown under starvation-, [9] hypoxic- [10], and 
multi-stress conditions [11], as well as expression in Mtb persister populations [12]. 
SmtB/ArsR transcriptional repressors control resistance to metal ions and bind to DNA 
elements in genes involved in metal-metabolism and -detoxification. Upon metal binding the SmtB/
ArsR family repressor protein dissociates from the ligand DNA, thus activating transcription. The 
SmtB/ArsR family regulator is widely present and at least one SmtB/ArsR member is encoded 
by most (sequenced) bacterial genomes. Notably, the Mtb genome encodes 12 SmtB/ArsR-like 
repressors, which is highly unusual compared to bacteria other than Actinobacteria [13]. Recent 
work identified several DNA binding sites for Rv2034, including promoter regions of  major stress 
response genes such as the DosR gene Rv2031c (α-crystallin/ hspX), Rv0350-Rv0353 (DnaK, 
GrpE), Rv0440 (GroEL2), Rv1907c-Rv1912c (katG, FurA) and Rv3197A (WhiB7), as well as genes 
involved in fatty acid metabolism; Rv3543c-Rv3545c (FadE28, FadE29), Rv3504-Rv3505 (FadE26, 
FadE27), Rv1094 (DesA2) and Rv0244 (FadE5) [7]. Interestingly, besides displaying self-regulation, 
the Rv2034 protein, in contrast to its predicted function as a repressor, positively regulates the 
expression of  groEL2 and phoP, an important virulence gene of  Mtb [6;8]. Thus, Rv2034 gene 
expression and protein function support a role in adaptation to stress environment and regulation 
of  lipid metabolism, both essential in in vivo Mtb infection. In view of  its potential mechanistic 
function in Mtb’s strategy to survive inside the human host, the induction of  immune responses 
against Rv2034 would be an attractive option to direct immunity towards Mtb proteins that are 










































In this study, we have investigated the vaccine potency of  the Rv2034 protein in the context of  
HLA using the HLA-DR3 transgenic mouse model [14] and describe the in vivo immunogenicity 
of  the Rv2034 protein and synthetic peptides thereof, as well as their efficacy to reduce the number 
of  Mtb bacteria after intranasal challenge with live Mtb.
Materials and methods
Mouse strains. HLA-DRB1*03:01/DRA, murine class II-deficient (designated HLA-DR3) 
mice were generated as described [14], backcrossed for 10 generations with C57Bl/10 and 
eventually intercrossed. During breeding, PBMCs of  each mouse were typed by flow cytometry 
for HLA-DR (FITC-conjugated mouse IgG2 κ anti-HLA-DR; BD Biosciences, Franklin Lakes, 
NJ), murine-CD4 (PE-Cy5-conjugated Rat IgG2a, κ anti-mouse CD4; BD Biosciences) and PE-
conjugated mouse (BALB/c) IgG2a κ anti-mouse I-Ab; BD Biosciences). Littermates lacking HLA-
DR expression (designated HLA-DR3neg) were used as negative controls. HLA-A*02:01/H2-D 
Enge/J (designated HLA-A2) mice were purchased from Jackson Laboratory (Bar Harbor, ME) 
[15]. Surface expression of  HLA-A*02:01 was confirmed by flow cytometry analysis. HLA-A2.
DR3 transgenic mice were generated by mating the HLA-DR3 with HLA-A2 mice. All mice were 
bred under specific pathogen-free conditions.
Synthetic peptides. Peptides were purchased from Peptide 2.0 Inc. (Chantilly, VA, USA). 
Homogeneity and purity were confirmed by analytical HPLC and by mass spectrometry. Purity 
of  all peptides was ≥ 80%. All impurities consist of  shorter versions of  the peptides caused by < 
100% coupling efficiency in each round of  synthesis. 
Recombinant proteins. Mtb genes were amplified by PCR from genomic Mtb DNA and cloned 
using Gateway technology (Invitrogen, Carlsbad, CA) [16]. Purified recombinant proteins were 
produced and analyzed as described [16;17] and contained endotoxin levels below 50 IU per mg 
recombinant protein as tested using a Limulus Amebocyte Lysate (LAL) assay (Cambrex, East 
Rutherford, NJ). Recombinant proteins were tested to exclude protein non-specific T-cell stimulation 
and cellular toxicity in IFN-g release assays using PBMC of  in vitro purified protein derivative (PPD)-
negative, healthy Dutch donors recruited at the Blood Bank Sanquin, Leiden, The Netherlands. 
None of  these controls had experienced any known prior contact with TB patients. 
Immunizations. For protein immunization, mice (4 - 5 animals per group) were injected 
subcutaneously (s.c.) three times with 25 μg protein generally in combination with 50 mg CpG 
(ODN1826 5’-TCC ATG ACG TTC CTG ACG TT -3’; InvivoGen, San Diego, CA; TLR9 
ligand) in 200 ml PBS in the right flank with two weeks intervals. Control mice were injected s.c. 
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Institute, Copenhagen, Denmark) from frozen ampoules. Splenocytes were harvested 21 days after 
final injections. Since ODNs containing unmethylated CpG motifs can activate immune cells to 
produce cytokines [18], we routinely immunize with CpG alone as a (negative) control to assess 
the antigen specificity of  immunization. For adjuvants comparison experiments identical amounts 
of  Rv2034 protein were administered s.c. with either: 50 μg PAM3CysK4 (N-Palmitoyl-S-[2,3-
bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]- lysyl-[S]-lysyl-[S]-lysyl-[S]-lysine; 
Invivogen; TLR2 ligand), 50 μg Poly(I:C) HMW (polyinosinic-polycytidylic acid high molecular 
weight; Invivogen; TLR3 ligand), 10 μg MPL/TDM (monophosphoryl lipid A/ trehalose 
dicorynomycolate; Sigma-Aldrich, St. Louis, MO; TLR4 ligand), 10 μg Flagellin (Invivogen; 
TLR5 ligand) or 50 μg R848 (Imidazoquinoline compound, Invivogen; human TLR7/8 and 
mouse TLR7 ligand).
Ethics statement. The handling of  mice was conducted in accordance with the regulations 
set forward by the animal care committee of  the LUMC and in compliance with European 
Community Directive 86/609 for the care and use of  laboratory animals.
Welfare monitoring. All animals included in the experiments were weighed once a week and 
observed daily in order to ensure ethics requirements and to monitor any adverse effects possibly 
related to the vaccination. 
In vitro cultures. Splenocytes were isolated from individual animals by homogenizing spleens 
through a plastic cellstrainer (BD Biosciences) and splenocytes (3 x 106 cells/ml) were resuspended 
in IMDM (Invitrogen) supplemen ted with 2 mM L-glutamine (Invitrogen) penicillin (100 U/ml), 
strepto mycin (100 μg/ml) (Invitrogen), 8% heat-inactivated FCS (Greiner Bio-One) and 5x10-5 
M β-mercaptoethanol (Sigma). Cell suspensions (100 μl) were added to 96-well round-bottomed 
microtiter plates (Costar, Corning Incorporated). Cells were incubated in quadruplicates with 100 μl 
of  medium, recombinant protein (1 or 10 μg/ml), or synthetic peptide (1 or 10 μg/ml). The mitogen 
concanavalin A (conA; 2 μg/ml; Sigma) was used in all experiments as a positive control for cell 
viability. After 6 days supernatants were taken from each well, quadruplicates pooled and frozen at 
-20 ºC until performing IFN-γ ELISA assay. 
IFN-γ ELISA. Before ELISAs were performed on supernatants from Mtb infected murine 
material, supernatants or sera were transferred into 0.2 μM filter plates (Corning, NY, USA) and 
centrifuged for 3 minutes at 1300 rpm. The filtrated material was collected in clean 96-wells 
plates and transferred out of  the MLIII lab for further analyses. Detection of  IFN-γ in culture 
supernatants of  in vitro cultured splenocytes was performed by ELISA (BD Biosciences) according to 
the manufacturer’s instructions. OD values were converted into concentrations using Microplate 










































off value to define positive responses was set beforehand at 100 pg/ml. The assay sensitivity level 
was 20 pg/ml. Values for unstimulated whole blood cultures were typically < 30 pg/ml.
Intracellular cytokine staining. For polychromatic flow cytometry, splenocytes (3 x106cells/
ml) were cultured in vitro with peptide (5 mg/ml). After 7 days, cells were incubated with medium 
or fresh peptide (5 µg/ml). After 4 hours brefeldin A (Sigma; 2.5 µg/ml) was added for overnight 
(20 hour) incubation after which cells were permeabilized and fixed using Cytofix/Cytoperm (BD 
Biosciences) and Perm/Wash (BD Biosciences) according to the manufacturer’s instructions and 
stained using phycoerythrin (PE)-conjugated anti-CD8β2 (BD Pharmingen), PECy5-conjugated 
anti-CD4 (BD Pharmingen), eFluor450-conjugated anti-CD19 (eBioscience, San Diego, CA, USA), 
Vivid (Invitrogen), Allophycocyanin (APC)-conjugated anti-IL-2 (BD Pharmingen), Alexafluor700-
conjugated anti-IFN-γ (BD Pharmingen) and PeCy7-conjugated anti–TNF (BD Pharmingen). As 
positive controls for detection of  IL-2, IFN-γ or TNF, MiCK-1 cytokine positive control cells (BD 
Pharmingen) were used.
Determination of  anti-Rv2034 antibodies (Ab). Levels of  antibody directed against Rv2034 
in serum from immunized mice were determined by ELISA. Briefly, plates were coated overnight 
at 4 °C with recombinant Rv2034 protein or PBS (0.4% BSA) as a negative control. Plates were 
blocked for 2 hours using PBS containing 1% BSA and 1% Tween-20. Different sample dilutions 
(100 ml/well) were added to wells and incubated at 37°C for 2 hours. Plates were washed three 
times using PBS containing 0.05% Tween-20 and 100 ml/well horse radish peroxide (HRP)-
conjugated, rabbit-anti mouse total IgG, IgA and IgM (P0260 Dako, Glostrup, Denmark). After 2 
hours at 37°C, plates were washed three times using PBS containing 0.05% Tween-20 and 100 ml/
well tetramethylbenzidine substrate (TMB; Sigma) was added for 15 min at RT. The reaction was 
stopped by addition of  H2SO4 (1M; 100 ml/well). OD values at 450 nm were determined using 
BioRad Microplate reader 680 (BioRad Laboratories, Veenendaal, The Netherlands). Mean Ab 
concentrations were calculated from the linear part of  the titration curve. 
Infection with live Mtb and determination of  bacterial burden. Naive and immunized 
mice (5 animals per group) were infected with live Mtb strain H37Rv 3 weeks after the third 
protein immunization or 12 weeks after BCG immunization. The mice were anesthetized with 
isofluran (2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane; Pharmachemie BV, Haarlem, 
The Netherlands) and intranasal (i.n.) infected with 105 CFU Mtb from frozen ampoules. Mice 
were sacrificed 6 weeks after Mtb challenge and lungs were aseptically removed. The organs 
were homogenized in sterile PBS and the number of  bacteria was determined by culturing serial 
dilutions of  the homogenates on 7H11 agar plates (BD Biosciences) supplemented with BD BBL™ 
Middlebrook OADC enrichment (100 ml per bottle; BD Biosciences), PANTA [BD Biosciences; 1 
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mg), Trimethoprim (600 mg), Azlocillin (600 mg)] and ampicillin (3.4 mg/ml; Vepidan, Denmark). 
Colonies were counted after 3 weeks incubation at 37 ºC. In case of  animals that received Mtb 
infection combined with BCG vaccination, 7H11 agar plates containing 2-thiophene carboxylic 
acid hydrazide (2 μg/ml; Sigma) were used to distinguish BCG colonies from Mtb colonies. 
Protective efficacies are expressed as log10 bacterial counts in immunized mice compared to BCG 
immunized mice. 
Statistical analysis. Graph Pad Prism (version 5) software was used for statistical analysis. 
Bacterial titers were analyzed by the Mann-Whitney test. In vitro cytokine levels were compared 
using student’s t test. P-values ≤ 0.05 were considered significant.
Results
Identification of  Rv2034 T-cell epitopes in HLA-DR3 tg mice
In order to evaluate the in vivo immunogenicity of  Rv2034 different HLA-transgenic (tg) mouse 
models were used: HLA-DR3 tg mice lacking murine MHC class II (HLA-DR3.Ab0), which has 
been shown to be suitable for in vivo identification of  HLA-DR3 restricted T-cell epitopes [14;19], 
and HLA-A*0201 mice [20;21] which express endogenous MHC class II in addition to the hybrid 
class I MHC (a1 and a2 domains of  HLA-A2*0201; a3 of  H-2Dd) [15]. 
Mice were immunized three times with Rv2034 protein in CpG as adjuvant and IFN-g levels in 
splenocytes induced by the Rv2034 protein as well as ten 20-mer peptides spanning the entirety of  
Rv2034, were analyzed (Figure 1). Immunization with Rv2034 in CpG induced significant levels of  
IFN-g in HLA-DR3 and HLA-A2.DR3 transgenic mice against both the protein and peptides p31-
50, p41-60 and p51-70. These peptides represent 20-mers which each overlap 10 amino acids with 
the previous and subsequent peptide (Table 1). Rv2034-immunized HLA-A2 mice responded to a 
13-fold lower extent to the whole protein, but not to any of  the 20-mer peptides, perhaps due to the 
low IFN-g production observed in these mice in response to the protein. 
HLA-DR3neg/murine MHC class IIneg mice did not respond to any of  the stimuli except the 
conA control. Also HLA-DR3 mice that received CpG alone did not show any IFN-g response 
except to conA. None of  the Rv2034-immunized mice recognized the control protein (HPV16E6) 
or peptide (HLA-DR3-restricted peptide hsp65 p3-13) [22], indicating the Rv2034-specificity. 
Thus, these results indicate that IFN-g secretion after Rv2034 immunization in the models used, is 
predominantly HLA-DR3-restricted and that presentation of  Rv2034 protein most likely does not 










































Figure 1. IFN-g secretion after Rv2034 immunization is HLA-DR3-restricted. HLA-DR3 mice were 
immunized three times with CpG alone (A) or Rv2034 recombinant protein in CpG (B). In addition HLA-A2 
(C), HLA-A2.DR3 (D) or HLA-DR3neg (E) mice were immunized three times with Rv2034 recombinant 
protein in CpG. IFN-g secretion was analyzed by ELISA after 5 days in vitro stimulation of  splenocytes with 
Rv2034 protein (10 mg/ml), 10 synthetic Rv2034 peptides (20-mers overlapping 10 amino acids; 10 mg/ml), 
mitogen (conA; positive control), HPV16E6 recombinant protein (10 mg/ml as negative protein control) and 
HLA-DR3-restricted epitope hsp65 p3-13 (10 mg/ml as negative peptide control). All groups included five 
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Table 1. Rv2034 overlapping 20-mers and 30-mer 













Rv2034 peptide immunization in HLA-DR3 mice
Synthetic long peptides (SLP) are able to induce CD4+ and CD8+ T cells more efficiently than 
shorter epitopes [23]. SLP require professional APC such as dendritic cells (DCs) for antigen 
processing and presentation which increases their vaccine efficacy significantly compared to shorter 
peptides that are loaded directly onto MHC class II molecules [24]. Therefore, we synthesized the 
30-mer sequence Rv2034 p31-60 covering the three immunogenic Rv2034 peptides (p31-50, p41-
60, p51-70) and used this to immunize HLA-DR3 mice (Figure 2A). Immunization of  HLA-DR3 
mice with SLP p31-60 induced efficient responses to Rv2034 p31-50 and p31-60 but also to the 
Rv2034 protein. 
Most current immunization strategies aim at priming immune responses against antigens and 
epitopes that already are dominant T-cell targets during natural infection. A broader T-cell repertoire 
including T cells specific for subdominant epitopes not recognized during natural infection, may, 
when primed sufficiently through immunization, offer additional protection. Peptide epitope-
based vaccines can circumvent the propensity of  the immune system to focus on immunodominant 
epitopes by simultaneously targeting the response to dominant as well as subdominant epitopes [25]. 
Thus, we also used Rv2034 peptide pool composed of  ten overlapping peptides with or without 
the immunodominant p31-50 to immunize HLA-DR3 mice. Rv2034 peptide pool immunization 
induced responses to the same three core p31-50 related peptides as did the whole Rv2034 protein 
(Figure 2B). Instead, immunization with a pool of  Rv2034 peptides lacking p31-50 induced IFN-g 
responses to p41-60, p51-70 and p31-60 but did not result in IFN-g responses to any of  the other 
peptides, indicating that Rv2034 does not contain any subdominant epitopes in the context of  










































Figure 2. IFN-g production after Rv2034 peptide immunization. HLA-DR3 mice were immunized 
three times with Rv2034 30-mer p31-60 in CpG (A and D), Rv2034 peptide pool composed of  ten 20-mers 
overlapping 10 amino acids (10 mg/ peptide) including p31-50 in CpG (B and E) or without p31-50 in CpG 
(C and F). IFN-g secretion was analyzed by ELISA (A, B, C) after 5 days in vitro stimulation of  splenocytes 
with Rv2034 protein or peptides, control protein HPV16E6, control peptide hsp16 p3-13 (all 10 mg/ml) or 
control mitogen (1 mg/ml). Intracellular IFN-g production by CD4+ T cells was measured (D, E, F) after in vitro 
stimulation of  splenocytes of  immunized mice with the same antigen as used for immunization. After 7 days, cells 
were incubated with medium or fresh peptides for 1h before addition of  brefeldin A and analysis for intracellular 
IFN-γ production. No IFN-g was detected in CD8+ T cells (data not shown). All groups included five mice. All 
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Since T-cell subtypes differ in their ability to induce protection against Mtb, we identified the 
phenotype of  Rv2034-responsive T cells: splenocytes of  HLA-DR3 mice immunized with Rv2034 
peptide or peptide pools were stimulated in vitro for 7 days. Subsequently, intracellular IFN-γ production 
was assessed by flow cytometry analysis (Figure 2D-F). Rv2034 peptide pool immunization of  HLA-
DR3 mice induced IFN-γ production by CD4+ T cells after in vitro stimulation with Rv2034 protein, 
Rv2034 peptides and peptide pool, whereas no responses were observed in mice that were injected 
with CpG alone nor in HLA-DR3-negative littermates and HLA-A2 mice (data not shown). The 
control protein HPV16E6 and HLA-DR3-restricted peptide hsp65 p3-13 did not induce IFN-γ in 
any of  the immunized mice. As expected, immunization with the peptide pool lacking the dominant 
peptide Rv2034 p31-50 did not induce any responses to p31-50 or p31-60, whereas immunization 
with 30-mer p31-60 induced strong responses to the whole protein as well. CD8+ T cells did not 
produce IFN-γ following in vitro peptide re-stimulation (data not shown) confirming CD4+ T cell-
specificity for the HLA-DR3-restricted response to Rv2034.
Induction of  polyfunctional T cells in response to Rv2034
Antigen-specific IFN-g production is often used as a proxy biomarker of  vaccine-induced and 
protection-associated Th1 responses. More recently, the induction of  polyfunctional CD4+ Th1 cells 
was found to correlate better with vaccine-induced protection [26] in several model settings, even 
though the value of  polyfunctional T cells as biomarkers of  protection in Mtb infection remains 
questionable [27-29]. To estimate the frequency of  polyfunctional T cells in the Rv2034-immunized 
HLA-DR3 mouse vaccine model, intracellular production of  TNF, IL-2 and IFN-γ was assessed 
simultaneously using polychromatic flow cytometry (Figure 3). Splenocytes of  immunized HLA-DR3 
mice that were in vitro restimulated with medium mainly showed TNF+ (0.5%) single positive and 
IFN-g+ (0.12%) single positive CD4+ T cells. In vitro restimulation with Rv2034 protein and Rv2034 
p31-60 increased the number of  IFN-g+ CD4+ T cells to 1.28% and 1.93%, and induced 0.71 % and 
0.54 % double (IFN-g+/TNF+) positive CD4+ T cells, respectively. The percentages of  triple (IFN-g+/
IL-2+/TNF+) positive CD4+ T cells, however, remained low. These data indicate that immunization 
of  HLA-DR3 mice with Rv2034 or Rv2034 p31-60 induces a significant proportion of  single and 










































Figure 3. Frequency of  polyfunctional CD4+ T cells. Percentage of  IFN-γ, IL-2 and/or TNF 
producing CD4+ T cells in splenocytes of  HLA-DR3 mice immunized with Rv2034 protein or Rv2034 p31-
60 in CpG and re-stimulated in vitro with medium (A), Rv2034 protein (B) or Rv2034 p31-60 (C). Each symbol 
represents one mouse immunized with Rv2034 protein (●), Rv2034 p31-60 (▲) or unimmunized (■). The 
total number of  CD4+ T cells analyzed in immunized mice was 56,000. Only CD4+ populations of  > 5 x 104 
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Rv2034 immunization induces antibodies directed against Mtb 
Since we recently showed that even mycobacterial peptides can induce specific antibody responses 
in vivo in HLA-A2 mice [20] and HLA-DR3 [19], we also analyzed the humoral response induced 
by the Rv2034 protein. A high antibody titer against Rv2034 protein was observed after Rv2034/ 
CpG immunization of  HLA-DR3 mice (Figure 4). Mock-immunized mice did not show any 
antibody reactivity, nor were antibodies detected in Rv2034-immunized mice against an unrelated 
recombinant protein HPV16 E6. Finally, no antibodies were generated in Rv2034-immunized 
HLA-A2 mice. These data indicate that Rv2034 protein induces strong cellular as well as humoral 
immune responses in vivo.
Effect of  the use of  different TLR ligands as adjuvants for Rv2034 immunization
Besides the Mtb antigen, the adjuvant used also plays a major role in the induction of  an effective 
Th1/Th2 balance and subsequent protection in vivo [30]. In order to estimate the adjuvant-
effect on protection-associated Th1 immunity, HLA-DR3 mice were immunized three times 
with identical amounts of  Rv2034 protein adjuvanted with different TLR ligands: PAM3CysK4 
(TLR2), Poly(I:C) (TLR3), MPL/TDM (TLR4), Flagellin (TLR5) and R848 (Imidazoquinoline; 
TLR7). The TLR9 ligand (CpG) as well as the TLR3 ligand, Poly(I:C), induced strong Th1 
responses as measured by IFN-γ+CD4+ T cells, whereas the TLR4 ligand, MPL/TDM, induced 
detectable but significantly reduced numbers of  IFN-g+ CD4+ T cells in response to Rv2034 
(Figure 5A). TLR2, 5 and 7 ligands did not induce IFN-g+ CD4+ T cells at all. In none of  the 
conditions CD8+ IFN-g+ T cells were detected (data not shown). In contrast, analyses of  humoral 
responses induced by immunization with various adjuvants showed that all different TLR ligands 
induced strong, Rv2034-specific antibody responses (Figure 5B), indicating a clear separation of  











































Figure 4. Quantification of  serum antibodies to Rv2034. Following immunization of  HLA-DR3 mice 
with Rv2034 in CpG (A) or with CpG alone (B) antibody titer (OD450) against Rv2034 (■) was determined 
by ELISA. As a specificity control HPV16E6 (▲) or 0.4% BSA in PBS alone (●) were tested. Rv2034/CpG 
immunization of  HLA-A2 mice were included as negative control (C). Serum dilutions are shown on the x-axis. 
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Figure 5. Rv2034 immunization of  HLA-DR3 mice using different adjuvants. (A) HLA-DR3 mice 
were immunized three times with Rv2034 protein in either PAM3CysK4, Poly(I:C), MPL/TDM, Flagellin, 
R848 or CpG. Splenocytes were stimulated in vitro with Rv2034 protein, HPV16E6 (control recombinant protein), 
Rv2034 p31-60 or hsp65 p3-13 (control HLA-DR3-restricted peptide). After 7 days, cells were incubated with 
medium or fresh antigen for 1h before addition of  brefeldin A and analyzed for intracellular IFN-γ production. 
Adjuvants are indicated on the x-axis.
(B): Sera of  HLA-DR3 mice immunized as above or with CpG only were used to determine antibody titers 
(OD450) by ELISA against Rv2034 (■) or BSA (0.4% in PBS) alone (●). Adjuvants are indicated above each 
figure. Serum dilutions are shown on the x-axis. Groups included 4-5 mice. Results are shown for one animal, 










































Protective efficacy of  Rv2034 immunization against live Mtb challenge
To assess the vaccine potential of  the Rv2034 protein adjuvanted by CpG, its prophylactic protective 
effect was evaluated in a live Mtb challenge model, by enumerating the colony forming units (CFU) 
in the lungs. Interestingly, Rv2034 immunization reduced the number of  CFU in the lungs by almost 
one log (from 6x106 to 9x105) whereas BCG caused a reduction of  over a log to 1.8x105 CFU (Figure 
6). As a reference, recombinant hybrid protein Ag85-ESAT6 (H1) [31] adjuvanted in CpG was used 
as well: immunization with H1/CPG decreased the number of  Mtb bacteria in the lung to a similar 
extent as Rv2034 (to 5x105) being slightly less effective than BCG. The combination of  BCG followed 
by Rv2034/CpG immunization 6 weeks afterwards also resulted in a decreased CFU load, but did 
not lead to an improvement compared to BCG alone. Importantly, in HLA-DR3neg mice Rv2034 
vaccination did not reduce the number of  CFU, confirming the HLA-DR3-restriction of  the T-cell 
mediated protection.
Figure 6. Determination of  colony forming units (CFU) in the lungs of  Mtb- infected mice. 
CFU were determined in lung homogenates derived from Mtb infected HLA-DR3 mice (●) or HLA-DR3neg 
(○) mice that were left unimmunized or had been immunized with BCG, Rv2034 in CpG, H1 in CpG or 
immunized with BCG followed by a boost with Rv2034 in CpG as indicated on the x-axis. Protective efficacies 












































New vaccines against TB need to induce immune responses that target Mtb at the primary site of  
infection, which is the lung. Thus, Mtb antigens in vivo expressed during pulmonary Mtb infection 
(IVE-TB) might represent interesting vaccine candidates. In this study we have analyzed one of  
our newly identified IVE-TB proteins, the ArsR protein Rv2034, and show that it is strongly 
immunogenic in vivo in HLA-DR transgenic mice. Immunization of  HLA-DR3 mice with Rv2034 
induced specific cellular as well as humoral immunity against the protein and its dominant HLA-
DR3-restricted epitope p31-50. Importantly, prophylactic immunization of  HLA-DR3 mice with 
Rv2034 in CpG induced a significant protective response to Mtb which was similar to BCG, as 
judged by decreased bacterial numbers upon Mtb challenge. Importantly, previous work showed 
that Rv2034-specific T cells were induced by Mtb infection in mice and humans [4], supporting a 
biological role for Rv2034 in in vivo infection and rendering it an interesting vaccine target antigen.
Recently, we have shown that immunization of  HLA-DR3 mice with an Mtb polyepitope in CpG 
induced strong cellular as well as humoral (antigen-specific Ig) responses [19]. Similar to Rv2034 
immunization, this Mtb polyepitope immunization caused a significant reduction of  bacterial load 
upon Mtb challenge. In contrast to the role of  T cells, the role of  Mtb antigen-specific antibodies 
in the control of  Mtb remains largely unknown and has long been debated [32;33]. Antibodies 
can induce multiple immune-modulatory effects which can play a role in reducing the bacterial 
load such as mediating effector functions via binding to Fc receptors on immune cells, including 
activation of  T-cell immunity and antibody-dependent cell-mediated cytotoxicity (ADCC) [34]. 
Indeed, several studies showed that immunoglobulins mediate protection against TB [35-37], 
whereas the organs of  mice that are deficient for humoral immunity [µ-chain knock out (B cell-
/- or Ig-) and γ-chain subunit knock out (Fcγ-chain−/−)] displayed 3- to 8-fold elevated numbers of  
viable bacilli compared with normal littermates, while splenic IFN-g responses to whole antigen 
were unimpaired [38-40]. Moreover, in Mtb infected non-human primates active B cells were 
present in clusters within granulomas. Furthermore, high levels of  Mtb antigen specific antibodies 
were detected within Mtb infected tissues, indicating that B cells play a role in Mtb infection [41]. 
Thus, Rv2034 antibody responses may substantially contribute to protection against Mtb infection. 
Studies on animal models have shown that polyfunctional T cells which secrete IFN-g, TNF-a 
and IL-2 simultaneously, are functionally superior in vaccine-induced protection and also often 
induced in Mtb vaccine studies [31;42-44]. In our current study, Rv2034 immunization of  HLA-
DR3 mice induced strong IFN-γ+/TNF+ and IFN-γ+ CD4+ T cells specific for Rv2034, but no 
IFN-g+/TNF+/IL-2+ CD4+ T cells. Importantly, control cytokine producing cells (MiCK-1) displayed 
IL-2 production demonstrating that IL-2 was detectable using this assay. Thus, despite the lack of  
substantial numbers of  triple positive (IFN-γ+/TNF+/IL-2+) CD4+ T cells, Rv2034 immunization 
reduced the number of  bacteria in HLA-DR3 mice, but not in HLA-DR3neg littermates or HLA-A2 










































is an absolute requirement for vaccine-induced protection against Mtb. In view of  our data, it is of  
note that the described Mtb vaccine studies also identified double and single cytokine producing 
CD4+ T cells [31;42-44]. Interestingly, it is uncertain whether polyfunctional T cells correlate with 
TB protection [27-29]. Multiple factors are suggested to be involved in development or detection 
of  polyfunctional T cells such as antigen dose and time point of  T-cell analysis [28;45;46]. Also, 
previous work showed that the frequency of  IFN-γ producing CD4+ T cells does not directly associate 
to vaccine-induced protection [47] or might even be irrelevant in killing Mtb [48;49]. This further 
indicates that other (yet unknown) mechanisms are involved in controlling Mtb infection [50;51].
The use of  TLR9 ligand as adjuvant in mouse models has shown efficient induction of  both 
humoral and cellular immunity [19;20;52]. Of  note is that the distribution of  TLR9 in mice 
differs from that in humans being either broadly expressed on all types of  DC in C57BL/6 mice 
or restricted to plasmacytoid DC in humans [53]. Out of  the TLRs tested in this study that are 
broadly expressed on several DC types of  both species (TLR2, 3, 4, 5 and 7) [54], only poly(I:C) 
(TLR3) and to a lesser extent MPL/TDM (TLR 4) induced Th1 responses. In contrast, regardless 
of  the TLR ligand used as adjuvant for Rv2034 immunization in this study (TLR2, 3, 4, 5, 7 or 
9), strong Ig responses were observed specific for Rv2034. Thus, these findings clearly show the 
separation of  the effect on humoral and cellular responses by these adjuvants. Similar data have 
been reported in a single long peptide vaccination model in which all different adjuvants activated 
DC in vitro but only MPL and CpG (TLR4 and TLR9) induced a strong functional T-cell response 
in vivo [30]. This effect depended mainly on the capacity of  ligands to mature pro-inflammatory 
DC and the duration of  their in vivo stimulatory effect. 
Besides the choice of  adjuvant, the route of  administration might play an important role in 
the development of  robust Th1 immunity upon immunization [30;55]. In this study, adjuvanted 
Mtb antigens were administered subcutaneously representing a custom vaccination route in human 
vaccination programs.
Immunization with Rv2034/CpG resulted in decreased bacterial load in the lung after Mtb 
challenge, which was dependent on induced HLA-DR3-restricted T-cell immunity. Although Rv2034 
immunization resulted in reduction of  CFU, boosting BCG with Rv2034 did not further improve 
the protective effect of  BCG alone. In addition, immunization with Ag85B/ESAT6 (H1) in CpG 
decreased the number of  Mtb bacteria in the lung to a similar extent as Rv2034, slightly less than the 
BCG induced reduction. Interestingly, fusion protein H1, Ag85B/ESAT6/Rv2660 (H56), Ag85B/
TB10.4 (HyVac4) and Mtb10.4/HspX (MH) showed an improved CFU reduction when used as 
BCG booster [44;56;57]. However, when administered as a subunit vaccine alone, the fusion proteins 
showed less protection compared to BCG, in line with previous findings [44;57] and this study. Thus, 
since Rv2034 is highly expressed in the lungs during Mtb infection, incorporating Rv2034 in a fusion 
protein may induce efficient protection when used as BCG booster. Rv2034 may thus have potential 
prophylactic and therapeutic vaccine properties when combined with early stage and TB latency 
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of  the Mtb infection cycle. Additionally, the immunogenic peptide may also be integrated in a poly-
epitope vaccine, containing multiple immunogenic epitopes from different Mtb proteins [19]. 
In summary, we have shown that the IVE-TB protein Rv2034 is immunogenic in vivo and has 
protective efficacy as evidenced by its ability to reduce the bacterial load in vivo after a live challenge 
with Mtb. Thus Rv2034 represents an interesting new antigen for subunit TB vaccination.
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Clonal analysis of  the T-cell response to in vivo expressed 
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expression based T-cell cloning method
Susanna Commandeur, Karin Dijkman, Annemieke H. Friggen, Krista E. van Meijgaarden, 
Susan J.F. van den Eeden, Louis Wilson, Jolien J. van der Ploeg-van Schip, Kees L.M.C Franken, 
Annemieke Geluk and Tom H.M. Ottenhoff













































Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a leading cause of  death 
worldwide. A better understanding of  the role of  CD4+ and CD8+ T cells, which are both 
important to TB protection, is essential to unravel the mechanisms of  protection and to identify 
the key antigens seen by these T cells. We have recently identified a set of  in vivo expressed Mtb 
genes (IVE-TB) which is expressed during in vivo pulmonary infection in mice, and shown that 
their encoded antigens are potently recognized by polyclonal T cells from tuberculin skin test-
positive, in vitro ESAT6/CFP10-responsive individuals. Here we have cloned T cells specific 
for one of  these newly identified in vivo expressed Mtb (IVE-TB) antigens, Rv2034. T cells 
were enriched based on the expression of  CD154 (CD40L), which represents a new method 
for selecting antigen-specific (low frequency) T cells independent of  their specific function. An 
Rv2034-specific CD4+ T-cell clone expressed the Th1 markers T-bet, IFN-γ, TNF-α, IL-2 and the 
cytotoxicity related markers granzyme B and CD107a as measured by flow cytometry. The clone 
specifically recognized Rv2034 protein, Rv2034 peptide p81-100 and Mtb lysate. Remarkably, 
while the recognition of  the dominant p81-100 epitope was HLA-DR restricted, the T-cell clone 
also recognized a neighboring epitope (p88-107) in an HLA-DR- as well as HLA-DQ1-restricted 
fashion. Importantly, the T-cell clone was able to inhibit Mtb outgrowth from infected monocytes 
significantly. The characterization of  the polyfunctional and Mtb inhibitory T-cell response to 
IVE-TB Rv2034 at the clonal level provides further insights into the potential of  IVE-TB antigens 












































Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), accounts for ≥ 1.5 million deaths each 
year and remains one of  the leading causes of  death due to infectious disease. There is no efficient 
vaccine against TB yet, since the only Mtb vaccine available, Mycobacterium bovis bacille Calmette-
Guerin (BCG), induces limited and variable protection against pulmonary TB, the transmissible 
form of  the disease. Novel Mtb vaccines, including improved BCG strains, attenuated Mtb strains 
and subunit vaccines, are currently under study [1]. Given the major role of  CD4+ and CD8+ 
T cells during infection with Mtb, better understanding of  the role and function of  these T cells 
during Mtb infection and post (BCG) vaccination is of  key importance to developing further 
improved vaccines [2]. 
Advanced flow cytometry allows for detailed characterization of  specific T-cell subsets. Due to 
major advances in the development of  improved instruments and reagents an increasing number 
of  parameters can be measured simultaneously [3;4]. The measurement of  IFN-γ production 
is generally used to detect Mtb antigen-specific T cells. However, this approach is inherently 
biased towards detecting Th1 cells, and potentially falls short of  detecting other antigen specific 
T-cell subsets. Although in theory the use of  T-cell activation markers, such as CD25 and CD69 
can circumvent such bias, substantial levels of  CD25 and CD69 expression are detected also 
in unstimulated samples, indicating that their induction is not strictly antigen induced [5;6]. 
Expression analysis of  CD154 (CD40L) may provide a suitable alternative to overcome these 
issues. CD154 has previously been described as an antigen-specific induced cell surface marker, 
which is transiently expressed on T cells upon specific antigen recognition via TCR [6;7]. CD154 
interacts with CD40, which leads to subsequent activation of  APC, driving both humoral and 
cellular immunity [8;9].
Recently we identified a set of  novel in vivo expressed Mtb (IVE-TB) antigens as possible 
TB vaccine candidate antigens [10]. One of  the IVE-TB encoding genes, Rv2034, was found 
to be expressed during inflammatory pulmonary infection, and its encoded protein was strongly 
recognized by T cells from mycobacteria exposed individuals [10]. Moreover, vaccination of  
HLA-transgenic mice with Rv2034 protein significantly reduced Mtb load (Commandeur et al. 
unpublished data). Understanding the immunological response to IVE-TB antigens, as well as to 
early-phase expressed (e.g. ESAT-6) or late phase-expressed (e.g. DosR regulon and Rpf) proteins 
[11;12] is important to the development of  better TB vaccines and TB biomarkers. Therefore we 
performed a more detailed analysis of  the T-cell response to Mtb IVE-TB antigen Rv2034 using 
an Rv2034 specific CD4+ T-cell clone that was generated using a novel CD154-expression based 
cell selection method described here, and analyzed both its specificity and phenotype. The T-cell 
clone was specific for an HLA-DR restricted epitope in Rv2034 p81-100. Surprisingly, this was 
neighbored (p88-107) by a both HLA-DR and HLA-DQ presentable epitope, and in agreements 










































features. Furthermore, the T-cell clone recognized Mtb lysate, and expressed the Th1 markers 
T-bet, IFN-γ, TNF-α and IL-2 and cytotoxic markers granzyme B and CD107a, consistent with a 
Th1 phenotype that co-expresses cytotoxicity granule markers. Importantly, the T-cell clone was 
able to inhibit Mtb outgrowth from infected monocytes. 
Materials and methods
Recombinant proteins. Recombinant (fusion) proteins were produced as previously described 
[13]. In short, gene amplified PCR products were cloned by Gateway Technology (Invitrogen, San 
Diego, CA, USA) in a bacterial expression vector containing an N-terminal hexa-histidine (His) 
tag. Generated vectors were sequenced to confirm correct insertion of  the product. Recombinant 
proteins were overexpressed in Escherichia coli strain BL21 (DE3) and further purified. The size 
and purity of  the proteins were analyzed by gel electrophoresis, using Coomassie brilliant blue 
and Western blotting using an anti-His antibody (Invitrogen, Carlsbad, CA, USA). Endotoxin 
contents were below 50 EU (endotoxin unit) per mg of  recombinant protein as tested using a Limulus 
Amebocyte Lysate (LAL) QCL-1000 assay (Lonza Inc., Basel, Switzerland). Recombinant proteins 
were tested to exclude protein non-specific T-cell stimulation and cellular toxicity in IFN-g release 
assays using PBMC of  in vitro PPD-negative, healthy Dutch donors recruited at the Blood Bank 
Sanquin, Leiden, The Netherlands [14;15]. None of  these controls had experienced any known 
prior contact with TB patients. 
Study subjects. Blood samples were collected by venipuncture. Peripheral blood mononuclear 
cells (PBMCs) were isolated from heparinized venous blood by Ficoll density gradient centrifugation 
and stored in liquid nitrogen until further use. 
Ethical Statement. Donors gave written informed consent before blood donation. The study 
protocol (P207/99) was approved by the Institutional Review Board of  the Leiden University 
Medical Center. 
Synthetic peptides. Rv2034 20-mer peptides with 10 aa overlap were synthesized by Peptide 2.0 
Inc. (Chantilly, VA, USA) [16] Generated peptides were analyzed by HPLC to determine purity of  
peptide products (> 75%). Mass-spectrometry was performed to determine the molecular weight 
of  the peptides. 
Enzymatic digestion of  Mtb lysate. Mtb lysate was generated as previously described [10]. 
To generate hypoxic Mtb lysate, H37Rv was grown to late log phase under a flow of  nitrogen 
containing oxygen tension for 24 hours in a shaking incubator at 37 °C [17]. To generate starvation 
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at 37 °C [18]. Mtb lysates were treated with Proteinase K (Promega, Madison, WI, USA) and 
Lysozyme (Sigma Aldrich, St. Louis, MO, USA), both at a final concentration of  5 µg/ml for 1 
hour at 37 °C in a shaking incubator. Subsequently, the enzymes were inactivated for 90 minutes 
at 99 °C.  
Lymphocyte stimulation test. PBMC (1.5*10^5) were cultured in triplicates in 96-well round-
bottom plates (Nunc, Roskilde, Denmark) and incubated with or without protein (10 μg/ml) in a 
final volume of  200 μl AIM-V medium (Invitrogen, Breda, Netherlands) at 37°C and 5% CO2. 
After 6 days, supernatants were harvested and used for IFN-γ determination. Subsequently, cells 
were pulsed with [3H]-thymidine (0.5 μCi/well) and incubated 16-18 hours at 37°C and 5% CO2. 
Incorporation of  [3H]-thymidine was measured using a Wallac 1450 MicroBeta TriLux Liquid 
Scintillation Counter (Wallac, Turku, Finland).  
Generation of  CD154 specific T-cell clones. PBMC (0.5-1*10^6) were seeded in 96-wells 
round-bottom plates together with peptide pool mix (1 µg/ml per peptide) in Iscove’s Modified 
Dulbecco’s Medium (IMDM; Gibco, Invitrogen, Breda, the Netherlands) containing 10% pooled 
human serum (HuS) and human IL-2 (Proleukin; Novartis Pharmaceuticals UK Ltd., Horsham, 
UK) at a final concentration of  100 IU/ml and incubated for 1 week at 37°C and 5% CO2. 
After 1 week, the cells were restimulated with peptide pool (1 µg/ml per peptide) and autologous 
PBMC (0.5-1*10^6) in IMDM containing 10% HuS and 1:100 diluted anti-CD40 antibody (clone 
HB14, Miltenyi Biotec, Auburn, CA, USA) and incubated 16 hours at 37°C and 5% CO2. CD154 
positive cells were sorted and seeded in 96-wells round-bottom plates (0.3, 1 and multiple cell(s)/
well) containing IMDM, irradiated (3000 rad) feeders (5*10^4 cells/well), IL-2 (100 IU/ml), 10% 
HuS and phytohemagglutinin (PHA) at a final dilution of  4 µg/ml (Remel, Oxoid, Haarlem, the 
Netherlands). After one week IL-2 was added (100 IU/ml) and cultured for approximately another 
1-2 weeks until clonal expansion was established.
Magnetic-activated Cell Sorting (MACS) of  CD154 positive cells. Stimulated PBMC 
were collected and labeled with anti-CD154 phycoerythrin (PE) (Miltenyi Biotec, Auburn, CA, 
USA). Subsequently cells were washed and incubated with anti-PE MicroBeads (Miltenyi Biotec, 
Auburn, CA, USA). Labeled and washed cells were applied to a MS Column (Miltenyi Biotec, 
Auburn, CA, USA) to enrich for CD154 positive T cells. Samples collected prior cell sort, CD154-
enriched population and flow through were additionally stained for anti-CD3 Pacific Blue (PB) 
(Biolegend), anti-CD4-Alexa Fluor® 700 (eBioscience), anti-CD8 HorizonV500 (BD Biosciences) 
(Supplementary figure 1). MACS buffer (PBS supplemented with 2mM EDTA and 2% FCS) was 










































RNA isolation and cDNA synthesis. RNA was isolated from 5*10^6 T cells using 1 ml Trizol® 
Reagent (Invitrogen, Life Technologies, Paisley UK) according to the manufacturer’s protocol and 
dissolved in 40 μl RNAse free H2O (Ambion, Invitrogen, Life Technologies, Paisley, UK). RNA 
concentration was determined by measuring the OD260 with the Nanodrop ND1000 (Thermo 
Scientific, Waltham, MA). Complementary first strand DNA was synthesized from 0.6 µg RNA, 
and with 10 pmol oligoDt primer (Life Technologies, Paisley, UK). This mixture was first incubated 
at 72 °C for 2 minutes to facilitate primer annealing. Superscript III Reverse Transcriptase (1μl), 
10 nmol dNTPs, 0.1 mM DTT (all Invitrogen, Life Technologies, Paisley, UK) were added to 
this mixture and subsequently incubated at 42°C for 60 minutes. Amplification was performed 
by adding 2 μl of  cDNA, 10 nmol dNTPs, 20 pmol oligoDt primer, 20 pmol capswitch primer 
and 38 μl H20 in a total volume of  50 μl. The amplification PCR program consisted of  an initial 
denaturation cycle of  1 minute at 95 °C, followed by 20 amplification cycles (5 seconds at 95 °C, 
5 seconds at 65 °C and 6 minutes at 68 °C). The quality of  the amplified cDNA was analyzed by 
gel electrophoresis.
Determination of  T-cell clonality. Clonality of  the clone was assessed by PCR amplification 
of  the Vβ and Vα regions, with a constant primer [19] for the Cα and Cβ region and 26 and 37 V 
region-specific primers for the Vβ and Vα region, respectively [19]. Mastermix contained 3 (Vβ) 
or 4 (Vα) µl cDNA, 5 pmol reverse primer, 200 µM dNTPs, 1.5 mM MgCl2, 0.5 unit of  GoTaq 
Flexi DNA polymerase and 1x Green GoTaq Flexi Polymerase Buffer (all Promega, Madison, 
WI) and 1x bovine serum albumin (BSA, New England Biolabs, Ipswich, MA). 5 pmol of  each 
V-specific primer was added. A total volume of  10 µl was used for PCR amplification. An initial 
denaturation step at 95 °C for 2 minutes was followed by 35 cycles of  denaturation at 94 °C for 
30 seconds, annealing at 65 °C (Vα) or 60 °C (Vβ) for 30 seconds and extension at 72 °C for 30 
seconds. Finally, a 5 minute extension step was performed at 72 °C. PCR products were analyzed 
by standard gel electrophoresis. Sequencing templates were amplified using Phusion DNA 
Polymerase (New England Biolabs, Ipswich, MA) and a constant primer extended with a M13 
sequence (TGTAAAACGACGGCCAGT). Amplicons spanning the variable, CDR3 and joining 
regions were purified using Wizard® SV Gel and PCR clean up system (Promega, Madison, WI) 
according to manufacturers’ protocol. Samples were sequenced at Baseclear (www.baseclear.com) 
using a separate M13 primer. 
Restimulation of  T-cell clones. Irradiated (3000 rad) feeders were pulsed with peptide mix 
(20 µg/ml per peptide) for 2 hours and washed. Clones were seeded in 96 wells at 2*10^4/ well 
together with the feeders (1*10^5/ well). For CD4+ T cells, clones were incubated in IMDM 
containing 10% HuS and 1% LeucoA (Sigma Aldrich, St. Louis, MO, USA) at 37°C and 5% 
CO2. After three days, IL-2 was added (25 IU/ml). For CD8
+ T cells, clones were incubated in 
IMDM contain 10% HuS, IL-7 and IL-15 both at a final concentration of  5 ng/ml (PeproTech 
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T-cell subset analysis using flow cytometry. Feeders (3000 rad) were seeded to 96 flat- 
bottom plate (1*10^5) and incubated for 4-6 hours. The plates were washed three times with 
RPMI. T cells were added, together with antigen (10 µg/ml), peptide or peptide pool (5 µg/ml 
per peptide). After 2-4 hours 3 µg/ml Brefeldin A (BFA; Sigma Aldrich, St. Louis, MO, USA) 
was added and incubated overnight (o/n). Cells were harvested and collected in 5 ml round-
bottom FACS tubes (BD Biosciences), washed and stained for T-helper markers. For additional 
flow cytometry, irradiated PBMC (2000 rad) were seeded together with antigen (10 µg/ml) or 
peptide (5 µg/ml) to 96 flat-bottom plate (1*10^5) and incubated o/n. plates were washed with 
RPMI and T cells were added (1*10^5). After 2-4 hours 3 µg/ml Brefeldin A (BFA; Sigma Aldrich, 
St. Louis, MO, USA) was added and incubated overnight (o/n). Cells were harvested and collected 
in FACS tubes, washed and stained. 
Cells were stained with LIVE/DEAD® fixable violet dead cell stain (ViViD; Invitrogen, 
Carlsbad, CA, USA) prior surface and intracellular staining to discriminate between live and 
dead cells according to manufacturer’s instructions. CD14 and CD19 markers were included to 
eliminate monocytes and B cells using a DUMP channel [20]. Following ViViD, surface markers 
were stained in PBS 0.1% BSA for 1/2-1 hour at 4 °C. Subsequently intracellular staining (ICS) 
was performed using fixation and permeabilization (Intrastain) kit (DakoCytomation, Glostrup, 
Denmark). Unstimulated and unstained samples were included as negative controls. Different 
T-cell subset panels were used. All included, surface staining; anti-CD3 PE-Cy5 or anti-CD3 
PE-Cy7, (both BD Biosciences), anti-CD4 Texas Red (Caltag), anti-CD8 HorizonV500 (BD 
Biosciences), anti-CD14 PB (Invitrogen) and anti-CD19 PB (Invitrogen), ICS; anti-CD154 APC-
Alexa eFluor® 780 (eBioscience). In addition, the following markers were used for (i) T-helper 
subset panel, surface staining; anti-TCRα/β Fluorescein isothiocyanate (FITC), ICS; anti-IFN-γ 
Alexa Fluor® 700 (BD Pharmingen), anti-TNF-α PE-Cy7 (BD Biosciences) and anti-IL-2 PE 
(BD Pharmingen) (anti-Granzyme B APC (Caltag)). (ii) Transcription factor subset panel, 
ICS; anti-IFN-γ Alexa Fluor® 700 (BD Pharmingen), anti-T-bet eFluor®660 (eBioscience), anti-
GATA-3 PerCP-eFluor® 710 (eBioscience), anti-Ror-γt PE (eBioscience) and anti-IL-17 FITC 
(eBioscience). (iii) Regulatory T cell subset panel, surface staining; anti-CD25 PE-Cy5 (BD 
Biosciences) and anti-CD39 PE (Biolegend), ICS; anti-Foxp3 Alexa Fluor® 700 (eBioscience) and 
anti-IL-10 APC (Miltenyi Biotec). (iv) T cell cytotoxicity subset panel, ICS; anti-Granzyme B 
APC (Caltag), anti-IFN-γ Alexa 700 (BD Pharmingen), anti-CD107a PE-Cy5 (BD Pharmingen) 
and anti-Perforin PE (BD Pharmingen). Of  note, anti-CD107a PE-Cy5 was already added during 
incubation of  the T cells with APC and antigen. Fluorescence minus one (FMO) controls were 
included for each T-cell subset panel. Data were acquired on a BD LSRFortessa (BD Biosciences) 










































Antigen specificity test. T cells (1*10^4) were seeded in 96 flat-bottom plates in presence of  
HLA class I and/or class II (mis)matched irradiated (2000 rad) PBMC (5*10^4) [21]. T cells were 
stimulated with either protein (10 µg/ml), peptide (10 µg/ml), PHA (2 µg/ml) or purified protein 
derivative (PPD; Statens Serum Institute, Copenhagen, Denmark; 5 µg/ml) and incubated for 3 
days at 37°C and 5% CO2. At day 3, supernatant was harvested and tested for IFN-γ production. 
Subsequently, cells were pulsed with [3H]-thymidine and incubated 16-18 hours at 37°C and 5% 
CO2. Incorporation of  [
3H]-thymidine was measured using a Wallac 1450 MicroBeta TriLux 
Liquid Scintillation Counter.  
Blocking of  HLA-DR and HLA-DQ molecules. Irradiated (2000 rad) PBMC (5*10^4) and 
monoclonal antibodies (20 µg/ml) directed against HLA-DR (B8.11.2) or HLA-DQ (SPV-L3) 
molecules (provided by Prof. F. Claas, Department of  Immunohematology and Blood Transfusion, 
Leiden University Medical Center, Leiden, The Netherlands) were seeded in 96 flat-bottom plates 
and incubated for 2 hours. T cells (1*10^4) and protein antigen, peptide (5 µg/ml) or PHA (2 µg/
ml) were added and co-incubated for 3 days at 37°C and 5% CO2. Both IFN-γ production and 
proliferation were determined as previously described. Rp151-1 was included as reference CD4
+ 
T-cell clone [22;23].
Western blot analysis. Recombinant protein (0.4 µg), Mtb lysates (10 µg) and ultralow 
molecular weight marker (Color Marker Ultra Low Range; Sigma Aldrich, St. Louis, MO, USA) 
were separated under denaturizing conditions using a 17% Tricine sodium dodecyl sulfate-
polyacrylamide gel (SDS-PAGE) at 100-200 V for 2-3 hours [24]. Proteins were transferred onto 
a polyvinylidene difluoride (PVDF) membrane by electroblotting (40V; 250 mA). The membranes 
were blocked using 5% skim milk (Fluka, Biochemika, Sigma Aldrich, 70166), washed (PBS 0.1% 
Tween20) and incubated with Rv2034-immunized or naive mouse serum. After incubation blots 
were washed and incubated with secondary horseradish peroxidase (HRP)–conjugated rabbit 
anti-mouse Ig, detecting total IgG, IgA and IgM (P0260 Dako, Glostrup, Denmark). Protein bands 
were visualized using chemiluminescence (ECL) HRP substrate (Amersham™ ECL Select™, 
GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Blots were developed using Fuji super RX 
medical X-ray films.
Generation of  monocyte derived DC. PBMC were thawed and monocytes were isolated by 
positive selection using MACS CD14 MicroBeads (Miltenyi Biotec, Auburn, CA, USA) following 
manufacturer’s instructions. Monocytes were seeded in T75 flasks (Corning) in RPMI medium 
containing 10% heat-inactivated fetal calf  serum (FCS), 50 U/ml penicillin, 50 μg/ml streptomycin 
(Gibco, Paisley, United Kingdom), IL-4 and GM-CSF (Biosource International, Camarillo, CA, 
USA) both at 10 ng/ml for 6 days to generate monocyte-derived immature DCs. Mature DCs were 
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DC differentiation and maturation was validated by flow cytometry using anti-CD14 PE (BD 
Pharmingen), anti-HLA-DR FITC (BD Pharmingen), anti-CD1a Alexa Fluor® 700 (Biolegend), 
anti-CD163 Alexa Fluor® 647 (Biolegend), anti-CD80 PE-Cy7 (Biolegend), anti-CD86 PE-Cy5 
(BD Pharmingen) and anti-CD3 PB (Biolegend).
Matured DCs were loaded with Rv2034 protein, Rv2034 p81-100 and different conditions of  
Mtb lysate and incubated for 24 hours. Cells were washed and Rv2034 CD4+ T-cell clone added. 
After 2 hours BFA was added and culture incubated o/n. Activation of  T cells was determined by 
detection of  CD154 and Th1 markers using the T-helper subset panel. 
Mtb inhibition assay. Autologous PBMC were isolated using Ficoll density centrifugation from 
venous, heparinized blood and plated in quadruplicate cultures (1*10^6 cells/well; assuming 10% 
monocytes) in 48-wells plates (Costar Corporation, Cambridge, Mass.) in PBS. After overnight 
incubation at 37°C, PBS was removed and replaced by IMDM containing 10% human serum of  
37°C. The adhering monocytes were infected with Mtb H37Rv at an MOI of  10. After overnight 
incubation at 37°C, T-cell clone were added at effector:target (E:T) ratios of  20:1 and 50:1. After 
an additional o/n incubation, cells were lysed. Lysates were homogenized in PBS and the number 
of  bacteria was determined by culturing serial dilutions of  the homogenates on 7H10 agar plates 
(BD Biosciences) supplemented with BD BBL™ Middlebrook OADC enrichment (100 ml per 
bottle; BD Biosciences). Colonies were counted after 2-3 weeks incubation at 37 ºC. 
Results and discussion
Generation of  T-cell clones for subsequent phenotypic and functional analysis
We previously reported that in vivo expressed Mtb (IVE-TB) antigens have significant vaccine 
potential [10] [Commandeur et al. unpublished data]. It is thus important to characterize the 
underlying immune responses to these antigens in more detail, particularly in humans. To this end, 
clonally expanded antigen specific T cells are powerful tools [25;26]. To generate IVE-TB specific 
T cells we used a T-cell cloning method based on CD154 expression to enrich for antigen-specific 
T cells irrespective of  function. We selected two Mtb antigens; the well-studied TB10.4 protein 
[27] and the recently described in vivo expressed Mtb (IVE-TB) antigen Rv2034 [10]. 
First, PBMC of  an in vitro PPD+ donor known to respond to these antigens (Figure 1A and 
1B) were stimulated with peptide pools from TB10.4 or Rv2034 for one week in the presence of  
IL-2, followed by re-stimulation with the peptide pool for 16 hours, in the presence of  anti-CD40 
antibodies to inhibit CD154-CD40 interactions [6] preventing loss of  surface expressed CD154 
[28;29]. CD154 positive cells were then sorted using Magnetic-activated Cell Sorting (MACS) 
and seeded at 0.3 or 1 cell per well densities as described in detail in the materials and methods 
section. To analyze the antigen specificities of  the expanded T-cell clones, cell populations were 










































TB10.4 peptide pool stimulation (Table 1). Out of  these, five T-cell clones were CD154+CD4+ and 
produced either IFN-γ, TNF-α and IL-2, or TNF-α and IL-2. Two clones appeared to be CD8+ 
T cells that produced IFN-γ, with one of  these producing a relatively low amount of  IL-2 as well. 
CD154 is known to be expressed on activated CD4+ T cells, but can also be upregulated on a 
fraction of  CD8+ T cells [30]. However, none of  the CD8+ T cells expressed CD154. Somewhat 
surprisingly, one T-cell clone was CD3+/CD4-/CD8-, (double negative (DN) T cells) and did not 
express CD154 either, nevertheless, CD3+ CD4-/CD8- are able to express CD154 [31]). This DN 
T-cell clone produced IFN-γ in response to TB10.4 antigen. The remaining expanded T-cell 
cultures were TB10.4 non-responsive and are indicated in Table 1. 
Figure 1. PBMC recognition of  TB10.4 and IVE-TB antigen Rv2034. PBMC from a PPD+ donor 
were stimulated with different stimuli for 6 days and IFN-γ production (pg/ml) was determined in the 
supernatants. Both TB10.4 protein (10 µg/ml) (A) and Rv2034 protein (10 µg/ml) (B) were analyzed as well as 
control mitogen PHA and Mtb derived PPD (A and B). Medium values (unstimulated PBMC) were subtracted. 
Table 1. Analysis of  TB10.4 clonal cultures
Clone Subset a CD154 IFN-γ TNF-α IL-2
1 CD4 + - + +
2 CD4 + + + +
3 DN - +/- - -
4 CD4 +/- +/- +/- +/-
5 CD4 + + + +
6 CD8 - + - +/-
7 CD8 - + - -
8 CD4 + +/- + +
a Single live CD14-CD19-CD3+ cells (population > 100 cells)
Non-responding clonal cultures included CD4 (n=9), CD8 (n=2) and DN (n=2) cells 
DN = Double negative
+ = > 1% positive cells
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For Rv2034, eight antigen responsive T-cell clones were generated using the same approach as 
described for TB10.4, among which three were CD4+ T cells (Table 2). One of  these CD4+ T-cell 
cultures showed specific CD154, IFN-γ, TNF-α and IL-2 expression, whereas the remaining two 
only produced IL-2 in response to antigen. All three identified CD8+ T cells produced IFN-γ. 
As for TB10.4, two potential clones appeared to be DN T cells and also showed a potential to 
produce IFN-γ and/or IL-2. Proliferating Rv2034 non-responsive T-cell clones are also indicated 
in Table 2. Thus, using CD154 sorting we were able to generate IVE-TB Rv2034 induced T-cell 
clones which included CD4+, CD8+ and DN T cells. Interestingly, besides CD4+ and CD8+ T cells 
also DN T cells have been associated with control of  intracellular bacteria including Mtb [32;33]. 
Furthermore, DN T cells also show possible regulatory functions [34;35]. Besides classically 
HLA-class Ia restricted cells, the CD8+ T-cell clones we isolated might also represent circulating 
alternative T-cell subsets, such as mucosal associated invariant T (MAIT) cells [36;37] or HLA-E 
restricted CD8 T cells [38]. 
Table 2. Analysis of  Rv2034 clonal cultures
Clone Subset a CD154 IFN-γ TNF-α IL-2
1 DN - - - +/-
2 CD4 - - - +/-
3 CD8 - + - -
4 CD8 - + - -
5 DN - +/- - +/-
6 CD4 + + + +
7 CD8 - + - -
8 CD4 - - - +/-
a Single live CD14-CD19-CD3+ cells (population > 100 cells)
Non-responding clonal cultures included CD4 (n=18), CD8 (n=0) and DN (n=1) cells
DN = Double negative
+ = > 1% positive cells
+/- = <1% positive cells
CD4+ T-cell clone specific for Mtb IVE-TB antigen Rv2034
Thus, both TB10.4 and Rv2034 T-cell clones could be generated using the CD154 sorting method. 
As the main aim of  this work was the analysis of  IVE-TB specific T-cell responses, we further 
studied a CD4+ T-cell clone that responded to Rv2034 peptide pool stimulation by CD154, IFN-γ, 
TNF-α and IL-2 expression (Figure 2). First, its clonality was further confirmed by PCR for both 
TCRα and TCRβ. The detected variable regions consisted of  Vα13, Vα27 and Vβ14, following 
Arden nomenclature [39] (data not shown). Vα27 was predicted to be an unproductive TCRA 
rearranged sequence due to an out-of-frame junction, whereas Vα13 was successfully rearranged 
(the international ImMunoGeneTics database (IMTG)). Thus the clone represents a truly clonal 










































Figure 2. Rv2034 responsive CD4+ T-cell clone phenotype. The shown CD4+ T-cell clone that had 
been expanded was restimulated with the Rv2034 peptide pool and analyzed for the expression of  CD154 
expression, IFN-γ, TNF-α and IL-2 (black dots). CD154 and Th1 cytokine expression of  non-activated T cells 
is indicated in grey dots. Dot blots show single live CD14-CD19-CD3+CD4+ T cells. 
Identification of  immunogenic epitope(s) of  Rv2034 recognized by the CD4 T-cell 
clone
To identify the specific T cell epitope(s) of  Rv2034, the CD4+ T-cell clone was restimulated 
with single 20-mer peptides from Rv2034. As expected, the Rv2034 peptide pool was strongly 
recognized by the clone as measured by IFN-γ production and T-cell proliferation (Figure 3A). 
Rv2034 p81-100 was identified as the dominant immunogenic epitope, while variable responses 
were observed to Rv2034 p88-107, which overlapped 13 amino acids with Rv2034 p81-100. In 
addition, recombinant protein Rv2034 and fusion protein Ag85B/ESAT-6/Rv2034 were both 
recognized, suggesting that Rv2034 epitope is adequately processed from this protein. The fusion 
protein Ag85B/ESAT-6/Rv2034 includes two early infection phase expressed Mtb proteins 
(Ag85B and ESAT6; together designated as H1), fused to the in vivo expressed Rv2034 protein. 
Inclusion of  multiple infection phase related Mtb proteins in a single fusion construct has been 
shown to improve vaccine efficacy in both mouse and non-human primate models of  TB [40;41], 
especially if  the antigens are expressed during different phases of Mtb infection. It is therefore 
relevant that the immunogenic epitope present in Rv2034 p81-100 is efficiently processed and 
presented from both the Rv2034 protein and the trimeric Ag85B/ESAT6/Rv2034 fusion protein. 
The negative control proteins HPV16E6, Ag85B and ESAT6/CFP10 fusion protein, and the 
negative control peptide HIV-GAG were not recognized, in agreement with the strict Rv2034-
specificity. As expected, expression of  CD154 and Th1 cytokines was detected upon stimulation of  
the CD4+ T-cell clone with Rv2034 p81-100 (Figure 3B) and Rv2034 protein (Figure 3C) whereas 
no activation was observed upon stimulation with negative control peptide p11-30 of  Rv2034 
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Figure 3. Identification of  immunogenic epitope(s) of  Rv2034 recognized by CD4 T-cell 
clone. To identify the immunogenic epitope(s) in Rv2034, the CD4+ T-cell clone was stimulated with all 
individual Rv2034 20-mer peptides with 10 aa overlap; Rv2034 recombinant protein; Rv2034 peptide pool; 
control ESAT6/CFP10 fusion protein; an Ag85B/ESAT6/Rv2034 trimeric fusion protein; and negative and 
positive control conditions. Autologous irradiated PBMC were used as APCs. Both IFN-γ (open bars) and 
T-cell proliferation (black bars) were determined (A). To determine the Rv2034 p81-100 specific response 
by flow cytometry, the CD4+ T-cell clone was stimulated with Rv2034 p81-100 (B), Rv2034 protein (C) and 
Rv2034 p11-30 (D) using autologous irradiated PBMC, in the presence of  BFA. Intracellular CD154 and Th1 
cytokine expression was determined. Flow cytometry plots show single live CD14-CD19-CD3+CD4+ T cells, 










































T-cell subset panel analysis
The Rv2034 responding CD4+ T-cell clone was subsequently analyzed for Th17, Th2, regulatory 
and cytotoxicity T cell (CTL) markers to further specify its functional activities. The Rv2034 p81-
100 peptide-induced CD154 expression correlated with IFN-γ expression (Figure 4A) while no 
IL-17 expression was observed. Transcription factor analysis revealed expression of  T-bet (Figure 
4B), a transcription factor that regulates Th1 development and controls IFN-γ production [42;43], 
but there was no expression of  GATA-3 (Th2 [44]), RORγt (Th17 [45;46]) or FOXP3 (Treg 
[47]). T-bet was constitutively expressed in both p81-100 peptide stimulated and unstimulated T 
cells. Furthermore, the clone did not reveal any specific combination(s) of  other reported T-cell 
regulatory markers (Figure 4C): no IL-10 could be detected although CD25 and CD39 [48] were 
constitutively expressed, which, however, are also expressed by activated non-Tregs [49;50]. Of  
note, CD25 expressing non-Treg cells mostly express intermediate levels of  CD25 (CD25int), 
whereas Tregs typically express high levels of  CD25 (CD25hi) [49]. The expansion of  our T-cell 
clone was mediated by IL-2 which theoretically could have enhanced CD25 expression [51]. 
Finally, the T-cell clone expressed granzyme B and CD107a but no detectable perforin (Figure 
4D). The expression of  granzyme B and CD107a was antigen-stimulation dependent. Cytotoxic 
CD4+ T cells have been reported not only in viral but also in mycobacterial infections [52-54]. The 
expression of  the degranulation marker CD107a indicates the release of  lysosomal products from 
granules after antigen-specific activation of  the T cell, which likely includes granzyme B. Anti-
CD107a antibodies were administered during antigen stimulation of  the T-cell clone, because once 
CD107a is released with its vesicles’ granule contents and becomes integrated in the membrane 
of  the cell, the antibodies will bind to CD107a and are subsequently internalized together with 
CD107, enabling detection of  degranulation. Further studies are required to determine whether 
granulysin and other granzymes are released by the T-cell clone. These data were obtained by 
ICS using brefeldin A to accumulate intracellular cytokines by preventing their secretion. All 
subset conditions were also analyzed using monensin, which acts as protein transport inhibitor 
via disruption of  trans-Golgi protein transport whereas BFA inhibits protein transport between 
endoplasmic reticulum (ER) and the Golgi apparatus. Monensin, however in our hands did not 
enhance any of  the responses (data not shown). Taken together, these observations show that the 
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Figure 4. Subset analysis of  the CD4 T-cell clone. The CD4+ T-cell clone was stimulated with Rv2034 
p81-100 in presence of  BFA and analyzed the expression of  CD154 (A-D), IFN-γ and IL-17 (A) and additional 
markers: the transcriptional factor markers T-bet (Th1), GATA-3 (Th2), RORγt (Th17) and FoxP3 (Treg) (B); 
T-cell regulatory markers: CD39, IL-10 and CD25 (C); T-cell cytotoxicity markers: Granzyme B, CD107a 
and Perforin (D). Markers were analyzed using the mAb subset panels described in the materials and methods 
section. Stimulated T cells are indicated in black and unstimulated T cells in grey. Dot blots show single live 










































Determination of  genetic HLA-restriction of  CD4+ T-cell clone
To identify the genetic HLA-restriction of  T-cell recognition of  Rv2034 p81-100, the T-cell clone 
was cultured with (irradiated) PBMC from donors expressing various matching or mismatching 
HLA class II alleles in the presence of  Rv2034 p81-100 (Figure 5A), Rv2034 protein (Figure 5B) 
and Ag85B/ESAT-6/Rv2034 fusion protein (Figure 5C). The autologous HLA genotype was 
HLA-DR2(15),-DR3(17),-DQ1(6),-DQ2,-DR51,-DR52. As expected, completely HLA-DRB1 
and HLA-DQ mismatched PBMC (HLA-DR11,13 and HLA-DQ3(7)) failed to present peptide 
or protein antigens to the T-cell clone, even though these cells were matched for HLA-DRB3 
(DR52), indicating that DR52 was not involved in Rv2034 p81-100 presentation. Both HLA-
DR2(15)+/DQ1(6)+ and HLA-DR3(17)+/DQ1(5)+ PBMC induced strong T-cell activation. Since 
HLA-DR2(15) is in strong genetic linkage disequilibrium with HLA-DQ1(6) it was impossible to 
match for HLA-DR2(15) while mismatching for HLA-DQ1(6). HLA-DQ1(5,6)+ PBMC, which 
were mismatched for HLA-DR3(17) and HLA-DR2(15), also induced T-cell proliferation and 
IFN-g in response to Rv2034 (fusion) protein and p81-100, whereas HLA-DQ2+ PBMC failed 
to present antigen. While the results were suggestive of  HLA-DR3 and HLA-DQ1 presentation, 
the addition of  purified monoclonal antibodies specific for only HLA-DR but not HLA-DQ 
backbone determinants resulted in a strong reduction of  autologous APC presented Rv2034 p81-
100 induced T-cell proliferation (Figure 5D). Thus the autologous responses towards Rv2034 p81-
100 is predominantly HLA-DR and not HLA-DQ-restricted. 
Surprisingly, however, while responses to the Rv2034 peptide p81-100 were HLA-DR 
restricted, the response to the whole Rv2034 protein was inhibited both by HLA-DR and by HLA-
DQ-blocking antibodies (Figure 5D). Thus, while the epitope contained with p81-100 is HLA-DR 
restricted, the Rv2034 protein also contains an HLA-DQ1(6) restricted epitope sequence that can 
be recognized by the same T-cell clone. Of  note, variable recognition was observed for Rv2034 
p88-107 by the T-cell clone (Figure 4A and data not shown). Strong responses to p81-100 were 
observed at a concentration of  1 µg/ml (Figure 5D), whereas no responses to p88-107 could be 
detected at this concentration (data not shown). However, at a concentration of  5 µg/ml, p88-107 
was able to activate the T-cell clone and, importantly, this could be blocked by both HLA-DR and 
HLA-DQ antibodies (Figure 5D). Thus, the Rv2034 p81-107 sequence possesses HLA-DR and 
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Figure 5. Restriction of  Rv2034 p81-100 and p88-107 presentation by HLA-DR and -DQ 
molecules. To determine the HLA-DR and -DQ restriction of  Rv2034 p81-100 responding CD4+ T-cell 
clone, T cells were incubated with Rv2034 p81-100 (A), Rv2034 protein (B) or Ag85B/ESAT-6/Rv2034 
fusion protein (C), in the presence of  irradiated PBMC with (mis)matched HLA-DR and/or DQ molecules. 
Both IFN-γ production (white bars) and proliferation (CPM) (black bars) was determined. CPM bars represent 
median ranging the highest and lowest value. Matching HLA alleles are indicated in bold on the X-axis. HLA-
DR and HLA-DQ molecules of  APCs pulsed with either Rv2034 protein, Rv2034 p81-100, Rv2034 p88-107 
(5 µg/ml) or control conditions, were blocked using monoclonal antibodies directed against HLA-DR or -DQ 
[21], and T-cell proliferation was analyzed (CPM) (D). 
In silico HLA class II peptide binding predictions (SYFPEITHI [55], NetMHCIIpan 2.1, 
NetMHCII 2.2 and IEDB) revealed that Rv2034 p81-100 (LRTDLDRFWTRALTGYAQLI) 
indeed contains sequences with high predicted binding affinity for multiple HLA-DRB1 and 
HLA-DQ molecules (Supplementary table 1). HLA-DR2(15) and HLA-DR3(17) show binding 
potential for LDRFWTRAL, which is located at the beginning of  the peptide while the 
TRALTGYAQ sequence has predicted potential to bind to HLA-DQ1(6). Although Rv2034 
p88-107 (FWTRALTGYAQLIDSEGDDT) contains a potential epitope (ALTGYAQLI) that 
could bind to HLA-DR2(15), it contains limited predicted epitopes available for HLA-DR3(17). 
Nevertheless, predicted HLA-DQ1(6) epitopes were identified (TRALTGYAQ and TGYAQLIDS) 
(Supplementary table 2). As a control, very few predicted epitopes were observed for Rv2034 
p11-30 (Supplementary table 3), indicating that the p81-107 sequence has a rather unique high 










































recognizes Rv2034 p81-100 and Rv2034 p88-107 via multiple HLA molecules, possibly including 
HLA-DR2, -DR3 as well as HLA-DQ1 registers, but that the dominant response to the protein 
is HLA-DR restricted. Such promiscuous peptides, capable of  being presented by multiple HLA 
molecules, have been shown for several mycobacterial proteins [56], including HspX (16 kDa 
protein) [57], TB10.4 [58] and Hsp65 [59]. In addition, some (Mtb antigen) studies showed 
possible presentation of  a single epitope, specific for one clone, via both HLA-DR and HLA-DQ 
[57;60]. Other studies also demonstrated promiscuity of  viral epitope presentation [61;62]. The 
presentation of  a specific epitope via multiple HLA molecules has been described as HLA cross-
restriction [63;64] and this promiscuity phenomenon is suggested to be extensively present [65;66]. 
Promiscuous Mtb peptides are particularly interesting for development of  novel Mtb vaccines since 
they would be able to cover many different HLA alleles throughout different populations. 
Recognition of  Rv2034 in Mtb lysate
We next wished to demonstrate recognition of  native Mtb expressed Rv2034 protein by the T-cell 
clone in order to better understand its possible role during Mtb infection. First we examined 
whether Rv2034 protein was expressed in Mtb lysates by western blot analysis. Using sera of  
Rv2034-immunized (HLA-DR3 transgenic) mice, expression of  Rv2034 was identified in both log 
phase Mtb lysate and Mtb grown during hypoxic and starvation conditions (Figure 6A). Although 
the protein size was predicted to be approximately 12 kDa (http://www.sciencegateway.org/
tools/proteinmw.htm), the native Rv2034 present in the lysates was larger than expected. The 
recombinant Rv2034 protein includes a histidine tag and thus was expected to have a molecular 
weight of  ~14 kDa. Since Rv2034 contains dimerization sites [67], this higher relative molecular 
mass could be due to formation of  multimers. Alternatively but not mutually exclusive, post-
translational modifications or binding to other molecules might be responsible for the higher 
molecular weight. Two bands were clearly visible, the smallest band likely relating to Rv2034 
protein monomer, whereas the upper band probably indicates multimer formation. The binding 
of  antibodies present in the sera of  Rv2034-immunized mice was specific since no bands were 
observed using sera from non-immunized HLA-DR3 mice. Indeed, Rv2034 protein was also 
previously identified in in vitro grown Mtb cultures [10;68;69], specifically in lipid (membrane) 
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Figure 6. Recognition of  native Rv2034 in Mtb lysate by CD4+ T-cell clone. Mtb lysates (10 μg) 
derived from Mtb grown in log-phase-, starvation- and hypoxic- conditions and recombinant protein Rv2034 
(0.4 µg) were analyzed by western blotting for their recognition by specific antibodies using sera of  Rv2034-
immunized or non-immunized HLA-DR3 transgenic mice (A). Monocyte derived matured DCs were loaded 
with Rv2034 p81-100, Rv2034 protein and different conditions of  Mtb lysate for 24h. Subsequently, the 
CD4+ T-cell clone was incubated with these antigen-loaded DCs and after 2 hours BFA was added and 
incubated o/n. CD154 and IFN-γ expression was determined using flow cytometry. Percentage of  responding 










































We next analyzed the T-cell clone’s reactivity against Mtb lysate to see if  the T-cell clone was 
able to detect the native Rv2034 protein. HLA-matched matured dendritic cells (DC) were used 
as antigen-presenting cells and activated CD4+CD154+ and CD4+CD154+IFN-γ+ responding 
T cells analyzed (Figure 6B). Both Rv2034 protein and Rv2034 p81-100 strongly activated the 
T-cell clone, whereas Mtb lysate at 10 µg/ml did not. Increasing the Mtb concentration to 100 
µg/ml, however, induced CD154 expression. Rv2034 might be difficult for DC to process and 
present due to possible posttranslational modifications, dimer formation [67], or associations to 
other molecules (Rv2034 is lipid or membrane associated [68;69]). It should be noted, however, 
that Rv2034 is efficiently recognized by T cells from tuberculin skin test-positive, in vitro ESAT6/
CFP10-responsive individuals in whole blood or PBMC assays [10]. To improve processing of  
the lysate by the APC, the lysate was further digested and homogenized using proteinase K 
(serine protease) and lysozyme (peptidoglycan degradation) enzymes. Treating the Mtb lysate 
concentration resulted in an increased population of  activated CD154+ and CD154+/IFN-γ+ 
CD4+ T cells. Importantly, incubating the cells with a control sample containing the same amount 
of  inactivated enzymes as used for the lysate did not show any recognition, indicating that T-cell 
activation is Mtb lysate-specific. 
Nonetheless, activation of  the T-cell clone using the enzyme treated Mtb lysate did not reach 
the full level of  activation as observed for recombinant Rv2034 protein and Rv2034 p81-100. 
Obviously, Mtb lysate is a very crude product containing many different proteins as well as other 
molecules and fragments, such that only low levels of  Rv2034 might be present in the lysate. 
Furthermore, only activation was observed after enzyme treatment verifying that Rv2034 was 
associated to certain structures that prevented or hindered correct processing by the matured DC. 
A lysate concentration dependent effect on T cells has been observed previously [52]. 
The T-cell clone thus expressed cytotoxic markers (Figure 4) and recognized native Rv2034 in 
Mtb lysate (Figure 6B). To test whether the T-cell clone could directly inhibit Mtb outgrowth from 
infected APCs, autologous monocytes were infected with Mtb and the T-cell clone was added in 
an effector/target ratio of  20:1 and 50:1. Interestingly, addition of  the T-cell clone resulted in a 
significant decrease of  CFU in a dose-dependent fashion (Figure 7). Thus the T-cell clone is able 
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Figure 7. CD4+ T-cell clone has Mtb inhibitory properties. Autologous PBMC were loaded with 
Mtb (10 MOI) and CD4+ T-cell clone was added at different effector/target (E/T) ratios as indicated on the 
x-axis. CFU were determined after o/n incubation. Four replicates were performed for each condition. The 
horizontal bar indicates the mean value of  the four replicates.  
Concluding remarks
A better understanding of  T-cell immunity during infection and following vaccination is important 
in many diseases, including tuberculosis. Here, we describe an approach that can be used for the 
rapid generation of  antigen specific T-cell clones irrespective of  functional properties such as 
cytokine secretion, in order to study antigen specific T-cell subsets in more detail, even for low 
frequency responses. Both CD4+, CD8+ and DN T-cell clones could be generated, which showed 
responses to the secreted TB10.4 or the IVE-TB Rv2034 Mtb antigens. An Rv2034 specific CD4+ 
T-cell clone was further analyzed, its antigen-specificity confirmed for (native) Rv2034 protein, 
a dominant peptide epitope identified and a promiscuous HLA-DR/DQ restriction pattern 
elucidated. Furthermore, the T-cell clone expressed Th1 and cytotoxicity related markers, and 
had significant Mtb inhibition activity. Using this approach, the T-cell responses to different Mtb 
specific antigens, including phase-dependent and IVE-TB antigens, can be further analyzed 
which should help to understand the immune response to Mtb. This can eventually be useful for 
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Supplementary Figure 1. MACS sort of  CD154 positive T cells from Rv2034 peptide pool 
stimulated PBMC. PBMC were stimulated for 16 hours and labeled with anti-CD154 PE and anti-PE 
microbeads and sorted. A small sample was collected to analyze the positive CD154 positive population. 










































Supplementary Table I. HLA-DR and DQ binding predictions Rv2034 p81-100 
(LRTDLDRFWTRALTGYAQLI)
HLA-DR Allele molecule SYFPEITHI 
a NetMHCIIpan 
2.1 NetMHCII 2.2 IEDB IEDB
Sequence HLA-DRB1 Score Affinity nM Affinity nM arbpython (ARB) Affinity nM
SMM        
Affinity nM
DRFWTRALTGYAQLI 0101 25 9.71 (SB) WTRALTGYA
18.2 (SB)  
TRALTGYAQ 21.7 (SB) WTRALTGYA
148.0 (WB) 
TRALTGYAQ























































DRFWTRALTGYAQLI 0801 ND 45.80 (SB) WTRALTGYA ND ND ND





DRFWTRALTGYAQLI 1001 ND 36.40 (SB) WTRALTGYA ND ND ND















DRFWTRALTGYAQLI 1201 ND 30.49 (SB) WTRALTGYA ND 24.7 (SB) DRFWTRALT
584.0 
FWTRALTGY
TDLDRFWTRALTGYA 1201 ND 54.33 (WB) LDRFWTRAL ND 24.7 (SB) DRFWTRALT
598.0 
FWTRALTGY
RTDLDRFWTRALTGY 1301 ND 896.73 LDRFWTRAL ND ND ND
LDRFWTRALTGYAQL 1401 ND 518.20 WTRALTGYA ND ND ND
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HLA-DQ Allele molecule SYFPEITHI 
a NetMHCIIpan 
2.1 NetMHCII 2.2 IEDB IEDB
Sequence HLA-DQA1-DQB1 Score Affinity nM Affinity nM
arbpython (ARB) 
Affinity nM
SMM        
Affinity nM







































a SYFPEITHI scores ≥ 25 are considered positive
Affinity nM:  Strong binder (SB) = between 1 and 50 nM
 Weak binder (WB) = between 50 and 500 nM










































Supplementary Table II. HLA-DR and DQ binding predictions Rv2034 p88-107 
(FWTRALTGYAQLIDSEGDDT)
HLA-DR Allele molecule SYFPEITHI 
a NetMHCIIpan 
2.1 NetMHCII 2.2 IEDB IEDB
Sequence HLA-DRB1 Score Affinity nM Affinity nM arbpython (ARB) Affinity nM
SMM        
Affinity nM







TRALTGYAQLIDSEG 0101 9 181.26 (WB) ALTGYAQLI
92.6 (WB) 
ALTGYAQLI 24.6 (SB) ALTGYAQLI
160.0 (WB) 
ALTGYAQLI
FWTRALTGYAQLIDS 0101 10 19.73 (SB) WTRALTGYA
35.8 (SB) 
TRALTGYAQ 21.7 (SB) WTRALTGYA
199.0 (WB) 
TRALTGYAQ
































FWTRALTGYAQLIDS   0801 ND 114.75 (WB) WTRALTGYA ND ND ND





FWTRALTGYAQLIDS 1001 ND 90.27 (WB) WTRALTGYA ND ND ND










WTRALTGYAQLIDSE 1201 ND 130.28 (WB) WTRALTGYA ND 76.9 (WB) GYAQLIDSE
5793.0 
ALTGYAQLI





FWTRALTGYAQLIDS 1301 ND 1301.10 ALTGYAQLI ND ND ND
FWTRALTGYAQLIDS 1401 ND 1119.26 WTRALTGYA ND ND ND
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HLA-DQ Allele molecule SYFPEITHI 
a NetMHCIIpan 
2.1 NetMHCII 2.2 IEDB IEDB
Sequence HLA-DQA1-DQB1 Score Affinity nM Affinity nM
arbpython (ARB) 
Affinity nM
SMM        
Affinity nM
























































a SYFPEITHI scores ≥ 25 are considered positive
Affinity nM: Strong binder (SB) = between 1 and 50 nM
 Weak binder (WB) = between 50 and 500 nM










































Supplementary Table III. HLA-DR and DQ binding predictions Rv2034 p11-30 
(WQALADGTRRAIVERLAHGP)
HLA-DR Allele molecule SYFPEITHI 
a NetMHCIIpan 
2.1 NetMHCII 2.2 IEDB IEDB
Sequence HLA-DRB1 Score Affinity nM Affinity nM arbpython (ARB) Affinity nM
SMM        
Affinity nM







ADGTRRAIVERLAHG 0101 10 548.27 TRRAIVERL




















































DGTRRAIVERLAHGP 0801 ND 102.49 (WB) RAIVERLAH ND ND ND










ADGTRRAIVERLAHG 1001 ND 1264.06 TRRAIVERL ND ND ND
























DGTRRAIVERLAHGP 1301 ND 1347.99 TRRAIVERL ND ND ND
DGTRRAIVERLAHGP 1401 ND 1333.73 RAIVERLAH ND ND ND
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HLA-DQ Allele molecule SYFPEITHI 
a NetMHCIIpan 
2.1 NetMHCII 2.2 IEDB IEDB
Sequence HLA-DQA1-DQB1 Score Affinity nM Affinity nM
arbpython (ARB) 
Affinity nM
SMM        
Affinity nM










ADGTRRAIVERLAHG 0102-0602 (DQ1(6)) ND ND














QALADGTRRAIVERL 0401-0402 (DQ4) ND ND
1364.5 
DGTRRAIVE 10443.7  TRRAIVERL
2530.0 
GTRRAIVER





























a SYFPEITHI scores ≥ 25 are considered positive
Affinity nM: Strong binder (SB) = between 1 and 50 nM
 Weak binder (WB) = between 50 and 500 nM











































 1.   Ottenhoff,T.H. and Kaufmann,S.H., 
Vaccines against tuberculosis: where are 
we and where do we need to go? PLoS.Pat-
hog. 2012. 8: e1002607.
 2.   Ottenhoff,T.H., The knowns and un-
knowns of  the immunopathogenesis of  
tuberculosis. Int.J.Tuberc.Lung Dis. 2012. 
16: 1424-1432.
 3.   Perfetto,S.P., Chattopadhyay,P.K., 
and Roederer,M., Seventeen-colour 
flow cytometry: unravelling the immune 
system. Nat.Rev.Immunol. 2004. 4: 648-655.
 4.   Corti,D., Sallusto,F., and Lanza-
vecchia,A., High throughput cellular 
screens to interrogate the human T and 
B cell repertoires. Curr.Opin.Immunol. 2011. 
23: 430-435.
 5.   Wehler,T.C., Karg,M., Distler,E., 
Konur,A., Nonn,M., Meyer,R.G., 
Huber,C., Hartwig,U.F., and Her-
r,W., Rapid identification and sorting of  
viable virus-reactive CD4(+) and CD8(+) 
T cells based on antigen-triggered CD137 
expression. J.Immunol.Methods 2008. 339: 
23-37.
 6.   Frentsch,M., Arbach,O., Kirch-
hoff,D., Moewes,B., Worm,M., 
Rothe,M., Scheffold,A., and 
Thiel,A., Direct access to CD4+ T cells 
specific for defined antigens according to 
CD154 expression. Nat.Med. 2005. 11: 
1118-1124.
 7.   Lindgren,H., Axcrona,K., and Le-
anderson,T., Regulation of  transcrip-
tional activity of  the murine CD40 ligand 
promoter in response to signals through 
TCR and the costimulatory molecules 
CD28 and CD2. J.Immunol. 2001. 166: 
4578-4585.
 8.   Banchereau,J., Bazan,F., 
Blanchard,D., Briere,F., Gal-
izzi,J.P., Van,K.C., Liu,Y.J., Rous-
set,F., and Saeland,S., The CD40 
antigen and its ligand. Annu.Rev.Immunol. 
1994. 12: 881-922.
 9.   Elgueta,R., Benson,M.J., de 
Vries,V.C., Wasiuk,A., Guo,Y., and 
Noelle,R.J., Molecular mechanism and 
function of  CD40/CD40L engagement 
   in the immune system. Immunol.Rev. 2009. 
229: 152-172.
 10.   Commandeur,S., van Mei-
jgaarden,K.E., Prins,C., 
Pichugin,A.V., Dijkman,K., van 
den Eeden,S.J., Friggen,A.H., 
Franken,K.L., Dolganov,G., Kram-
nik,I., Schoolnik,G.K., Oftung,F., 
Korsvold,G.E., Geluk,A., and 
Ottenhoff,T.H., An Unbiased Ge-
nome-Wide Mycobacterium tuberculosis 
Gene Expression Approach To Discover 
Antigens Targeted by Human T Cells 
Expressed during Pulmonary Infection. 
J.Immunol. 2013.
 11.   Commandeur,S., van Mei-
jgaarden,K.E., Lin,M.Y., Fran-
ken,K.L., Friggen,A.H., Drijf-
hout,J.W., Oftung,F., Korsvold,G.E., 
Geluk,A., and Ottenhoff,T.H., 
Identification of  human T-cell responses 
to Mycobacterium tuberculosis resusci-
tation-promoting factors in long-term 
latently infected individuals. Clin.Vaccine 
Immunol. 2011. 18: 676-683.
 12.   Commandeur,S., Lin,M.Y., van 
Meijgaarden,K.E., Friggen,A.H., 
Franken,K.L., Drijfhout,J.W., 
Korsvold,G.E., Oftung,F., Geluk,A., 
and Ottenhoff,T.H., Double- and 
monofunctional CD4 and CD8 T-cell 
responses to Mycobacterium tuberculosis 
DosR antigens and peptides in long-term 
latently infected individuals. Eur.J.Immunol. 
2011. 41: 2925-2936.
 13.   Franken,K.L., Hiemstra,H.S., van 
Meijgaarden,K.E., Subronto,Y., 
den,H.J., Ottenhoff,T.H., and Dri-
jfhout,J.W., Purification of  his-tagged 
proteins by immobilized chelate affinity 
chromatography: the benefits from the use 
of  organic solvent. Protein Expr.Purif. 2000. 
18: 95-99.
 14.   Leyten,E.M., Lin,M.Y., Fran-
ken,K.L., Friggen,A.H., Prins,C., 
van Meijgaarden,K.E., Vo-
skuil,M.I., Weldingh,K., Ander-
sen,P., Schoolnik,G.K., Arend,S.M., 








































Rv2034-specific CD4+ T-cell clone 
179
6
Human T-cell responses to 25 novel an-
tigens encoded by genes of  the dormancy 
regulon of  Mycobacterium tuberculosis. 
Microbes.Infect. 2006. 8: 2052-2060.
 15.   Black,G.F., Thiel,B.A., Ota,M.O., 
Parida,S.K., Adegbola,R., 
Boom,W.H., Dockrell,H.M., Fran-
ken,K.L., Friggen,A.H., Hill,P.C., 
Klein,M.R., Lalor,M.K., Mayan-
ja,H., Schoolnik,G., Stanley,K., 
Weldingh,K., Kaufmann,S.H., Wal-
zl,G., and Ottenhoff,T.H., Immuno-
genicity of  novel DosR regulon-encoded 
candidate antigens of  Mycobacterium 
tuberculosis in three high-burden popula-
tions in Africa. Clin.Vaccine Immunol. 2009. 
16: 1203-1212.
 16.   Geluk,A., van den Eeden,S.J., van 
Meijgaarden,K.E., Dijkman,K., 
Franken,K.L., and Ottenhoff,T.H., 
A multistage-polyepitope vaccine pro-
tects against Mycobacterium tuberculosis 
infection in HLA-DR3 transgenic mice. 
Vaccine 2012. 30: 7513-7521.
 17.   Rosenkrands,I., Slayden,R.A., 
Crawford,J., Aagaard,C., Bar-
ry,C.E., III, and Andersen,P., Hy-
poxic response of  Mycobacterium tuber-
culosis studied by metabolic labeling and 
proteome analysis of  cellular and extra-
cellular proteins. J.Bacteriol. 2002. 184: 
3485-3491.
 18.   Betts,J.C., Lukey,P.T., Robb,L.C., 
McAdam,R.A., and Duncan,K., 
Evaluation of  a nutrient starvation mod-
el of  Mycobacterium tuberculosis per-
sistence by gene and protein expression 
profiling. Mol.Microbiol. 2002. 43: 717-
731.
 19.   Unger,W.W., Pearson,T., Abreu,J.R., 
Laban,S., van der Slik,A.R., der 
Kracht,S.M., Kester,M.G., Ser-
reze,D.V., Shultz,L.D., Griffioen,M., 
Drijfhout,J.W., Greiner,D.L., and 
Roep,B.O., Islet-Specific CTL Cloned 
from a Type 1 Diabetes Patient Cause 
Beta-Cell Destruction after Engraftment 
into HLA-A2 Transgenic NOD/SCID/
IL2RG Null Mice. PLoS.One. 2012. 7: 
e49213.
 20.   Perfetto,S.P., Chattopadhyay,P.K., 
Lamoreaux,L., Nguyen,R., Am-
brozak,D., Koup,R.A., and Roed-
erer,M., Amine-reactive dyes for dead 
cell discrimination in fixed samples. Curr.
Protoc.Cytom. 2010. Chapter 9: Unit.
 21.   Ottenhoff,T.H., Neuteboom,S., Elf-
erink,D.G., and de Vries,R.R., Mo-
lecular localization and polymorphism of  
HLA class II restriction determinants de-
fined by Mycobacterium leprae-reactive 
helper T cell clones from leprosy patients. 
J.Exp.Med. 1986. 164: 1923-1939.
 22.   Geluk,A., van Meijgaarden,K.E., 
Janson,A.A., Drijfhout,J.W., Melo-
en,R.H., de Vries,R.R., and Ot-
tenhoff,T.H., Functional analysis of  
DR17(DR3)-restricted mycobacterial T 
cell epitopes reveals DR17-binding motif  
and enables the design of  allele-specif-
ic competitor peptides. J.Immunol. 1992. 
149: 2864-2871.
 23.   Joosten,S.A., van Meijgaarden,K.E., 
van Weeren,P.C., Kazi,F., Ge-
luk,A., Savage,N.D., Drijfhout,J.W., 
Flower,D.R., Hanekom,W.A., 
Klein,M.R., and Ottenhoff,T.H., 
Mycobacterium tuberculosis peptides pre-
sented by HLA-E molecules are targets for 
human CD8 T-cells with cytotoxic as well 
as regulatory activity. PLoS.Pathog. 2010. 6: 
e1000782.
 24.   Schagger,H. and Von,J.G., Tricine-so-
dium dodecyl sulfate-polyacrylamide gel 
electrophoresis for the separation of  pro-
teins in the range from 1 to 100 kDa. Anal.
Biochem. 1987. 166: 368-379.
 25.   Ottenhoff,T.H., Elferink,D.G., 
Klatser,P.R., and de Vries,R.R., 
Cloned suppressor T cells from a lepro-
matous leprosy patient suppress Myco-
bacterium leprae reactive helper T cells. 
Nature 1986. 322: 462-464.
 26.   Ottenhoff,T.H., Klatser,P.R., Ivany-
i,J., Elferink,D.G., de Wit,M.Y., 
and de Vries,R.R., Mycobacterium 
leprae-specific protein antigens defined by 
cloned human helper T cells. Nature 1986. 
319: 66-68.
 27.   Billeskov,R., Elvang,T.T., Ander-
sen,P.L., and Dietrich,J., The Hy-
Vac4 subunit vaccine efficiently boosts 
BCG-primed anti-mycobacterial protec-










































 28.   Yellin,M.J., Sippel,K., Inghi-
rami,G., Covey,L.R., Lee,J.J., Sin-
ning,J., Clark,E.A., Chess,L., and 
Lederman,S., CD40 molecules induce 
down-modulation and endocytosis of  T 
cell surface T cell-B cell activating mole-
cule/CD40-L. Potential role in regulating 
helper effector function. J.Immunol. 1994. 
152: 598-608.
 29.   Graf,D., Muller,S., Korthauer,U., 
Van,K.C., Weise,C., and Krocze-
k,R.A., A soluble form of  TRAP (CD40 
ligand) is rapidly released after T cell ac-
tivation. Eur.J.Immunol. 1995. 25: 1749-
1754.
 30.   Hermann,P., Van-Kooten,C., 
Gaillard,C., Banchereau,J., and 
Blanchard,D., CD40 ligand-positive 
CD8+ T cell clones allow B cell growth 
and differentiation. Eur.J.Immunol. 1995. 
25: 2972-2977.
 31.   Horner,A.A., Jabara,H., Ra-
mesh,N., and Geha,R.S., gamma/
delta T lymphocytes express CD40 ligand 
and induce isotype switching in B lympho-
cytes. J.Exp.Med. 1995. 181: 1239-1244.
 32.   Cowley,S.C., Hamilton,E., 
Frelinger,J.A., Su,J., Forman,J., and 
Elkins,K.L., CD4-CD8- T cells control 
intracellular bacterial infections both in 
vitro and in vivo. J.Exp.Med. 2005. 202: 
309-319.
 33.   Derrick,S.C., Evering,T.H., Sam-
bandamurthy,V.K., Jalapathy,K.V., 
Hsu,T., Chen,B., Chen,M., Rus-
sell,R.G., Junqueira-Kipnis,A.P., 
Orme,I.M., Porcelli,S.A., Ja-
cobs,W.R., Jr., and Morris,S.L., 
Characterization of  the protective T-cell 
response generated in CD4-deficient mice 
by a live attenuated Mycobacterium tu-
berculosis vaccine. Immunology 2007. 120: 
192-206.




valho,A., Martins-Filho,O.A., and 
Toledo,V.P., CD4-CD8-alphabeta and 
gammadelta T cells display inflammatory 
and regulatory potentials during human 
tuberculosis. PLoS.One. 2012. 7: e50923.
 35.   D’Acquisto,F. and Crompton,T., 
CD3+CD4-CD8- (double negative) T 
cells: saviours or villains of  the immune 
response? Biochem.Pharmacol. 2011. 82: 
333-340.
 36.   Gold,M.C., Cerri,S., Smyk-Pear-
son,S., Cansler,M.E., Vogt,T.M., 
Delepine,J., Winata,E., Swar-
brick,G.M., Chua,W.J., Yu,Y.Y., 
Lantz,O., Cook,M.S., Null,M.D., 
Jacoby,D.B., Harriff,M.J., Lewin-
sohn,D.A., Hansen,T.H., and Lew-
insohn,D.M., Human mucosal associat-
ed invariant T cells detect bacterially in-
fected cells. PLoS.Biol. 2010. 8: e1000407.
 37.   Martin,E., Treiner,E., Duban,L., 
Guerri,L., Laude,H., Toly,C., 
Premel,V., Devys,A., Moura,I.C., 
Tilloy,F., Cherif,S., Vera,G., La-
tour,S., Soudais,C., and Lantz,O., 
Stepwise development of  MAIT cells in 
mouse and human. PLoS.Biol. 2009. 7: 
e54.
 38.   Joosten,S.A., van Meijgaarden,K.E., 
van Weeren,P.C., Kazi,F., Ge-
luk,A., Savage,N.D., Drijfhout,J.W., 
Flower,D.R., Hanekom,W.A., 
Klein,M.R., and Ottenhoff,T.H., 
Mycobacterium tuberculosis peptides pre-
sented by HLA-E molecules are targets for 
human CD8 T-cells with cytotoxic as well 
as regulatory activity. PLoS.Pathog. 2010. 6: 
e1000782.
 39.   Arden,B., Clark,S.P., Kabelitz,D., 
and Mak,T.W., Human T-cell receptor 
variable gene segment families. Immunoge-
netics 1995. 42: 455-500.
 40.   Aagaard,C., Hoang,T., Dietrich,J., 
Cardona,P.J., Izzo,A., Dolganov,G., 
Schoolnik,G.K., Cassidy,J.P., 
Billeskov,R., and Andersen,P., A 
multistage tuberculosis vaccine that con-
fers efficient protection before and after 
exposure. Nat.Med. 2011. 17: 189-194.
 41.   Lin,P.L., Dietrich,J., Tan,E., Aba-
los,R.M., Burgos,J., Bigbee,C., Big-
bee,M., Milk,L., Gideon,H.P., Rod-
gers,M., Cochran,C., Guinn,K.M., 
Sherman,D.R., Klein,E., Jans-
sen,C., Flynn,J.L., and Andersen,P., 
The multistage vaccine H56 boosts the 








































Rv2034-specific CD4+ T-cell clone 
181
6
macaques against active tuberculosis and 
reactivation of  latent Mycobacterium 
tuberculosis infection. J.Clin.Invest 2012. 
122: 303-314.
 42.   Hatton,R.D. and Weaver,C.T., Im-
munology. T-bet or not T-bet. Science 
2003. 302: 993-994.
 43.   Szabo,S.J., Kim,S.T., Costa,G.L., 
Zhang,X., Fathman,C.G., and 
Glimcher,L.H., A novel transcription 
factor, T-bet, directs Th1 lineage commit-
ment. Cell 2000. 100: 655-669.
 44.   Zheng,W. and Flavell,R.A., The tran-
scription factor GATA-3 is necessary and 
sufficient for Th2 cytokine gene expres-
sion in CD4 T cells. Cell 1997. 89: 587-
596.
 45.   Ivanov,I.I., McKenzie,B.S., 
Zhou,L., Tadokoro,C.E., Lepel-
ley,A., Lafaille,J.J., Cua,D.J., and 
Littman,D.R., The orphan nuclear 
receptor RORgammat directs the differ-
entiation program of  proinflammatory 
IL-17+ T helper cells. Cell 2006. 126: 
1121-1133.
 46.   Manel,N., Unutmaz,D., and Litt-
man,D.R., The differentiation of  hu-
man T(H)-17 cells requires transforming 
growth factor-beta and induction of  the 
nuclear receptor RORgammat. Nat.Immu-
nol. 2008. 9: 641-649.
 47.   Hori,S., Nomura,T., and Sakagu-
chi,S., Control of  regulatory T cell devel-
opment by the transcription factor Foxp3. 
Science 2003. 299: 1057-1061.
 48.   Boer,M.C., van Meijgaarden,K.E., 
Bastid,J., Ottenhoff,T.H., and Joost-
en,S.A., CD39 is involved in mediating 
suppression by Mycobacterium bovis 
BCG-activated human CD8 CD39 regu-
latory T cells. Eur.J.Immunol. 2013.
 49.   Triplett,T.A., Curti,B.D., Bonafed-
e,P.R., Miller,W.L., Walker,E.B., 
and Weinberg,A.D., Defining a func-
tionally distinct subset of  human memo-
ry CD4+ T cells that are CD25POS and 
FOXP3NEG. Eur.J.Immunol. 2012. 42: 
1893-1905.
 50.   Moncrieffe,H., Nistala,K., Kamhie-
h,Y., Evans,J., Eddaoudi,A., Ea-
ton,S., and Wedderburn,L.R., High 
expression of  the ectonucleotidase CD39 
on T cells from the inflamed site identifies 
two distinct populations, one regulatory 
and one memory T cell population. J.Im-
munol. 2010. 185: 134-143.
 51.   Malek,T.R., The biology of  interleu-
kin-2. Annu.Rev.Immunol. 2008. 26: 453-
479.
 52.   Mutis,T., Cornelisse,Y.E., and Ot-
tenhoff,T.H., Mycobacteria induce 
CD4+ T cells that are cytotoxic and dis-
play Th1-like cytokine secretion profile: 
heterogeneity in cytotoxic activity and 
cytokine secretion levels. Eur.J.Immunol. 
1993. 23: 2189-2195.
 53.   Bastian,M., Braun,T., Bruns,H., 
Rollinghoff,M., and Stenger,S., 
Mycobacterial lipopeptides elicit CD4+ 
CTLs in Mycobacterium tuberculosis-in-
fected humans. J.Immunol. 2008. 180: 
3436-3446.
 54.   Ottenhoff,T.H. and Mutis,T., Role of  
cytotoxic cells in the protective immunity 
against and immunopathology of  intra-
cellular infections. Eur.J.Clin.Invest 1995. 
25: 371-377.
 55.   Rammensee,H., Bachmann,J., 
Emmerich,N.P., Bachor,O.A., and 
Stevanovic,S., SYFPEITHI: database 
for MHC ligands and peptide motifs. Im-
munogenetics 1999. 50: 213-219.
 56.   Blythe,M.J., Zhang,Q., Vaughan,K., 
de,C.R., Jr., Salimi,N., Bui,H.H., 
Lewinsohn,D.M., Ernst,J.D., Pe-
ters,B., and Sette,A., An analysis of  
the epitope knowledge related to Myco-
bacteria. Immunome.Res. 2007. 3: 10.
 57.   Caccamo,N., Barera,A., Di,S.C., 
Meraviglia,S., Ivanyi,J., Hudecz,F., 
Bosze,S., Dieli,F., and Salerno,A., 
Cytokine profile, HLA restriction and 
TCR sequence analysis of  human CD4+ 
T clones specific for an immunodominant 
epitope of  Mycobacterium tuberculosis 
16-kDa protein. Clin.Exp.Immunol. 2003. 
133: 260-266.
 58.   Axelsson-Robertson,R., We-
ichold,F., Sizemore,D., Wulf,M., 
Skeiky,Y.A., Sadoff,J., and Maeur-
er,M.J., Extensive major histocompati-
bility complex class I binding promiscuity 










































peptides and immune dominance of  hu-
man leucocyte antigen (HLA)-B*0702 
and HLA-B*0801 alleles in TB10.4 CD8 
T-cell responses. Immunology 2010. 129: 
496-505.
 59.   Mustafa,A.S., Lundin,K.E., Melo-
en,R.H., Shinnick,T.M., and 
Oftung,F., Identification of  promiscuous 
epitopes from the Mycobacterial 65-kilo-
dalton heat shock protein recognized by 
human CD4(+) T cells of  the Mycobac-
terium leprae memory repertoire. Infect.
Immun. 1999. 67: 5683-5689.
 60.   Ho,P.C., Mutch,D.A., Winkel,K.D., 
Saul,A.J., Jones,G.L., Doran,T.J., 
and Rzepczyk,C.M., Identification of  
two promiscuous T cell epitopes from tet-
anus toxin. Eur.J.Immunol. 1990. 20: 477-
483.
 61.   Rao,X., Hoof,I., Costa,A.I., 
van,B.D., and Kesmir,C., HLA class I 
allele promiscuity revisited. Immunogenetics 
2011. 63: 691-701.
 62.   Geluk,A., van Meijgaarden,K.E., 
and Ottenhoff,T.H., Flexibility in 
T-cell receptor ligand repertoires depends 
on MHC and T-cell receptor clonotype. 
Immunology 1997. 90: 370-375.
 63.   Yousef,S., Planas,R., Chakroun,K., 
Hoffmeister-Ullerich,S., Bind-
er,T.M., Eiermann,T.H., Martin,R., 
and Sospedra,M., TCR bias and HLA 
cross-restriction are strategies of  human 
brain-infiltrating JC virus-specific CD4+ 
T cells during viral infection. J.Immunol. 
2012. 189: 3618-3630.
 64.   Sospedra,M., Zhao,Y., Giulianot-
ti,M., Simon,R., Pinilla,C., and 
Martin,R., Combining positional scan-
ning peptide libraries, HLA-DR trans-
fectants and bioinformatics to dissect the 
epitope spectrum of  HLA class II cross-re-
stricted CD4+ T cell clones. J.Immunol.
Methods 2010. 353: 93-101.
 65.   Greenbaum,J., Sidney,J., Chung,J., 
Brander,C., Peters,B., and Sette,A., 
Functional classification of  class II human 
leukocyte antigen (HLA) molecules reveals 
seven different supertypes and a surprising 
degree of  repertoire sharing across super-
types. Immunogenetics 2011. 63: 325-335.
 66.   McKinney,D.M., Southwood,S., 
Hinz,D., Oseroff,C., Arle-
hamn,C.S., Schulten,V., Taplitz,R., 
Broide,D., Hanekom,W.A., Scrib-
a,T.J., Wood,R., Alam,R., Peters,B., 
Sidney,J., and Sette,A., A strategy to 
determine HLA class II restriction broad-
ly covering the DR, DP, and DQ allelic 
variants most commonly expressed in the 
general population. Immunogenetics 2013.
 67.   Gao,C.H., Yang,M., and He,Z.G., 
Characterization of  a novel ArsR-like 
regulator encoded by Rv2034 in Myco-
bacterium tuberculosis. PLoS.One. 2012. 7: 
e36255.
 68.   Malen,H., Pathak,S., Softeland,T., 
de Souza,G.A., and Wiker,H.G., 
Definition of  novel cell envelope associ-
ated proteins in Triton X-114 extracts 
of  Mycobacterium tuberculosis H37Rv. 
BMC.Microbiol. 2010. 10: 132.
 69.   de Souza,G.A., Leversen,N.A., 
Malen,H., and Wiker,H.G., Bacterial 
proteins with cleaved or uncleaved signal 
peptides of  the general secretory pathway. 























































































Currently, only one TB vaccine is available: Mycobacterium bovis Bacille Calmette-Guérin (BCG). 
This vaccine induces highly variable protection against pulmonary TB, the most common and 
contagious form of  TB. There is an urgent need for an effective TB vaccine which is safe also in 
the immunocompromised host. 
Multiple subunit vaccines are currently under study and consist mostly of  antigens that are 
expressed by actively replicating Mtb. However, Mtb has the ability to enter into a less active, latent 
or dormant state. Mtb uses this adaptation strategy to survive harsh and stressful conditions inside 
human cells. Mtb adapts to these conditions by changing its gene expression pattern. A gene cluster 
specifically upregulated in response to hypoxia is known as the dormancy regulon encoded (DosR) 
gene cluster. A second set of  proteins is involved in the reactivation of  dormant bacteria, and is 
known as resuscitation promoting factors (Rpfs). 
DosR regulon encoded proteins and Rpf  proteins are associated with certain phases of  the 
Mtb infection cycle, and have therefore been coined Mtb infection-phase related antigens. It 
remains unclear how many other proteins are regulated during Mtb infection. These phase related 
proteins could represent antigens which might represent efficient subunit vaccine candidates for 
prophylactic or therapeutic vaccines during essential steps of  the infection cycle. To qualify as an 
efficient vaccine candidate, an antigen should meet several prerequisites: 
(i) The antigen should be immunogenic, that is, the protein should be recognized by 
antigen-specific T cells from mycobacteria exposed individuals.
(ii) The antigen should be expressed during in vivo infection in infected tissue, such 
that vaccine-induced T cells are able to recognize Mtb infected cells. 
(iii) The antigen should induce TB protection, that is: the protein should generate an 
immune response that is able to limit the growth of  Mtb or eliminate the bacteria, 
with limited tissue damage.
(iv) The protein sequence should be conserved among multiple Mtb strains, such that 
vaccines based on these antigens can be applied globally against multiple Mtb 
strains.
The work in this thesis has focused on Mtb infection-phase related antigens as possible TB subunit 
vaccine candidates, and will be discussed here with a particular focus on these four requirements. 
Immunogenic Mtb infection-phase related antigens as new TB vaccine candidates
Understanding Mtb specific T-cell responses in clinically relevant human populations is an 
important step in identifying essential mechanisms of  protective immunity against TB, which 
in turn will facilitate the design of  better TB vaccines. We have studied the ability of  T cells 
to recognize three different classes of  new candidate Mtb antigens, described in this thesis, as 










































were identified previously by our group as Mtb infection-phase related antigens, whereas in vivo 
expressed Mtb (IVE-TB) antigens are described here for the first time. 
Vaccine induced, Rpf-specific T cells might be useful in enhancing immune surveillance of  
reactivating and resuscitating Mtb and thereby help to control Mtb reactivation. Of  the five Rpf  
homologous proteins encoded by Mtb (Rv0867c, Rv1009, Rv1884c, Rv2389c, Rv2450c: RpfA-E) 
two, Rv0867c and Rv2389c, were screened for their immunogenicity. Both Rpf  antigens were 
immunogenic (chapter 2), based on antigen-specific T-cell cytokine production, the presence 
of  immunogenic epitopes and highly specific T-cell frequencies in latent infected individuals. 
Therefore, these proteins fulfill at least one of  the requirements for a potential Mtb vaccine 
candidate, and this was confirmed by other groups studying mycobacteria exposed individuals [1-
3]. The immunogenicity of  Rpf  antigens has also been analyzed in C57BL/6 and BALB/c mice 
[4]. Rv0867c and Rv2389c did not show any responses either induced by mycobacterial infection 
(Rv0867c) or DNA vaccination (Rv2389c). This was surprising in view of  their immunogenicity 
in humans, and is most likely by the lack of  proper MHC molecules able to present Rv0867c 
or Rv2389c immunogenic epitopes.  In any event, this demonstrates the difficulty of  translating 
results across species. Using humanized HLA-transgenic mice for such analyses could limit these 
species differences (chapter 5) [5]. 
Mtb DosR regulon encoded antigens Rv1733c, Rv2029c and Rv2031c (HspX) were shown to 
be immunogenic as measured by proliferation of  CD4+ and CD8+ T cells from purified protein 
derivative positive (PPD+) donors and the presence of  cytokine producing CD4+ and CD8+ T 
cells in long-term latently infected individuals (ltLTBI) (chapter 3), corresponding to previous 
work [2;6;7]. These ltLTBI donors had been exposed to Mtb decades ago yet did not develop any 
clinical signs of  TB despite never having received prophylactic treatment. Thus, they represent 
a group of  “naturally protected” individuals. Multiple immunogenic regions were detected for 
both CD4+ and CD8+ T cells. A recent study incorporated HLA-DR3 restricted epitopes of  
Rv1733c (Rv173363-77), Rv2031c (Rv2031c31-50) and Ag85B (Ag85B56-46) in a poly-epitope vaccine 
which induced an HLA-DR3-specific reduction of  Mtb CFU in HLA-DR3 transgenic mice [5], 
indicating that these antigens are of  particular interest as vaccine candidates. 
Recognition of  the dormancy antigen HspX by mycobacteria exposed individuals is 
inconsistent (ranging from being well recognized e.g. [8;9] to limited recognition e.g. [6;7;10]) 
but despite these contrasting findings HspX has been analyzed in multiple vaccination  studies 
[5;11-15], showing protective efficacy against Mtb. Importantly, BCG vaccination does not induce 
antigen-specific T cells against Mtb DosR regulon encoded antigens, including HspX [9;16] 
whereas overexpression of  HspX in BCG enhances Mtb protection, indicating that HspX may 
play a role in TB control depending on the precise vaccine background [11]. Interestingly, in one 
particular study recombinant HspX vaccination did not provide TB protection, whereas the native 
form of  HspX did [13]. It was suggested that the native form chaperones an immunogenic and 
protective antigen or peptide(s) [13]. Thus, despite the variable immunogenicity results, HspX 











































In chapter 4 we describe a novel set of  antigens, namely in vivo expressed Mtb antigens (IVE-
TB). These were identified from Mtb gene expression profiles detected in the lungs of  Mtb infected 
mouse strains across a spectrum of  TB susceptibility. Recombinant proteins were produced from 
a selection of  these genes and their immunogenicity was analyzed using PBMC from tuberculin 
skin test positive (TST+) donors. The IVE-TB antigens were specifically recognized by cells from 
TST+ ESAT-6/CFP-10 (E/C+) individuals. Furthermore, the IVE-TB protein sequences were 
conserved within Mtb strains. The immunogenicity of  Rv0079, Rv1284 and Rv1956 has been 
analyzed previously.  Rv0079 was recognized by a minority of  mycobacteria exposed individuals 
[3;6;7], whereas Rv1284 and Rv1956 were strongly recognized in Mycobacterium bovis exposed cattle 
[17]. Indeed, we observed limited recognition of  Rv0079 and strong recognition of  Rv1284 and 
Rv1956 (chapter 4). Nevertheless Rv1284 could not induce protection against Mtb challenge in 
C57BL/6 mice, which was attributed to the lack of  presentation of  H-2b restricted T-cell epitopes 
[18]. Importantly, seven of  the sixteen analyzed IVE-TB antigens were previously identified in 
studies analyzing the gene expression profile of  Mtb grown under in vitro conditions that are thought 
to mimic those encountered by Mtb in vivo, including Rv0079, Rv1284 and Rv1956 [19-21]. This 
suggests that these conditions are also relevant during in vivo infection. Finally, immunization of  
HLA-DR transgenic mice with IVE-TB antigen Rv2034 resulted in a decrease of  CFU after Mtb 
challenge. Thus, Rv2034 is able to induce a protective response against Mtb (chapter 5). Finally, 
(native) Rv2034 contains an HLA-DR restricted epitope that could be recognized by an Rv2034-
specific CD4+ T-cell clone as determined in chapter 6. Overall, the analyzed IVE-TB antigens 
are immunogenic, conserved, expressed in vivo and -at least for Rv2034- able to induce responses 
that reduce Mtb burden in vivo.  
 
IVE-TB antigens: revealing potential Mtb pathways as targets for intervention
Analyzing Mtb gene expression patterns during in vivo infection can provide insight into microbial 
stress response pathways during infection, which may facilitate the selection of  interesting 
vaccine candidate antigens.  It is of  obvious importance to select Mtb vaccine candidates that 
are expressed in vivo during infection. These antigens should include proteins that are not only 
expressed -and often secreted- during the early active replication phase (such as the current 
vaccine proteins ESAT-6 and Ag85B), but also proteins that are strongly expressed at later time 
points during infection. Studies reported the rather limited recognition of  antigens from the Ag85 
complex in mycobacteria exposed individuals, both in active TB patients and LTBI [1;3;22]. This 
unexpectedly low recognition may be explained by a low expression level of  the gene encoding 
Ag85B (fibronectin-binding protein B (fbpB)) in vivo in the chronic phase of  infection, as shown by 
Bold et al. [23], an effect they interpreted as an immune evasion mechanism. A related proposed 
mechanism is ‘immunological decoy’, implying that a non-essential (secreted) protein is highly 
produced initially (in the early phase of  infection) and thus generates a pool of  antigen-specific T 










































the immune system by hampering strong immunity against late infection-phase associated proteins 
[24]. This hypothesis argues against the use of  only early secreted antigens as vaccine candidates 
since some of  these may be down-regulated later in time. Thus (persistently) in vivo highly expressed 
antigens might have interesting potential as vaccine candidates.
In chapter 4 a group of  68 genes was identified to be highly expressed in vivo, independent of  
genetic differences in host background of  the mouse strains studied.  Within the group of  highly 
expressed Mtb genes, a cluster of  three genes, Rv2380c, Rv2381c and Rv2382c was identified which 
encode for proteins MbtE, MbtD and MbtC. These proteins are involved in the synthesis of  
mycobactins, which are lipophylic siderophores. Mycobactins, together with carboxymycobactins, 
are required for iron acquisition from the host environment by hijacking iron from host iron-
binding proteins [25], which supports the view that Mtb requires iron from the host in vivo for 
survival. Importantly, upon APC activation, the expression of  the natural resistance associated 
macrophage protein (NRAMP1) metal transporter protein’s expression is enhanced. This host 
protein is involved in the reduction of  intraphagosomal iron levels [26]. Polymorphisms of  
the NRAMP/solute carrier 11A1( SLC11A1)) gene are associated with TB susceptibility [26;27], 
supporting iron-competition between host and pathogen during Mtb infection. ESX-3, a secretion 
system suggested to be essential for survival, is involved in transport of  iron-loaded mycobactins 
[28;29]. Interestingly, this cluster expresses two Esx-like molecules, EsxG and EsxH (Rv0287 and 
Rv0288) which were both present in our set of  highly expressed genes (chapter 4). Thus Mtb iron 
acquisition seems to be important during in vivo infection. 
Not surprisingly, multiple genes were detected in our highly expressed set of  genes that are 
linked to the virulence associated ESX-1 secretion system (Rv3615c (EspC), Rv3616c (EspA), 
Rv3864 (EspE), Rv3865 (EspF) and Rv3875 (ESAT-6/EsxA)). 
Lastly, the gene coding for isocitrate lyase (Rv0467), which initiates the first step in the 
glyoxylate shunt and is required for in vivo survival, was also highly expressed during infection 
in the lung [30-32]. Also other genes were detected in this set that supposedly play a role in Mtb 
cell wall lipid assembly, lipid degradation and gluconeogenesis (e.g. FadD28 (DIM[33]), FadE5 
(β-oxidation (cholesterol[34])) and FadB2 (β-oxidation [35]). Thus, these lipid associated metabolic 
pathways are likely to be  important during in vivo infection.
Ex vivo and in vivo (whole genome) Mtb microarrays have been performed to identify genes that 
are expressed during infection as reviewed by Ward et al. [36] and Waddell et al. [37]. Limited overlap 
was observed between Mtb genes expressed during ex vivo and in vivo conditions, although the same 
categories of  genes could be identified [36]. Indeed the expression of  iron scavenger related genes, 
including genes from the above mentioned mbt gene cluster, was observed in Mtb infected murine 
and human host cells [38-42] and in in vivo infection [43], compatible with low levels of  iron 
within the host cell [44]. Also the expression of  genes associated with lipid metabolism, including 
isocitrate lyase were upregulated both ex vivo [37;39-42] and in vivo [37;43], further verifying our 











































discovery approaches.  These findings might further promote the identification of  novel vaccine 
candidates, but also help to understand the behavior of  Mtb in vivo.
Correlation of  IVE-TB antigens and expression with TB disease phenotypes
In addition to the highly expressed genes, a number of  different TB disease phenotype related 
Mtb gene expression groups were generated in chapter 4. Here, specific Mtb gene expression was 
correlated to particular TB disease key phenotypes such as necrosis and granuloma formation, 
based on comparisons made between C3H, B6, C3H.B6-sst1 and B6.C3H-sst1 mouse models. 
Unfortunately, limited data is available on the role of  Mtb in the development of  such phenotypes. 
The environmental host conditions associated with these phenotypes might influence the behavior 
and adaptation of  bacteria and alter the expression of  these genes, but it is also possible that 
Mtb shifts its genetic -and subsequently protein- expression to induce or enhance these host 
TB phenotypes. M. marinum mutagenesis studies revealed a role for (RD-1 specific) Mtb genes 
in the development and containment of  granulomas [45-48]. However, RD-1 specific proteins 
were highly expressed in all mouse strains in our system as discussed in the previous section, and 
therefore were not specifically associated with a granuloma phenotype. 
Furthermore, M. marinum specific granuloma activated genes (GAPs), were described to 
be expressed within granulomas of  infected frogs [49]. Unfortunately, no overlap between our 
detected granuloma associated genes and the GAPs was observed, which might be related to 
differences between animal models and mycobacterial species used. Nevertheless our approach 
described in chapter 4 attempted to minimize these TB pathology differences by rigorously 
selecting for the presence of  specific pathological phenotypes, known to be relevant in human TB 
[50;51]. Finally, Rachman et al. analyzed Mtb gene expression in different sites of  the lung from 
TB patients. Here, the necrosis associated Rv1607 (probable ionic transporter integral membrane 
protein, chaA) gene and granuloma associated Rv2465c (Ribose-5-phosphate isomerase, rpi) gene 
were upregulated in peri-cavity lesions [52], supporting the expression of  these genes at the site of  
infection. Overall, limited data is available concerning Mtb gene-specific influences on TB disease 
phenotypes. The above data thus demonstrate that Mtb expresses genes specifically associated with 
pulmonary granulomatous structures. 
HLA class I and class II restriction of  new Mtb T-cell epitopes 
Several recent studies have analyzed the presence of  T-cell epitopes in Mtb antigens using in silico 
and in vitro peptide binding to HLA class I and II e.g. [53-56], which represent approaches that 
increasing the chance of  detecting immunogenic Mtb antigens. An overview of  immunogenic 
epitopes is available at the Immune Epitope DataBase (IEDB http://iedb.org) [57]. An Mtb 
genome-wide in silico, ex vivo and in vitro epitope analysis [54] described nine antigens that were also 
(specifically) expressed in vivo in our work as described in chapter 4. Two antigens (Rv0291 and 










































from previous epitope screens [55;56]  (Table 1). Thus these IVE-TB antigens contain epitopes 
with a high HLA binding affinity and are immunogenic, further underpinning their potential as 
vaccine candidates.
 
Table 1. Predicted HLA class I and class II epitopes overlapping with IVE-TB antigens 





Rv3615c ESX-1 secretion-associated 
protein EspC
highly expressed II Lindestam Arlehamn et al.
Rv0288 EsxH highly expressed II Lindestam Arlehamn et al.
Rv0287 EsxG highly expressed II Lindestam Arlehamn et al.
Rv3875 ESAT-6 highly expressed II Lindestam Arlehamn et al.
Rv0291 Probable membrane-anchored 
mycosin MycP3
Inflammation II Lindestam Arlehamn et al.
Rv3015c Conserved hypothetical protein Relapse II Lindestam Arlehamn et al.
Rv3019c EsxR Resistance II Lindestam Arlehamn et al.
Rv3020c EsxS (PE28) Resistance II Lindestam Arlehamn et al.
Rv1243c PE_PGRS23 resistance/low inflammation II Lindestam Arlehamn et al.
Rv2460c ClpP2  highly expressed II Tang et al.
Rv0440 GroEL2  highly expressed II Tang et al.
Rv1482c  Conserved hypothetical protein resistance/inflammation I Hammond et al.
Immune recognition of  Mtb infection-phase related antigens by immune cells from 
mycobacteria exposed individuals
Both Rpf, DosR and IVE-TB antigens were recognized by CD4+ and CD8+ T cells from ltLTBI 
donors (Chapter 2, 3 and 4). CD4+ T cells are known to be important in control of Mtb infection 
[58]. Less is known about the role of  CD8+ T cells in Mtb infection but they likely play an important 
role in TB protection, particularly during latency [59-61]. Our work showed that CD8+ T cells 
are present in high frequencies in ltLTBI, suggesting that DosR, Rpf  and IVE-TB antigens are 
presented either via (i) cross presentation; (ii) translocation to the cytoplasm [62]; or (iii) alternative 
MHC class I presentation pathways [63]. Furthermore, (iv) apoptosis of  Mtb loaded cells can 
further enhance MHC-I antigen presentation and subsequent activation of  CD8+ T cells [64;65]. 
Using a short stimulation protocol (chapter 2, 3 and 4)  Rpf, DosR-regulon and IVE-TB 
antigen-specific immune responses could be detected in ltLTBI donors. This approach readily 
detected effector and effector memory T cells (Teff and Tem, respectively) whereas longer 
stimulation periods are typically required to detect full activation of  central memory T cells (Tcm).
[66] Indeed IFN-γ+/TNF-α+ CD8+ T cells were the most prominent DosR and Rpf  specific T 
cells identified in the PBMC of  ltLTBI population. Interestingly, this population showed mainly 
a Tem, (CCR7-/CD45RA-) and Teff (CCR7-/CD45RA+) CD8+ T-cell phenotype, which are 
considered to be important to early-phase protection by inducing effector functions at the site of  











































history of  TB and also questioned why such effector cells remained present, even after effective 
treatment [69;70]. It was suggested that either endured longevity of  the cells [69] or continued 
antigen exposure [70] due to insufficient clearance of  the infection after treatment [69] accounted 
for their presence. Interestingly, a subset of  untreated spontaneous ‘healed’ TB patients did not 
show IFN-γ specific T cells ex vivo, but had Tcm, suggesting clearance of  the bacteria in these 
particular donors [70].  It has been proposed that Tem cells can convert to Tcm in the absence of  
antigen [71;72]. However, it is as yet not possible to detect viable Mtb bacilli in LTBI, such that 
true Mtb persistence cannot be verified in LTBI.
Although such effector and/or effector memory CD4+ and CD8+ T cells were present in 
healthy Mtb exposed individuals (our work and [54;69;70;73;74], they cannot be associated firmly 
to protection as multiple studies have shown Teff and Tem (CD8+ [73]; CD4+ [74])  in active TB 
patients as well.  In addition, Tcm could be identified in LTBI (CD4 [2;10;54;74], CD8[2;10], TB 
patients (CD4[2;10], CD8[2;10]) and cured TB patients (CD4+ [70;74], indicating that Tcm is not 
always associated with protection. The plasticity of  particularly CD8+ memory T-cell subset might 
account for this diverse spread of  memory subsets among mycobacteria exposed individuals. 
CD8+ memory T cells are suggested not to follow a linear differentiation model, in contrast to 
CD4+ T cells [75;76].  Rather, activated CD8+ T cells might directly develop into Tem or Tcm 
which subsequently develop into Teff. In addition, CD8+ Tem seem to be able to differentiate 
into Tcm upon antigen clearance [75;77]. Interestingly, CD8+ Teff, as defined by CCR7-/CD45+, 
were not as terminally differentiated as previously thought as they may become Tem upon TCR 
activation and finally return to Teff, or, as suggested by the authors, become transitional resting 
cells, based on CD45RA re-expression during continued lack of  antigen [78]. The different CD8+ 
memory subsets observed in LTBI as shown by the studies described in the latter may reflect these 
alternative explanations. Of  note, the memory subsets of  IFN-γ+/TNF-α+ CD8+ T cells that were 
analyzed in this thesis were detected using a short stimulation protocol. It is possible that this 
might have biased towards the detection of  effector cells (and this also accounts for other studies 
mentioned in the latter). 
Taking the results of  the previous studies into account ltLTBI individuals analyzed in chapter 
2 and 3 probably remained exposed to Rpf  and DosR regulon encoded antigens either via Mtb, 
and thus Mtb infection was not fully cleared, or via cross-reactive immunity by, for example, 
exposure to (non-tuberculous) environmental mycobacteria (NTM).   
Limited antigen-specific T-cell responses (by IFN-γ) were observed in TB patients when 
compared to TST+ individuals (chapter 4), a phenomenon that has been described in other 
studies as well [10;79;80]. Sequestration (the preferential homing of  T cells to the site of  infection) 
[81] can result in a decrease in T cells in the periphery, thus leading to decreased antigen 
recognition by PBMC [82;83]. These peripheral blood responses normalize after successful 
treatment [81]. However, a continued lack of  full responses after TB treatment can persist as well 










































low responsiveness in TB patients [84;85]. Regulatory T cells (Tregs) are known to suppress T cell 
and APC activation, limiting the pro-inflammatory immune response [86;87].  In addition, anti-
inflammatory macrophages might further enhance non-responsiveness by inducing Tregs which 
further suppress pro-inflammatory responses via e.g. TGF-β [88]. Indeed, PPD non-responding 
TB patients showed no or low IFN-γ production or T-cell proliferation, but expressed the anti-
inflammatory cytokine IL-10 [89] which is known to dampen macrophage and T-cell activation 
[90]. Indeed, the absence of  IL-10 increased protection against Mtb infection via enhanced Th1 
immunity [91]. Other Mtb immune suppression mechanisms are described as well, including 
(i) specific inhibition and detoxification of  ROS production [92;93], inhibition of  phagosome 
maturation [93-95], avoiding of  apoptosis and inhibition of  autophagy [93]. The influence of  
additional, unknown host genetic factors [96-98] likely can also limit the development of  a robust 
Th1 immune response and lastly, differential expression of  Mtb antigens definitely influences the 
activation of  antigen-specific T cells. Thus, many factors can be involved in the decreased antigen 
recognition observed in TB patients.   
Polyfunctional T cells and anti-mycobacterial immunity 
The protective efficacy of  IVE-TB antigen Rv2034 was described in chapter 5. Immunization 
with Rv2034/CpG resulted in a decrease of  CFU after challenge with live Mtb when compared 
to non-immunized mice. Interestingly, immunization with Rv2034/CpG did not induce 
polyfunctional CD4+ T cells producing IFN-γ, TNF-α and IL-2, but rather showed enhanced 
levels of  CD4+ T cells producing IFN-γ+/TNF-α+ and IFN-γ+.  Although triple positive CD4+ 
T cells were not strongly induced, the vaccine nevertheless induced protection against Mtb. 
Therefore, triple positive (IFN-γ+/TNF-α+/IL-2+) CD4+ T cells do not seem to be strictly required 
for Mtb protection following vaccination. In addition, low frequencies of  IFN-γ+/TNF-α+/IL-
2+ CD4+ and triple positive CD8+ T cells were identified within the ltLTBI donors who did not 
develop TB (chapter 2, 3 and 4). Together these studies imply a minor role of  triple cytokine 
producing T cells in protection against Mtb during infection. Importantly, control SEB stimulation 
revealed substantial populations of  CD154+/CD4+ T cells producing IFN-γ, TNF-α and IL-2, 
demonstrating that these ltLTBI donors are able to produce triple positive T cells. 
Multiple studies have analyzed the presence of  IFN-γ+/TNF-α+/IL-2+ triple positive CD4+ 
and/or CD8+ T cells upon Mtb infection [99-102] and TB vaccination [103-109]. Contradictory 
results regarding the presence of  these cells and their association to protection were reported. 
Technical variability in cytokine detection between the studies described may have been 
responsible in part for these contrasting data as both incubation period during antigen stimulation 
and cytokine accumulation using Golgi transport inhibitors can influence the distribution of  Mtb 
specific polyfunctional T cells [110]. Furthermore, the timing of  the assay may be relevant since 
T cells can change their cytokine expression pattern over time such that subsets based on cytokine 











































antigen/bacterial load could play a role in the variation of  T-cell function and phenotype [100;113]. 
Mtb specific polyfunctional T cells were actually suggested to be correlates of  antigen load rather 
than correlates of  protection [114;115]. Hence, multiple factors may affect the development of  
polyfunctional T cells, complicating the interpretation of  their exact role in TB protection. 
TB vaccine candidates selection based on conservation between different 
mycobacterial strains
IVE-TB Rv2034 is conserved among multiple Mtb complex strains. It is important to vaccinate 
against conserved antigens in order to prevent Mtb escape from the immune system due to antigen 
variation (e.g. epitope mutation) as has been suggested for the PE and PPE families of Mtb proteins 
[116;117]. On the other hand, previously identified human T-cell epitopes of  Mtb were found to 
be particularly strongly conserved as shown by Comas et al.[118]. This finding was interpreted 
to indicate that Mtb may benefit from host T-cell immunity as the bacterium seems to avoid 
escaping host immune pressure through antigenic variation. An underlying mechanism may well 
be that T-cell immunity eventually induces pathology [119], such as Th1 induced granulomatous 
necrosis, which can ultimately lead to further transmission and dissemination of  infection [120]. 
This indicates that the balance between pathogen and host in Mtb infection is delicate and subtle. 
Immunity directed against broadly conserved antigens might already be present in unvaccinated, 
Mtb-unexposed individuals, induced by non-mycobacterial or (non-tuberculous) environmental 
mycobacteria (NTM) species encoding these conserved antigens. DosR regulon specific responses 
were observed in NTM exposed individuals who had no history of  TB exposure [121] and 
exposure to NTM can induce Mtb cross-protection [122-124] and enhance BCG protection 
[123]. However, NTM induced immunity might also limit the protective effect of  subsequent 
TB vaccination [124]. Notably, NTM-induced immunity could block BCG multiplication, thus 
preventing the development of  efficient BCG induced immunity [125]. Thus pre-existing memory 
induced by conserved antigens may act on live mycobacterial TB vaccines and as such influence 
the protective value of  this vaccine. 
Future perspective 
Different Mtb infection-phase related antigens were analyzed as possible TB subunit vaccine 
antigens, taking into account four criteria as specified in section 1. Both Rpf  and Mtb DosR 
regulon encoded antigens were recognized by mycobacteria exposed individuals and thus were 
immunogenic (first criterion). The antigens from both sets included immunogenic regions which 
can be used in future vaccines studies to determine their protective value against TB. A third set 
of  antigens, identified and described in this thesis (IVE-TB antigens), expressed in the lungs of  Mtb 
infected mice, was shown to be immunogenic as these were recognized by CD4+ and CD8+ T cells 
from Mtb exposed individuals, including long-term LTBI. IVE-TB protein Rv2034 fulfilled all four 










































could be studied in the highly TB susceptible C3H mouse strain as a more relevant model for TB 
protection and disease than classically used C57BL/6, which is relatively TB resistant.  Also future 
optimizing studies are required to define optimal adjuvant delivery strategy.
Based on our work and that of  others, TB vaccine candidates should include multiple Mtb 
infection-phase related antigen sets, including active-infection- as well as latency-and in vivo 
expressed antigens. Although complete clearance of  Mtb may be a challenging goal, it should be 
possible to prevent development of  active TB by maintaining optimal immune pressure, which could 
be boosted by vaccines aiming to prevent reactivation of  Mtb and thus help containing infection. 
To actually eradicate Mtb infection, other approaches may have to be used in combination with 
vaccine approaches. This might include the use of  vaccination and host modulatory drugs followed 
by antibiotic treatment. Combining a therapeutic vaccine and antibiotic treatment already showed 
potential [126].  Hopefully, the future will show whether these multi-stage vaccines and cocktail 
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Tuberculose (TB) wordt veroorzaakt door de bacterie Mycobacterium tuberculosis (Mtb). Men schat dat 
er in 2011 8.7 miljoen nieuwe TB gevallen bij zijn gekomen en dat het de levens van 1.4 miljoen 
mensen heeft gekost. Hiermee blijft TB de op één na grootste veroorzaker van sterfgevallen door 
infectieziekten, waarbij human immunodeficiency virus (HIV) de lijst aanvoert. 
Na infectie nestelt de tuberkel bacterie zich in de long en kan zich hier jarenlang schuilhouden. 
Dit leidt tot een latente infectie, zonder zichtbare klinische kenmerken. Echter 3-10% van de Mtb 
geïnfecteerde mensen zal in de loop der tijd TB ontwikkelen, met nieuwe Mtb besmettingen als 
gevolg. 
De bestrijding van TB wordt bemoeilijkt door; (i) de ontwikkeling van antibiotica resistentie, 
(ii) co-infectie van TB en HIV, (iii) beperkte methodes om latente en vroeg klinische Mtb infectie 
op te sporen en (iii) de afwezigheid van een effectief  TB vaccin. Op dit moment is er slechts één 
TB vaccin beschikbaar; Mycobacterium bovis Bacille Calmette-Guérin (BCG). Dit vaccin induceert 
echter zeer variabele, en incomplete bescherming tegen de meest voorkomende en besmettelijke 
vorm, open long TB. Daarbij is het vaccin een verzwakt, maar levende bacterie. Dit kan leiden 
tot ernstige BCG infectie in HIV geïnfecteerde kinderen en mensen met genetische afwijkingen in 
genen die betrokken zijn bij anti-TB immuun reacties. Daarom is de vraag naar een effectief  TB 
vaccin groter dan ooit. 
Subunit vaccins zijn niet-levende vaccins die bestaan uit immunogene componenten zoals 
eiwitten en/of  peptiden en kunnen worden toegediend in combinatie met een adjuvant of  via 
een viraal vector systeem. Er zijn verschillende TB subunit vaccins in ontwikkeling die bestaan uit 
Mtb eiwitten die door actief  groeiende Mtb bacteriën tot expressie worden gebracht. Echter, Mtb 
kan ook in een minder actieve, sluimerende/ “dormant” staat verkeren. Men neemt aan dat deze 
sluimerende staat van Mtb aanwezig is in latent geïnfecteerde individuen. Deze sluimerende staat 
is een aanpassingsmechanisme dat Mtb gebruikt om te kunnen overleven in moeilijke, stressvolle 
situaties. Mtb bacteriën worden opgenomen door antigeen presenterende cellen zoals macrofagen 
en verblijven in een zogenoemd fagosoom, dat zorgt voor een voor de bacteriën onaangenaam 
milieu. Hier wordt Mtb onder andere bloot gesteld aan zuurstoftekort en een gebrek aan 
voedingsstoffen. Om deze omstandigheden toch te kunnen overleven schakelt Mtb over op een 
sluimerende, rustende fase die wordt gekenmerkt door een veranderd gen expressie patroon. Een 
gen cluster dat specifiek verhoogd tot expressie komt gedurende zuurstof  depletie is het ‘dormancy 
regulon encoded’ (DosR) gen cluster. Verder blijkt dat er ook genen selectief  tot expressie komen 
bij een tekort aan voedingsstoffen. Daarnaast is een bepaalde eiwit groep, ‘resuscitation promoting 










































Dergelijke bovengenoemde eiwitten zijn dus betrokken bij specifieke fasen waar Mtb in kan 
verkeren. Het is nog niet volledig duidelijk welke andere genen en eiwitten de Mtb bacterie verder 
reguleert tijdens een in vivo infectie. Deze eiwitten zouden goede subunit vaccin kandidaten zijn, 
die zowel profylactisch als therapeutisch kunnen worden toegediend. 
Nieuwe en relevante antigenen die mogelijk als TB subunit vaccin kandidaat kunnen dienen, 
moeten voldoen aan een aantal voorwaarden:
i) Het antigen moet immunogeen zijn, dat wil zeggen: het eiwit zal efficiënt 
moeten worden herkend door specifieke T cellen in mycobacterie blootgestelde 
individuen. 
ii) Het eiwit moet in vivo tot expressie worden gebracht door Mtb in geïnfecteerde 
organen, zodat immuun cellen geïnduceerd tegen het antigen Mtb geïnfecteerde 
cellen ook daadwerkelijk kunnen herkennen. 
iii) Het antigen moet protectief  zijn, dat wil zeggen: het eiwit moet in staat zijn 
een immuun respons op te wekken die de groei van Mtb kan remmen of  Mtb 
kan doden. 
iv) De eiwit sequentie van het antigen moet onveranderd aanwezig zijn in alle 
stammen van Mtb, zodat een vaccin gebaseerd op dit antigeen effectief  kan 
zijn tegen alle verschillende Mtb stammen. 
Het onderzoek in dit proefschrift beschrijft de analyse van Mtb fase gerelateerde antigenen als 
mogelijke TB subunit vaccin kandidaten met specifieke focus op bovengenoemde factoren. 
Dit proefschrift
‘Resuscitation promoting factors (Rpfs)’, zijn kleine eiwitten die zeer waarschijnlijk betrokken zijn 
bij het ontwaken van Mtb uit zijn sluimerende staat. Zij kunnen dus een belangrijke rol spelen in 
de ontwikkeling van TB. Het toepassen van deze antigenen in een TB vaccin zou dan kunnen 
leiden tot afweer responsen die reactiverende Mtb meteen herkennen en bedwingen, en op die 
manier actieve TB ziekte helpen voorkomen. Deze antigenen zijn daarom mogelijk interessante 
TB vaccin kandidaten. In hoofdstuk 2 is de immunogeniciteit van twee Rpf  antigenen (Rv0867c 
en Rv2389c) bepaald en zijn tevens immunogene regio’s in deze eiwitten geïdentificeerd. Beide 
antigenen, vooral Rv2389c, werden herkend door witte bloedcellen van donoren die aan 
verschillende mycobacterium stammen waren blootgesteld (BCG gevaccineerde personen, latent 
geïnfecteerde personen (LTBI) en TB patiënten), zoals bepaald door de antigeen-specifieke 
productie van T helper 1 cytokines. De antigenen, maar nu vooral Rv0867c, bleken ook te worden 
herkend door de witte bloedcellen van een specifieke groep individuen die al tientallen jaren latent 
geïnfecteerd waren met Mtb, maar nooit TB ontwikkeld hadden (lt (long-term) LTBI). CD4+ 
en CD8+ T cellen van deze ltLTBIs reageerden op de antigenen en produceerden één of  twee 










































blijven. Ook bleken beide antigenen immunogene regio’s te bevatten, zoals bepaald door middel 
van het gebruik van T cel lijnen. Al met al voldoen deze antigenen dus al aan één belangrijke 
vaccin voorwaarde. 
‘Dormancy regulon encoded genes’ (DosR), zijn Mtb genen die sterk verhoogd worden 
afgeschreven wanneer de Mtb bacil wordt blootgesteld aan een tekort aan zuurstof. Sommige van 
de DosR eiwitten, afgeschreven van deze genen, worden vaker herkend door LTBI dan door TB 
patiënten. Het richten van een vaccin tegen deze antigenen zou dan ook mogelijk kunnen helpen 
bij het onder controle houden van de Mtb infectie. In hoofdstuk 3 zijn de immunogeniciteit 
en immunogene regio’s van drie verschillende DosR antigenen (Rv1733c, Rv2029c en Rv2031c) 
bepaald. Alle drie de antigenen werden herkend door dezelfde ltLTBI groep, en zowel CD4+ 
en CD8+ T cellen reageerden op de antigenen. De grootste populatie van T cellen produceerde 
één of  twee verschillende cytokines. Verder bleken deze T cellen “uitvoerende geheugen cellen” 
(effector memory cells) of  “uitvoerende cellen” (effector cells) te zijn. Dit betekent wederom dat ook 
immuun cellen specifiek voor deze DosR antigenen lange tijd na blootstelling aan Mtb aanwezig 
blijven. Alle drie antigenen bevatten ook immunogene regio’s, specifiek herkend door CD4+ en/of  
CD8+ T cellen. Ook deze drie DosR antigenen blijken immunogeen en dus te voldoen aan enkele 
belangrijke, bovengenoemde subunit vaccin voorwaarden. 
De boven genoemde Mtb fase gerelateerde antigenen werden alle ontdekt in in vitro studies 
welke de in vivo stress omstandigheden nabootsen. Een directe analyse van Mtb genen expressie 
tijdens een echte in vivo infectie is echter een krachtiger methode om relevante, hoog geexpresseerde 
Mtb genen te identificeren omdat hierbij meerdere factoren tegelijk van invloed zijn zoals het 
effect van het immuun systeem. Daarbij is het wellicht ook mogelijk om belangrijke respons 
systemen te identificeren die Mtb gebruikt om in vivo te overleven. Wij veronderstelden dat in vivo 
geexpresseerde genen tot de selectie van belangrijke nieuwe vaccin kandidaten zou kunnen leiden. 
In hoofdstuk 4 is daarom een set van in vivo Mtb geexpresseerde (IVE-TB) genen beschreven 
die zijn geïdentificeerd in de longen van Mtb geïnfecteerde muizen. Vier verschillende, genetische 
verwante muizen stammen zijn geanalyseerd. Deze stammen lieten een divers Mtb infectie patroon 
of  spectrum van TB gevoeligheid zien. Een associatie kon worden gelegd tussen gen expressie en 
TB ziekte fenotypes. Ook werd de immunogeniciteit van een selectie van deze IVE-TB antigenen 
bepaald in mycobacterie blootgestelde individuen. Deze selectie bevat antigenen waarvan de eiwit 
sequenties geconserveerd zijn tussen de verschillende Mtb stammen. De IVE-TB antigenen werden 
goed herkend door Mtb blootgestelde individuen met een positieve IGRA en TST, terwijl weinig 
herkenning zichtbaar was in IGRA negatieve, TST positieve donoren of  in negatieve controles. In 
TB patiënten werd ook herkenning gezien, zij het enigszins lager dan in de IGRA+TST+ donoren. 
Een aantal IVE-TB antigenen werden ook herkend door CD4+ en CD8+ T cellen van ltLTBI, 
dus immuun responsen tegen deze eiwitten waren wederom zeer langdurig aanwezig na infectie. 
Concluderend, de geteste IVE-TB antigenen zijn immunogeen, zijn geconserveerd en worden tot 










































Een belangrijke parameter voor een efficiënt TB vaccin kandidaat is de inductie van 
beschermende immuniteit. IVE-TB antigen Rv2034 uit hoofdstuk 4 werd verder bestudeerd als 
mogelijke vaccin kandidaat in vivo in HLA transgene muizen in hoofdstuk 5. Zoals beschreven 
in hoofdstuk 4 werd het antigen Rv2034 herkend door aan mycobacterie blootgestelde donoren 
maar niet door negatieve controles, wat betekent dat Rv2034 tot expressie wordt gebracht tijdens 
infectie én dat het immuun systeem in staat is om dit antigen te herkennen. Om Rv2034 als vaccin 
te gebruiken zal ook eerst de immunogeniciteit van het vaccin verder moeten worden bepaald. 
Hiertoe werden HLA transgene muizen gevaccineerd met Rv2034. Het bleek dat het antigen 
sterk herkend werd en een aantal HLA-DR3 specifieke epitopen bevatte. De geïnduceerde CD4+ 
T cellen produceerden voornamelijk een of  twee verschillende soorten cytokines. Vervolgens 
werd aangetoond dat in Rv2034 gevaccineerde muizen het aantal Mtb bacteriën in de longen 
sterk gereduceerd was na intranasale infectie met de pathogene H37Rv Mtb stam. Dit is in 
overeenstemming met de expressie van Rv2034 in vivo in de long, na infectie. Verder bleek de Rv2034 
eiwit sequentie geconserveerd. Rv2034 voldoet zo aan alle gestelde vaccin voorwaarden.  
Om de functie van de Rv2034 T cellen nader te kunnen bestuderen hebben we een CD154 
klonerings methode gebruikt om Rv2034 specifieke T cel klonen te genereren (hoofdstuk 6). 
CD4+, CD8+ en CD3+CD4-CD8- T cel klonen konden worden gegenereerd. De specificiteit van 
een CD4+ Rv2034 T cel kloon was verder onderzocht en bleek specifiek voor peptide p81-100 welke 
gepresenteerd wordt via HLA-DR. Verder herkende de T cel kloon ook Rv2034 in Mtb lysaat, wat 
aantoont dat de T cel kloon niet alleen recombinant eiwit en synthetische peptiden, maar ook 
het natuurlijke eiwit geproduceerd door Mtb herkent. Daarbij bleek de T cel kloon T helper 1 
en cytotoxische markers tot expressie te brengen. Om de mechanismen achter TB bescherming 
en infectie te ontrafelen is het van essentieel belang om de rol van (fase gerelateerde) antigeen 
specifieke CD4+ en CD8+ T cellen in dit proces te begrijpen. Het werk beschreven in hoofdstuk 
6 kan daar een bijdrage aan leveren wat uiteindelijk zal leiden tot meer efficiënte TB vaccins en 
verbeterde behandelingsmethodes met als gevolg een afname van of  zelfs het elimineren van TB. 
Concluderend/toekomst perspectief
In dit proefschrift zijn verschillende Mtb fase gerelateerde antigenen geanalyseerd als mogelijke 
TB subunit vaccin kandidaten, met een specifieke focus op vier vooraf  gestelde voorwaarden. 
Rpf  en DosR eiwitten werden herkend door mycobacterie blootgestelde individuen en bleken 
immunogeen. De antigenen bevatten immunogene regio’s welke mogelijk kunnen worden 
gebruikt in vaccin studies om verder het beschermende effect van deze antigenen te bestuderen. 
Een derde groep van antigenen, gevonden in dit proefschrift (IVE-TB antigenen) werden door Mtb 
tot expressie gebracht in de longen van muizen en bleken tevens immunogeen omdat ze werden 
herkend door Mtb blootgestelde individuen. Het IVE-TB antigen Rv2034 voldeed aan alle gestelde 
voorwaarden voor een effectieve vaccin kandidaat, dit zal verder moeten worden geoptimaliseerd 










































Om het effect van een vaccin te vergroten, zal het moeten bestaan uit meerdere antigenen 
welke in verschillende fasen van Mtb tot expressie komen. Op deze manier heeft het vaccin 
ook effect op de verschillende stadia, door het gebruik van deze fase gerelateerde antigenen en 
zal daarom ook toepasbaar zijn als profylactisch als ook therapeutisch vaccin. Tevens zullen 
immunogene epitopen aanwezig moeten zijn die via een wijd scala aan HLA moleculen kunnen 
worden gepresenteerd. De toekomst zal uitwijzen of  deze multi-fase vaccins inderdaad zullen 
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